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Voor Ufuk 
Voor mijn ouders 
 
 
 Voorwoord 
 
Het proefschrift dat voor u ligt is het resultaat van ruim 3 jaar onderzoek naar 
ontstekingsgerelateerde, gelokaliseerde en gegeneraliseerde osteoporose en botverlies in recent 
gediagnosticeerde reumatoïde artritis en in hand artrose. Een actueel en boeiend probleem vanwege 
het feit dat meer kennis over de mechanismen van botverlies kan en zal leiden tot betere en 
specifiekere behandelingsopties in beide aandoeningen; aandoeningen die het leven van vele 
patiënten negatief beïnvloeden en beperken. 
Zonder enige twijfel hebben veel mensen door hun harde, en vooral passievol, werk een significante 
bijdrage geleverd aan de totstandkoming van dit proefschrift. Woorden schieten mij tekort om hen 
te bedanken, maar hierbij toch een poging. En zoals u al gemerkt heeft, niet zoals gebruikelijk 
achter in het proefschrift, maar juist helemaal voor in, want zonder hen zou dit proefschrift er niet 
zijn geweest. 
 
Allereerst dank ik drs. J.M. de Jonge-Bok. Han, jij bent degene die me geïntroduceerd heeft in de 
wereld van de reumatologie, ik ben je dankbaar hiervoor.  
De mensen achter de BeSt studie, die eind jaren negentig de missie hadden om een goed 
uitgedachte studie te lanceren om daarmee de wetenschap en de individuele patiënt een grote dienst 
te bewijzen, ben ik erkenning verschuldigd: prof.dr. F.C. Breedveld, prof.dr. B.A.C. Dijkmans,  
dr. D. van Zeben, en de overige leden van de STRO groep, dank voor het opzetten en voortzetten 
van deze unieke studie. Mede dankzij de gezamenlijke en dynamische aanpak is de BeSt studie zo 
een succes geworden en gebleven! Alle deelnemende reumatologen, reumatologen in opleiding, 
onderzoeksverpleegkundigen, en reumaconsulenten, dank voor het includeren en blijven motiveren 
van de patiënten, en de enthousiaste betrokkenheid. Het secretariaat, Jacomien, Hanny, Joyce en 
Hughine, en het datamanegement, Jozé, dank voor alle ondersteuning. Al deze logistieke 
inspanningen om alle benodigde onderzoeksdata van alle partijen te verzamelen resulteerde in de 
immense, en tot vandaag de dag blijvend groeiende, prachtige database, die op vele 
onderzoeksvragen een licht geworpen heeft; en het einde lijkt nog niet in zicht.  
En uiteraard, achter alle getallen en nummers schuilen de mensen om wie het allemaal draait, de 
patiënten. Bovenal wil ik hen bedanken voor hun inzet, motivatie en loyaliteit.  
Ik dank prof.dr. W.F. Lems voor zijn begeleiding gedurende mijn promotieonderzoek.  
Beste Willem, al was ik helaas niet vaak in de VU, telefonisch discussieerden we lang over de 
gevonden resultaten, en jouw kennis met betrekking tot osteoporose was van onschatbare waarde bij 
de interpretatie en presentatie van de data. Dat ik de eerste ben die de eer heeft om bij jou te mogen 
promoveren! Ik wil prof.dr. T.W.J. Huizinga bedanken voor zijn waardevolle commentaar op de 
artikelen. Dr. C.F. Allaart, lieve Renée, jij pakte mijn hand, en sleepte mij mee de, als een speer 
gaande, BeSt studie in. Je liet me niet los. De lessen die ik van jou heb geleerd zijn ontelbaar en van 
 grote waarde; door jou ben ik gegroeid als wetenschapper. Dr. M. Kloppenburg, beste Margreet, ik 
heb veel geleerd van je epidemiologische visie en interpretatief vermogen, mijn oprechte dank 
hiervoor. Ook ben ik je erkentelijk voor het beschikbaar stellen van de GARP data; het is een fraai 
stuk geworden. 
Yvonne en Jeska, jullie hebben veel bijgedragen aan de opzet en het doen (hard)lopen van de studie, 
hierbij alle kinderziektes te lijf gaand, waardoor ik in 2006 belandde in een strak lopende studie. 
Mijn grote vriend Sjoerd, jij hebt me wegwijs gemaakt in het zogenaamde leven van een BeSt 
promovendus, dankjewel voor alles. Naomi, het was geweldig om met jou uitkomsten van lastige 
statistische analyses te bediscussiëren, lang leve de GEE analyse. Linda, bedankt voor het versterken 
van het BeSt team. Onze samenwerking krijgt nog hopelijk een vervolg met andere botgerelateerde 
projecten. Jessica, de osteoporose database die je had aangemaakt tijdens je studententijd, kwam me 
enorm van pas. Het was erg leuk, en vooral leerzaam met jouw epidemiologische kennis, om later 
samen met je onderzoek te doen naar hand artrose. Onno, jij was met je harde werken en grote 
ambities een goed voorbeeld, maar bovenal was je een gezellige overbuurman voor me. Karen, jij 
was vaak mijn inspiratiebron, ik heb altijd respect gehad voor jouw manier van aanpak van alle 
facetten van wetenschappelijk onderzoek. Daarnaast ben je ook een geweldige vriendin, ik kijk uit 
naar de dag dat we weer samen werken onder één dak (terug op de afdeling reumatologie). Ook 
Mohamed, Emalie, Diane, Rosanne, Wing-Yee, Angga, Rachel en Rosaline wil ik bedanken voor de 
zinnige en onzinnige (Angga) discussies, het uitwisselen van kennis en ervaring, het teamgevoel, de 
geweldige sfeer, en vooral voor jullie vriendschap. Mede dankzij jullie ben ik de reumatologie 
afdeling als mijn tweede thuis gaan beschouwen. 
Tot slot wil ik mijn dank betuigen aan mijn vrienden en familie. In het bijzonder Őzlem, voor haar 
stimulatie om de wetenschappelijke wereld te ontdekken, en Selma, mijn zuster, via wie ik lang 
geleden al enthousiast raakte voor het medisch onderzoek. Ik voel me vereerd dat jullie beiden mijn 
paranimfen zijn. 
Annem ve babam, sizin hayatımdaki őneminizi hiç bir sőzle ifade edemem. Çok sağolun, tűkenmez 
sevginiz, desteğiniz, gűveniniz ve dualarınız için. Size layık bir evlat olabiliyorsam ne mutlu bana. 
Sizleri seviyorum. 
Liefste Ufuk, met jouw oprechte interesse in de medische wetenschap, stimulatie tot kritisch 
denken, interpreteren en relativeren, en onvoorwaardelijke steun en begrip, vorm jij de kalme 
kracht achter mij. Met de ware loyaliteit en liefde waarmee je mij omhelst ben jij de 
verpersoonlijking van het beste wat het leven mij te bieden heeft. Samen gaan wij een mooie 
toekomst tegemoet waarin we, naast deze, vele mijlpalen zullen behalen. 
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Rheumatoid arthritis 
 
Rheumatoid arthritis (RA) is a systemic auto-immune inflammatory disease characterized by 
arthritis of particularly the smaller joints of the hands and feet, and to a lesser extent the larger 
joints.[1] Extra-articular manifestations, such as nodules, vasculitis, and pulmonary and ocular 
inflammation are seldom seen. The pathogenesis of RA is incompletely understood, but thought to 
be multifactorial involving multiple genes and environmental factors.[2] Worldwide, patients are 
classified as RA according to the in 1987 revised American College of Rheumatology (ACR) criteria 
when at least four of the seven following criteria are met (criteria 1-4 at least 6 weeks present): 1. 
morning stiffness lasting at least 1 hour, 2. swelling of at least three joint areas, 3. swelling of a hand 
joint area (wrist, metacarpalphalangeal, proximal interphalangeal), 4. symmetrical joint swelling, 5. 
subcutaneous nodules, 6. positive rheumatoid factor, and 7. erosions or juxta-articular osteoporosis 
on hand and wrist X-rays.[3] New classification criteria, including the (high) presence of anti-
citrullinated peptide antibodies (ACPA) and acute phase reactants, and excluding the earlier for 
diagnosis obligated disease duration of six weeks, and the presence of subcutaneous nodules and 
bone damage on X-rays, are developed to identify more early stages of the disease, in order that 
patients can benefit more from early institution of anti-rheumatic treatment to stop and prevent 
development of the disease.[4] Based on the 1987 criteria, the prevalence of RA is approximately 
0.5 to 1.0 percent of the general population, and the incidence varies between 20 and 50 per 
100.000 new patients per year.[5] Both prevalence and incidence of RA increases with age, and it 
affects more women by a ratio of three.  
The natural course of RA results in chronic inflammation leading to longstanding synovial 
hyperplasia, and subsequently articular damage, consisting of cartilage loss, subchondral cysts, and 
erosive damage. Both active inflammation and bone destruction lead to significant functional 
impairment and disability. Therefore, uncontrolled RA places a substantial burden on the patient, 
by reduced quality of life and life expectation, in particular by higher prevalence of cardiovascular 
disease and higher fracture risks due to osteoporosis, and on the society, by high health care costs 
and work loss.[6-8] Early and effective treatment of RA is necessary to stop the inflammatory 
process, and to prevent bone and cartilage destruction. 
 
Anti-rheumatic treatment 
 
The last decade considerable improvements were made with regard to treatment of RA, both on use 
of (combinations of) conventional disease-modifying anti-rheumatic drugs (DMARDs) with or 
without corticosteroids, and new biological drugs. Furthermore, target goals are set to improve 
disease outcomes. 
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Targeted therapy  
Several tools have been developed to measure disease activity in RA.[9] Objectifying disease activity 
has not only been important for the design and execution of clinical trials to test new drugs and 
drug combinations, it has also provided clinicians with means to follow up the effect of their 
therapeutic interventions in daily practice, and set themselves treatment goals. Several studies have 
shown that regular treatment adjustments aimed at achieving a predefined low level of disease 
activity result in better clinical and radiological outcomes of RA than non-target-steered 
treatment.[10-12]  
Conventional DMARDs 
Currently, methotrexate (MTX) is still regarded as the anchor drug in RA treatment due to high 
efficacy and low toxicity, well-reported in several randomized clinical trials.[13,14] The exact 
working mechanism remains unclear, however it is believed that MTX has immunosuppressive 
actions via various routes.[15] MTX is currently recommended as first choice in the treatment of 
RA by European league against rheumatism (EULAR), as monotherapy or in combination with 
other drugs.[16] MTX therapy combined with the systematic temporary use of corticosteroids 
adequately suppresses inflammatory activity and radiological damage progression in patients with 
early RA.[17] 
Other widely used DMARDs are sulfasalazine, leflunomide, and antimalarial drugs such as 
hydroxychloroquine, and, to a lesser extent, due to an unfavorable toxicity profile and the 
superiority of other drugs, azathioprine, cyclosporine, and gold salts. 
Biologicals 
Since the introduction in the 1990s of biologicals, drugs produced by molecular biology techniques 
targeting specific cells or cytokines in the pathophysiological pathways of RA, exciting 
improvements in the management of RA have been made. The first biologicals are the inhibitors of 
tumor necrosis factor alpha (TNFα), a pro-inflammatory cytokine playing a central role in 
inflammatory processes: 1. infliximab, a chimeric anti-TNFα, 2. etanercept, a recombinant human 
soluble anti-TNFα receptor, and 3. adalimumab, a recombinant humanized anti-TNFα.[18] The 
efficacy of these three agents seem comparable, but no head-to-head trials have been performed.[19] 
Two new TNF-blockers, certolizumab pegol and golimumab, and other mode of action biologicals, 
such as rituximab, a B-cell depletor, abatacept, an inhibitor of T-cell co-stimulatory pathways, 
anakinra, an interleukine (IL)-1 receptor antagonist, and tocilizumab, an IL-6 receptor antagonist, 
are also nowadays available in the Netherlands. For most of these therapies it is not yet fully clear at 
which stage of the disease course they would be most beneficial to the patients, in terms of rapid 
symptom relief and inhibition of damage progression in relation to possible toxicity risks and side 
effects, compared to other drugs. Dynamic treatment strategy trials rather than comparative drug 
trials should provide us the answers.  
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The BeSt study 
The BeSt study, Dutch acronym for Behandel Strategieën, i.e. treatment strategies, is a randomized 
clinical trial comparing the efficacy of the following four treatment strategies in a tight control 
setting aiming low disease activity in recent-onset, active RA patients: group 1. sequential 
monotherapy starting with MTX, group 2. step-up combination therapy starting also with MTX, 
group 3. initial combination therapy with MTX, sulphasalazine and a quickly tapered high dose of 
prednisone, and group 4. initial combination therapy with MTX and infliximab. Three-monthly 
evaluations of disease activity based on the validated disease activity score (DAS) were performed by 
for treatment blinded experienced research nurses. If the aim of low disease activity, defined as 
DAS≤ 2.4, was not achieved after 3 months, treatment was immediately adjusted by proceeding to 
the next step in the allocated treatment group. If after at least six months the DAS remained ≤2.4, 
medication was gradually tapered until one drug remained in a maintenance dose. In case of 
sustained clinical remission, defined as DAS< 1.6 during six consecutive months, the last drug was 
finally tapered until zero. The tight control setting resulted in a remarkable clinical improvement 
and reduction in joint damage progression.[11] In the initial combination groups, group 3 and 4, 
low disease activity was reached earlier, and therefore a greater reduction of joint damage 
progression was seen compared to the initial monotherapy groups, group 1 and 2. After 6 years, 
51% of the at baseline highly active RA patients were in clinical remission, and 17% of the patients 
in prolonged remission without any anti-rheumatic treatment and with no radiographic 
progression, suggesting that drug free remission is a achievable goal.[20]  
 
Bone destruction in RA 
 
Bone is a dynamic organ continuously formed and resorbed by osteoblasts and osteoclasts, 
respectively, along the surface. How the mechanisms between bone formation and bone resorption 
exactly are coupled is not completely understood, however it is believed that locally cytokines are 
playing a crucial role in this process.[21] In RA there is a clear imbalance with high bone resorption 
and low bone formation, resulting in structural joint damage, and bone mineral density (BMD) 
loss. 
 
Joint damage 
 
In RA, the hyperplastic inflammatory synovial tissue, the so-called pannus, invades, and thereby 
destroys the neighboring cartilage and subchondral bone by activated osteoclasts, while at the same 
time bone formation by osteoblasts is also impaired. Osteoclasts require essential signals which 
promote their differentiation from monocytic precursor cells, and activation.[22] Several 
inflammatory cytokines and mediators such as TNFα, IL-1, IL-6, IL-7, IL-17, and prostaglandin 
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E2 (PGE2) which are produced by macrophages, T cells, or fibroblasts stimulate osteoclast 
formation and activation by inducing the expression of receptor activator of nuclear factor κB 
ligand (RANKL) and macrophage colony stimulating factor (MCSF), expressed by synovial 
fibroblasts, activated T cells, or macrophages (see figure).[23] A decoy receptor, the osteoprotegerin 
(OPG), controls the amount of osteoclastogenesis. RANKL expression is increased in the synovial 
membrane, and the OPG expression is insufficient to counteract RANKL effects in RA, leading to 
subsequent bone loss. Moreover the activation of wingless and Int-1 (Wnt) genes, that play an 
important role in differentiation of osteoblasts from mesenchymal precursors, is strongly inhibited 
by expression of the Wnt-signaling antagonist Dickkopf-1 (Dkk-1), induced by TNFα and 
produced by synovial fibroblasts.[24,25] Furthermore, TNFα also induces the expression of 
sclerostin in osteocytes, which is a potent downregulator of bone formation.[26]  
To date, treatment of patients with RA is not merely aimed at relief of current symptoms of pain 
and limitations in daily functioning due to inflammation of joints, it is as important to suppress 
damage progression, since this determines functional ability in the long term. It is clearly proven 
that suppression of disease activity in RA, by intensive anti-inflammatory treatment with 
DMARDs, glucocorticoids, and biologicals results in effective suppression of progression of 
radiographic joint damage.[27-30] 
 
Figure. Influence of inflammation on bone remodeling. 
 
 
TNF, tumour necrosis factor; IL, interleukin; PGE2, prostaglandin E2; RANKL, receptor activator of nuclear factor κB 
ligand; MCSF, macrophage colony stimulating factor; Dkk-1, Dickkopf 1; OPG, osteoprotegerin. 
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Assessment of joint damage 
 
Plain radiographs of hands and feet still form the gold standard of assessing joint damage 
(progression) in RA. Probably the most widely used method is the by van der Heijde modified 
Sharp scoring method quantifying joint space narrowing and erosions in 44 joints locations in 
hands, wrists, and feet with a maximum score of 448 points.[31] The percentage of patients with 
joint damage progression above the measurement error can be calculated by the smallest detectable 
change (SDC).[32] 
 
Osteoporosis and BMD loss in RA 
 
Osteoporosis is the most common metabolic bone disease, resulting in micro-architectural 
deterioration and decreased mechanical strength of bone, leading to increased incidence of 
fractures.[33,34] Due to this higher fracture risk, it has a major impact both on patient and society 
by increased morbidity, mortality, and health care costs.[35] Bone strength is dependent on its 
structure, the material properties, and bone turnover, and can unfortunately not be tested in 
vivo.[36] Also assessment of bone quality is hampered by the inaccessibility of bone biopsies for 
investigation. At present, the assessment of BMD is the only aspect that can be easily and reliable be 
measured in clinical practice, and it forms the cornerstone for the diagnosis and general 
management of osteoporosis.  
In RA, osteoporosis or BMD loss occurs in two forms: 1. generalized BMD loss with axial 
distribution including the spine, pelvis, hips, ribs, and sternum, and 2. peri-articular or localized 
BMD loss, extra-articular bone loss seen in the proximity of the inflamed joints.[37]  
With regard to generalized BMD loss, the hip and spine are clinically the most relevant locations 
due to the highest fracture rates. In established RA, generalized osteoporosis is a well-known 
complication with overall occurrence of 7% to 26% in the hip, and 19% to 32% in the spine.[38-
43] In a population-based study of patients with established RA, a two-fold increase in generalized 
osteoporosis was seen in women, and a two-fold increase in reduced BMD in men compared with 
control groups.[41,44] Furthermore, a two-fold increase in risk of hip and vertebral fractures is seen 
in RA.[45,46] Over 1 year, BMD loss of 4.3% and 2.4% was observed in the hip and spine, 
respectively, in patients already fulfilling the in 1987 revised ACR criteria for RA, however not 
receiving any kind of anti-rheumatic therapy with DMARDs and/or corticosteroids, in a study that 
has been performed over 15 years ago.[47]  
There are several explanations for the increased prevalence of osteoporosis and accelerated BMD 
loss in established RA. Firstly, there is a significant overlap in demographics of patients with RA 
and patients with osteoporosis: both diseases are occurring predominantly in middle-, and high-
aged patients, and, especially postmenopausal, women. Secondly, advanced RA can lead to low 
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body mass index, a well-known risk factor of BMD loss. Thirdly, in established RA both active 
disease and severe structural damage might lead to reduced physical activity, and even immobility, 
and therefore to osteoporosis. Fourthly, the use and non-use of anti-inflammatory drugs, especially 
corticosteroids, might result in accelerated BMD loss. Lastly, the inflammatory disease itself might 
result in high BMD loss as a part of the development and progression of the disease, with the, by 
inflammation driven, osteoclast playing a crucial role in this process.[48-50]  
With regard to peri-articular or localized BMD loss, the hand and foot are clinically the most 
relevant locations due to involvement of particular the smaller joints in the hands and feet in RA. At 
present, the assessment of localized BMD can be readily measured only in the hands. In RA, a mean 
loss in hand BMD was 4.3% of baseline BMD in 1 year.[51] The earlier mentioned explanations 
for accelerated generalized BMD loss in RA are also applicable for localized BMD loss. However, it 
is strongly thought that localized BMD loss is more influenced by inflammatory activity in the 
proximity of the inflamed joints. Whereas accelerated generalized BMD loss seems to occur in a 
later phase of RA, localized BMD loss is found in the early phase of RA, and even in the 
undifferentiated phase of the RA process, probably due to a more direct and local effect of the 
inflammatory activity in the nearby joints.[51-54] When inflammation plays a crucial role in 
localized BMD loss in RA, the question is raised whether long-term absence of the inflammation 
will result in repair of bone destruction. It is known that repair of erosive damage is rarely seen, 
takes months to years to detect on plain radiographs, and is mostly seen in established, very 
destructive disease.[55-57] On the other hand gain in localized BMD in the hands might be earlier 
detectable in the disease process and during a shorter follow-up period due to the process itself, and 
the more sensitive way of measuring bone involvement.[52]  
Hence, in contrast to established RA, little is known about localized and generalized BMD loss in 
recent-onset RA with modern, tight controlled treatment. Knowledge about this is crucial to 
explore the direct effect of inflammation on BMD, both local and general, without the disturbance 
of factors due to advanced disease, such as reduced functional ability due to high structural damage, 
and long term use of corticosteroids. Furthermore, when localized BMD loss is likely in presence of 
inflammatory activity and BMD gain in absence of inflammatory activity, this indicates that 
changes in localized BMD over time might be an accurate and dynamic outcome measure for 
disease activity and bone involvement in RA. 
 
Localized BMD loss and prediction of destructive RA 
 
Since localized BMD loss is found in the early phase of RA or even in the undifferentiated phase of 
the disease, mostly before the stage of joint destruction, changes in localized BMD might be used as 
a predictor for subsequent joint destruction.[51-54,58] Two previous clinical studies showed that 
localized hand BMD loss predicted progressive joint damage in RA.[59,60] To incorporate hand 
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BMD loss as predictor for severe, destructive RA in prediction models, it is necessary to investigate 
the predictive value of hand BMD loss in comparison with other well-known predictors of 
destructive RA. 
 
Anti-rheumatic treatment and BMD 
 
Treatment with corticosteroids has a catabolic effect on generalized BMD by increased bone 
resorption, mediated by increased osteoclast formation and activity, and decreased bone formation, 
mediated particularly by osteoblast and osteocyte apoptosis.[25] However, more recent studies 
showed that this catabolic effect might be neutralized by the suppression of inflammatory 
activity.[61-64] Little is known about the effect of glucocorticoids on localized BMD.[65] 
Treatment with anti-TNFα might protect against generalized BMD loss, and might even result in 
BMD increase, however the results are inconclusive.[66-68] Again, even less is known about the 
effect of anti-TNFα on localized BMD.[69]  In general, conventional DMARDs seem not to have a 
positive nor negative effect on generalized BMD.[70-73] 
Besides the effect of single drugs on localized and generalized BMD, it is extremely important to 
explore the effect of dynamic treatment strategies on BMD, since this is mimicking daily clinical 
practice in which anti-rheumatic treatment adjustments are made continuously in order to resolve 
symptoms, and stop bone destruction. Furthermore, if necessary, it is essential to start anti-
resorptive treatment to reduce or prevent BMD loss. 
 
Anti-resorptive treatment and BMD 
 
While the efficacy of only calcium and vitamin D supplements remains inconclusive, use of 
bisphosphonates does protect against generalized BMD loss, which is particularly important in 
patients who are treated with corticosteroids.[74-76] In contrast, the influence of anti-resorptive 
treatment on localized BMD loss remains unclear.[77] 
 
Assessment of generalized BMD 
a 
The gold standard for assessment of BMD is the dual energy X-ray radiogrammetry (DXA) 
calculating total BMD, both cortical and trabecular, by measuring bone mineral content and bone 
area. The accuracy and precision is good, and the radiation exposure is very low.[78,79] The BMD 
is expressed in different ways: 1. the absolute value expressed in gram/cm2, and 2. the relative values 
expressed in T-scores and Z-scores. T-score is calculated by subtracting the mean BMD of a young-
adult reference population from the patient’s BMD, and dividing by the standard deviation (SD) of 
young-adult population. T-score ≤-2.5 SD is defined as osteoporosis. Z-score is calculated by 
subtracting the mean BMD of an age-, ethnicity-, and sex-matched reference population from the 
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patient’s BMD, and dividing by the SD of the reference population. Z-score is used to compare the 
patient’s BMD to a population of peers especially in case of secondary osteoporosis or BMD loss. Z-
score ≤-1.0 SD is defined as reduced BMD. Changes in BMD are expressed in changes in 
gram/cm2 between two time points or in percentages compared to baseline BMD. 
 
Assessment of localized BMD 
 
Digital X-ray radiogrammetry (DXR) is a computerized version of the traditional technique of 
radiogrammetry originally proposed by Barnett and Nordin.[80] The DXR technique uses plain 
hand radiographs to estimate the BMD in the metacarpals. On the radiograph the computer 
automatically identifies regions of interest around the narrowest part of the second, third, and 
fourth metacarpal bone.[81] A mean surrogate BMD, based on the mean volume per area, is 
calculated in gram/cm2 with correction for the estimated porosity. BMD measured by DXR is 
highly correlated with DXA measurements, and has even better reproducibility and higher 
sensitivity for detecting changes in BMD.[81-83] Furthermore, DXR measurements only require 
plain radiographs of the hands, which are used in routine clinical practice at present, and gives 
therefore no extra radiation exposure. 
 
Common pathways between RA and osteoarthritis 
 
Another common type of arthritis is osteoarthritis (OA), a heterogenous group of conditions with 
alterations in articular cartilage, subchondral bone, and synovium.[84] OA leads to as much loss in 
function and quality of life as RA.[85] While effective, remission-induction therapies are available 
in RA, at present, no disease modifying therapies are available in OA. Nevertheless, an increasing 
body of evidence supports a common inflammatory pathway between RA and hand OA, signaling 
potential new targets for the treatment of hand OA.[86]  
 
Inflammation in hand OA 
 
Both local and low-grade systemic inflammation is associated with hand OA. High resolution 
magnetic resonance imaging demonstrated subchondral bone edema, synovial enhancement, and 
bone erosions in interphalangeal joints in the majority of OA patients.[87,88] A two- to threefold 
increase in high sensitive C-reactive protein levels is seen in OA patients.[89-92] Pro-inflammatory 
cytokines are found in increased levels in synovial fluid of OA joints, and heritable differences in 
cytokine production are associated with the development and progression of OA.[93-97]  
Increased TNFα production and increased p55 TNFα receptor expression on chondrocytes imply 
the relevance of TNFα on joint destruction in OA.[98-100] It is shown that TNFα inhibitors are 
able to suppress nitric oxide production in human cartilage.[101]  
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If, as in RA,[102] accelerated localized BMD loss would be found to be associated with progressive 
osteoarthritic joint destruction in adjacent joints, this might indicate the presence of inflammatory 
activity in hand OA. At present, drug therapies used in OA are limited to symptomatic treatment. 
When inflammatory processes play a significant role in the development and progression of hand 
OA this might be a target for treatment. In theory TNFα inhibitors might be effective against hand 
OA. Two pilot studies using anti-TNF-α therapy in erosive hand OA reported some improvement 
in clinical efficacy measures.[103,104] 
  
State of the art: anti-TNFα against secondary OA in RA 
 
Since in RA simultaneous development and progression of secondary hand OA exists, the effect of 
local and systemic inflammation, and the effect of anti-TNFα treatment on secondary hand OA can 
be explored in RA. These observations will increase our knowledge about the role of inflammation 
and anti-TNFα treatment in secondary hand OA, and might lead to further research to new disease 
modifying treatment targets, such as TNFα inhibitors, in primary hand OA. 
 
Assessment of hand OA 
 
The most widely used method for scoring the presence and progression of hand OA is the Kellgren-
Lawrence overall scale based on plain radiographs.[105] OA damage is graded from 0 to 4 points 
per joint, defining OA by the presence of a definite osteophyte, and more severe grades by the 
presumed successive appearance of joint space narrowing, sclerosis, cysts, and deformity in the hand 
joints. In our studies, we have defined hand OA as K-L score of ≥2 points in at least two hand 
joints.  
The Osteoarthritis Research Society International (OARSI) atlas is used worldwide to assess joint 
damage progression in hands over time, quantifying changes in joint space narrowing, and 
osteophytes in the hand joints.[106] The percentage of patients with joint damage progression 
above the measurement error can be calculated by the SDC.  
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Outline of thesis 
 
This thesis evaluates the effect of inflammation and anti-inflammatory treatment on generalized and 
localized osteoporosis and accelerated BMD loss in recent-onset, active RA, and in hand OA. 
Chapter 2 evaluates the extent of generalized osteoporosis and reduced BMD in the hip and spine 
cross-sectionally, and the effect of high inflammatory activity on osteoporosis and reduced BMD in 
patients with recent-onset, untreated RA. Chapter 3 investigates generalized BMD loss in the first 
year of RA treated with intensive, tight-controlled, modern treatment strategies, including high 
dose of prednisone and anti-TNFα, and the effect of inflammatory variables on BMD loss. Chapter 
4 discusses the differences in generalized and localized BMD loss, and the effect of anti-rheumatic 
and anti-resorptive treatment on generalized and localized BMD loss in the first two years of RA 
treated with various therapeutic strategies. In chapter 5 changes in localized hand BMD, especially 
BMD gain, over 1 year in patients with RA in sustained clinical remission compared to patients 
with high or low disease activity are analyzed. In chapter 6 the value of localized hand BMD loss by 
DXR as potential predictor of subsequent destructive RA is studied. To increase knowledge in the 
role of inflammation in hand OA, localized hand BMD loss, as marker for inflammation, in 
progressive hand OA is investigated in chapter 7. Chapter 8 addresses the role of high 
inflammatory activity, and the effect of treatment with anti-TNFα on incident and progressive 
secondary hand OA in patients with RA. Finally, the findings in this thesis are summarized and 
discussed in chapter 9. 
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Abstract 
 
Objectives Osteoporosis is a well known extra-articular phenomenon in patients with uncontrolled, 
longstanding rheumatoid arthritis (RA). In the present study, the extent of osteoporosis and 
reduced bone mineral density (BMD) and the disease-related and demographic factors that are 
associated with osteoporosis and reduced BMD are examined in patients with recently diagnosed, 
active RA. 
Methods BMD of the total hip and the lumbar spine was measured in 381 DMARD and 
corticosteroid-naïve patients with recently diagnosed, active RA using dual energy x-ray 
absorptiometry. Osteoporosis was defined as T-score ≤-2.5 SD and reduced BMD as Z-score ≤-1 
SD. Multivariable logistic regression analyses were performed to detect associations of osteoporosis 
and reduced BMD with disease activity, functional disability and joint damage 
(Sharp/vanderHeijde Score), as well as with demographic factors.  
Results Osteoporosis and reduced BMD were found in 11% and 25%, respectively, of the patients 
in the spine and/or the hip. Longer symptom duration and presence of rheumatoid factor (RF) were 
the only RA-specific markers for osteoporosis and reduced BMD. Further, postmenopausal status in 
females, a low BMI and familial osteoporosis and, remarkably, male gender were independently 
associated with osteoporosis and reduced BMD. 
Conclusion In DMARD and corticosteroid-naïve patients with recently diagnosed active RA, 
BMD seems to be well preserved and predominantly related to demographic factors. Longer 
symptom duration and a positive RF, but not higher disease activity or more joint damage, were 
related to osteoporosis and reduced BMD.  
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Generalized osteoporosis is a well known extra-articular complication in uncontrolled, longstanding 
rheumatoid arthritis (RA).[1-3] Underlining the clinical significance of low bone mineral density 
(BMD) in RA, the risk of hip [4-6] and vertebral fractures [6-8] and associated morbidity, mortality 
and health care costs are increased in RA patients.  
It is thought that the pathogenesis of both peri-articular and generalized osteoporosis and local bone 
erosions share common pathways.[9] This hypothesis has been strengthened by the discovery that 
osteoclasts, stimulated mostly by the receptor activator of nuclear factor kappaB ligand (RANKL) 
pathway, play a central role in all of these processes.[10-12] A clinical study with early untreated RA 
patients showed that baseline RANKL:osteoprotegerin (natural decoy receptor of RANKL) ratio is 
independently predictive for joint damage progression after five years of follow-up.[13] 
Over the past few years, the extent of osteoporosis in patients with established RA became more 
clear. The overall occurrence of generalized osteoporosis in patients with longstanding RA patients 
ranges from 7% to 26% in the hip and 19% to 32% in the spine.[14-19] In a population-based 
study of patients with established RA, a 2-fold increase of osteoporosis was seen in 394 women [19] 
and a 2-fold increase of reduced BMD in men [20] compared with control groups. Previous studies, 
performed with patients with established RA, reported disease-related factors, such as long disease 
duration, high disease activity, joint damage, functional disability and corticosteroids use, as 
determinants of osteoporosis or reduced BMD.[14-22] Hence, patients with longstanding RA with 
destructive disease, functional disability or immobilisation or long-term corticosteroids use are at 
high risk for osteoporosis.[23]  
In the past, only a few studies focusing on BMD in patients with early RA were performed, 
however the disease duration in some were up to five years.[24-26] Very little is known about the 
extent of osteoporosis and the influence of disease-associated factors on BMD in patients with 
recently diagnosed RA.[27,28] These data are required in order to unravel the common 
mechanisms between generalized osteoporosis and RA.   
In this paper we present data from the BeSt study, a multicenter, randomized clinical trial with a 
large cohort of patients with recently diagnosed, active, DMARD and corticosteroid-naïve RA.[29] 
We evaluated the frequency of osteoporosis in the lumbar spine and total hip and studied the 
influence of disease and demographic factors on osteoporosis and reduced BMD in recent onset RA 
that might indicate a common pathway between rheumatoid inflammation and generalized 
osteoporosis.  
 
Patients and Methods 
 
Study design All measurements were performed in the setting of the BeSt study.[29]  
This was a multicenter, randomized clinical trial designed to compare the effectiveness of four 
different treatment strategies in patients with recently diagnosed, active RA. The BeSt study was 
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conducted by rheumatologists participating in the Foundation for Applied Rheumatology Research 
in 18 peripheral and two university hospitals in the Western part of the Netherlands. The medical 
ethics committee at each participating center approved the study protocol and all patients gave 
written informed consent prior to participation in the study. 
A total of 508 patients, who met the definition of RA as defined by the American College of 
Rheumatology 1987 revised criteria, were included in the trial. Other inclusion criteria were 
symptom duration less than 2 years, at least 18 years of age and active disease with ≥6 of 66 swollen 
joints, ≥6 of 68 tender joints and either an erythrocyte sedimentation rate (ESR) ≥28 mm/hour or a 
Visual Analogue Scale (VAS) global health, reported by the patient, of ≥20 mm (on a scale of 0-100 
mm, 0=best and 100=worst). Exclusion criteria were previous treatment with DMARDs other than 
antimalarials, concomitant treatment with an experimental drug, a malignancy within the previous 
five years, bone marrow hypoplasia, a serum liver enzymes (ALAT/ASAT) more than three times of 
the upper limit of normal, serum creatinine of more than 150 mmol/L or an estimated creatinine 
clearance of less than 75%, diabetes mellitus, alcohol and/or drug abuse, pregnancy, planning to 
conceive during the study period or inadequate contraception.  
BMD measurements In 381 patients, BMD of the lumbar spine, L2-L4 antero-posterior view, and 
the total hip was measured at baseline in 14 out of 20 centers participating in the BeSt trial where 
dual energy x-ray absorptiometry was available. The BMD measurements were carried out with a 
Hologic 4500 QDR (Hologic, Waltham, MA, USA) in eight centers and with a Lunar DPX-L 
(Lunar, Madison, WI, USA) in six centers. Osteoporosis, defined as T-score (number of standard 
deviations [SD] from the mean of young, healthy persons) ≤-2.5 SD and reduced BMD, defined as 
Z-score (number of SD from the mean of healthy age- and sex-matched persons) ≤-1 SD were 
determined according to locally used reference populations provided by the manufacturers. In the 
centers with Lunar equipment the United Kingdom or the United States spine and hip references 
were used and in centers with Hologic equipment Hologic’s spine reference group and the 
NHANES (National Health and Examination Survey) femur reference population were used. 
Absolute values of BMD, measured with the two densitometers, are not comparable due to 
calibration differences.[30] However, if there are no differences in the mean T- and the Z-scores 
between the different equipments and reference populations, the two measurement methods are 
probably reliable and interchangeable.[31]  
Demographic and clinical variables Socio-demographic and clinical data were obtained partly by self-
report questionnaires and partly by interview and clinical examinations that were performed by 
specially trained research nurses.  
The following variables were collected: age, gender, race, height, weight, symptom duration, body 
mass index (BMI), menopausal status, age at menopause and premature menopause (<40 years), 
current smoking and alcohol status, previous clinical fractures, osteoporosis in first degree relatives, 
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estimated daily calcium intake, use of calcium and vitamin D supplements, hormone replacement 
therapy (HRT) and bisphosphonates. Disease assessment was made using the disease activity score 
(DAS), based on the number of swollen joints and the ritchie articular index for pain in tender 
joints, the VAS for patient’s global assessment of disease activity (0-100 mm) and ESR. Functional 
ability as measured by the Dutch validated Health Assessment Questionnaire (HAQ) and 
laboratory tests (C-reactive protein [CRP], 25[OH]vitamin D level and serum IgM rheumatoid 
factor [RF], defined as positive or negative according to locally applied assays and cut-off points) 
were obtained. Radiographic joint damage according to the Sharp-van der Heijde Score (SHS) 
scored independently by two physicians, who remained blinded for patient-specific data and 
treatment group, was assessed. The intra-observer coefficients were 0.93 and 0.94, and the 
interobserver coefficient was 0.93. For this study the mean of the baseline scores of the two assessors 
was used for analysis. A patient was classified as having erosive disease if the mean erosion score was 
>0.5. 
Statistical Analysis The demographic and disease-related variables in relation to the occurrence of 
osteoporosis and reduced BMD in the different measurement sites were analyzed by regression 
analyses adjusted for possible confounders. Potential contribution of the variables, as independent 
risk factors of osteoporosis or reduced BMD was evaluated by stepwise multivariable regression 
analyses, performed as forward (conditional) procedures. All results were adjusted for age, gender, 
race, menopausal status, current smoking and alcohol status, except adjustment for themselves. 
Additionally, symptom duration, joint damage, RF status, DAS and HAQ were adjusted for each 
other. The adjusted odds ratios obtained by regression analyses were corrected into relative risks 
with the formula of Zhang et al. to interpret the magnitude of the associations more 
appropriately.[32] All tests were two tailed and p-values ≤0.05 were considered statistically 
significant.  
 
Results 
 
Patient characteristics 381 patients received BMD measurements: 378 patients of the lumbar spine, 
329 patients of the left total hip and 30 patients of the right total hip. For 22 patients no total hip 
measurement was performed, two of these due to bilateral hip prosthesis and others due to logistic 
reasons. Three patients did not receive spine measurements.  
Table 1 shows the characteristics of the 381 patients with BMD measurements. There were no 
significant differences in the demographic and disease variables between the group of patients with 
BMD measurements and the group without BMD measurements (n=127) (data not shown).  
There were no significant differences in the mean T- and Z-scores and the frequencies of 
osteoporosis and reduced BMD as a result of measurements with different equipments and 
references (data not shown). The study population consisted mainly of postmenopausal female  
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Table 1. Demographic and clinical characteristics of the 381 patients who received BMD measurement. 
† mean (standard deviation); ‡ median (interquartile range); BMI (body mass index); RF (rheumatoid factor); DAS 
(disease activity score); HAQ (health assessment questionnaire); SHS (Sharp-van der Heijde Score); CRP (C-reactive 
protein); HRT (hormone replacement therapy). 
 
patients, aged 55, with recent onset RA with median symptom duration of 23 weeks. All patients 
had active disease with a mean (SD) DAS of 4.4 (0.9) and 72% of the patients had erosive disease. 
The mean calcium intake per day was 926 mg, 7% and 2% of the patients received calcium and 
vitamin D supplements, respectively. Five patients (1%) used bisphosphonates and 21% of the 
women (had) used HRT. The mean T-score was -0.4 SD and the mean Z-score was 0.3 SD in both 
the hip and the spine.  
Prevalence of osteoporosis/reduced BMD The overall frequency of osteoporosis was 9% in the spine, 
4% in the total hip and 11% in either the spine or the hip. The proportion of all patients having 
reduced BMD was 19% in the spine, 14% in the hip and 25% in either the spine or the hip (table 
2). More men than women had reduced BMD and more postmenopausal women than 
premenopausal women had osteoporosis in the measured sites. With increasing age, the frequency 
of osteoporosis and reduced BMD increased as well, except for the highest age group. 
 
Demographic variables     Disease related variables   
Age, years, † (n=381) 55 (13)  Symptom duration, weeks, ‡ (n=381) 23 (13-53) 
BMI, kg/m2, † (n=378) 26 (4)  Positive IgM RF, % (n=381) 64 
Women, % (n=381)  71  DAS44, † (n=381) 4.4 (0.9) 
Postmenopausal, % (n=269)  68  HAQ score, 0-3 scale, † (n=370) 1.4 (0.7) 
Age at menopause, years, † 47 (5)  Total SHS, 0-448 scale, ‡ (n=375) 4.0 (1.5-
8.5) 
Premature menopause, % 7  Erosive disease, % (n=375) 72 
Surgical ovariectomy, % 33  CRP, mg/L, † (n=352) 37 (42) 
Premature ovarian failure, % 67  Calcium intake, mg/day, † (n=378) 924 (356) 
Caucasian race, % (n=381)  93  Calcium suppletion, % (n=381) 2 
Current smoker, % (n=381)  36  25(OH) vitamin D, nmol/L, † (n=323) 51 (30) 
Cigarettes/day, ‡ 13 (8-20)  Vitamin D suppletion, % (n=381) 1 
Current alcohol user, % (n=381) 52  HRT, % (n=271) 21 
Glasses alcohol/day, ‡ 7 (3-14)  No. of years used, ‡ 5 (2-14) 
Previous clinical fractures >30 years, % n=381) 14  Bisphosphonates use, % (n=381) 1 
Postmenopausal fractures, % (n=381) 4  Spine L2-4 (n=378)  
Familial (first degree) osteoporosis, % (n=379) 15  T-score, SD, † -0.44 (1.5) 
   
Z-score, SD, † 0.29 (1.5) 
   
Total hip (n=359)  
   
T-score, SD, † -0.43 (1.3) 
  
Z-score, SD, † 0.26 (1.2) 
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Table 2. Prevalence of osteoporosis and reduced BMD in the spine, total left hip or either.  
 Osteoporosis Reduced BMD 
 Spine Total hip Either Spine Total hip Either 
All (n=381)  9.0 4.0 11.3 19.1 14.2 24.7 
Men (n=109) 
Women 
All women (n=272) 
Premenopausal (n=83) 
Postmenopausal (n=187) 
9.3 
 
8.9 
2.3 
12.0 
3.3 
 
4.3 
0 
6.3 
11.0 
 
11.5 
1.3 
16.5 
31.0 
 
14.2 
9.9 
16.4 
19.0 
 
12.3 
12.5 
12.1 
32.1 
 
21.8 
16.7 
24.5 
Age, years  
20-49 (n=126) 
        50-59 (n=118) 
        60-69 (n=80) 
        70-89 (n=54) 
 
2.4 
11.0 
13.8 
13.0 
 
0 
4.8 
9.0 
4.1 
 
2.4 
15.2 
17.9 
14.3 
 
16.4 
24.0 
23.0 
8.7 
 
15.5 
15.8 
15.9 
4.9 
 
21.6 
29.5 
30.6 
12.2 
BMD (bone mineral density). 
 
Determinants of osteoporosis/reduced BMD All variables, listed in table 1, were entered in regression 
analyses adjusted for possible confounders. Regarding the disease variables, longer symptom 
duration before inclusion was associated with osteoporosis and reduced BMD in the hip and the 
presence of RF was associated with reduced BMD in the spine. DAS, HAQ and SHS were not 
related to osteoporosis or reduced BMD in the spine or the hip (table 3).  
 
Table 3. Regression analysis of osteoporosis and reduced BMD in the spine and the hip (dependent variables) 
and disease variables (independent variables).  
 Osteoporosis Reduced BMD 
RR (95% CI) Spine Total hip Spine Total hip 
Symptom duration, 
weeks 
1.001 (0.99-1.002) 1.004 (1.001-1.006) 1.001 (0.99-1.003) 1.002 (1.001-
1.004) 
Positive RF 1.17 (0.87-1.38) 1.24 (0.64-1.48) 1.31 (1.09-1.45) 1.07 (0.83-1.43) 
DAS 0.89 (0.64-1.15) 0.89 (0.48-1.36) 0.89 (0.70-1.08) 1.10 (0.85-1.34) 
HAQ 1.02 (0.70-1.36) 0.94 (0.43-1.54) 1.12 (0.85-1.39) 0.93 (0.63-1.27) 
Total SHS 1.00 (0.98-1.02) 0.96 (0.91-1.02) 1.00 (0.98-1.02) 1.00 (0.98-1.03) 
All variables are adjusted for age, sex, menopausal status, race, smoking and alcohol status, except for themselves.   
Symptom duration, RF (rheumatoid factor) status, DAS (disease activity score), HAQ (health assessment questionnaire) 
and total SHS (Sharp-van der Heijde Score) were additionally adjusted for each other. RR (95% CI) (relative risk (95% 
confidence interval)). 
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Table 4. Multivariable regression analysis of osteoporosis and reduced BMD in the spine and the hip 
(dependent variables) and demographic and disease variables (independent variables).  
All variables are adjusted for age, sex, menopausal status, race, smoking and alcohol status, except for themselves.   
Symptom duration, RF (rheumatoid factor) status, disease activity score, health assessment questionnaire and total Sharp-
van der Heijde Score were additionally adjusted for each other. BMI (body nass index); RR (95% CI) (relative risk (95% 
confidence interval)). 
 
Regarding the demographic variables, postmenopausal women, a low BMI and current smokers 
were associated with osteoporosis and male gender, a low BMI, familial (first degree family) 
osteoporosis and current smokers were associated with reduced BMD in the measured sites (data 
not shown). Variables that showed significant associations in the regression analyses, adjusted for 
possible confounders, were entered in a multiple regression analyses.  
Longer symptom duration and positive RF were independently associated with osteoporosis and 
reduced BMD in the hip and reduced BMD in the spine, respectively.  
Postmenopausal women and low BMI remained related with osteoporosis in the spine or the hip. 
Male gender, low BMI and familial osteoporosis were independently associated with reduced BMD 
in the spine or the hip (table 4). 
 
Discussion 
 
In this large cross-sectional study we examined BMD in a large group of patients with recent onset, 
active, DMARD and corticosteroid-naïve RA. We found that approximately 11% of both men and 
women with RA have osteoporosis (T-score ≤-2.5 SD) and 32% of the male RA patients and 22% 
of the female patients have reduced BMD (Z-score ≤-1 SD). The independent disease-related 
determinants of osteoporosis and reduced BMD in these patients were longer symptom duration 
and the presence of RF. 
Since the prevalence of osteoporosis is dependent of many population-specific factors, such as 
genetic factors, race, age and gender, it is important to compare our data on the prevalence of 
osteoporosis with data in the general Dutch population. Versluis et al. showed in a cohort of 449 
Dutch postmenopausal females, with a mean age of 67 years, that osteoporosis was present in 7% in 
 Osteoporosis Reduced BMD 
RR (95% CI) Spine Total hip Spine Total hip 
Male gender 2.54 (0.88-6.16) 2.05 (0.73-4.56) 1.80 (1.23-2.41) 1.43 (0.74-2.47) 
Postmenopausal women 1.93 (1.17-3.07) 1.60 (0.78-3.85) 2.05 (0.99-4.55) 1.45 (0.66-3.15) 
BMI, kg/m2 0.90 (0.84-0.96) 0.74 (0.58-0.90) 0.99 (0.94-1.04) 0.92 (0.87-0.97) 
Familial osteoporosis 1.54 0.93-2.02 1.15 (0.44-3.20) 2.16 (1.23-3.39) 2.47 (1.30-4.00) 
Symptom duration, 
weeks 
1.001 (0.99-1.002) 1.004 (1.001-1.006) 1.001 (0.99-1.003) 1.002 (1.001-
1.004) 
Positive RF 1.17 (0.87-1.38) 1.24 (0.64-2.48) 1.31 (1.09-1.45) 1.07 (0.83-1.43) 
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the femoral neck and this is in accordance with our results (6% osteoporosis in the hip in 
postmenopausal women, mean age 61 years).[33] In addition, Smeets-Goevaers showed the 
presence of osteoporosis in the lumbar spine in 13% of 1079 Dutch postmenopausal females with a 
mean age of 51 years and this matches the prevalence of osteoporosis in the spine in our 
postmenopausal females (12%).[34]  
These agreements might suggest that the prevalence of osteoporosis in our patients with recently 
diagnosed, untreated RA is not increased compared to the general Dutch population, however 
comparison of these populations should be done with caution due to differences in demographic 
characteristics, especially in age. In accordance with our results, Keller et al. showed in 227 
DMARD-naïve RA patients with a mean disease duration of 6 months that BMD values did not 
differ significantly between RA patients and controls.[27] However, the proportion of patients with 
reduced BMD (Z-score ≤-1 SD; 45% of women and 51% of men) was higher compared to the 
reference population (16%), even in this early stage of the disease. Unfortunately, no data exists on 
the prevalence of reduced BMD in the general Dutch population, however compared to the 
population of Keller et al. reduced BMD in our population seems to be less frequent (32% of men 
and 22% of women). In addition, Forslind et al. showed in 134 DMARD-naïve female RA patients 
with mean disease duration of 6 months BMD similar to that of age-matched controls, whereas the 
BMD in the 70 male RA patients was lower than the controls.[28] Hence, despite the bad 
prognostic markers in our study, with RF present in 64% and erosions in 72% of the patients after 
median symptom duration of 23 weeks, BMD is fairly well preserved in the very early stage of the 
disease. This could be explained by the fact that generalized osteoporosis is more associated with 
longstanding, destructive and disabling RA [35], whereas early RA is associated with peri-articular 
osteoporosis.[3] This is further underlined by the fact that longer symptom duration is 
independently associated with more generalized osteoporosis in studies, including the present 
one.[14]  
On the other hand, other studies have found lower BMD in early RA patients than in the reference 
population.[24-26] However, in these studies methodological aspects varied, such as the sample 
size, the selection of patients (with disease duration up to 5 years) and the (non-)treatment of RA 
and osteoporosis. In our study, none of the patients was treated for RA (at baseline) and only five of 
the 381 patients were using bisphosphonates for a few months and that did not disturb the analyses.  
Symptom duration and the presence of RF were the only RA-specific markers for osteoporosis and 
reduced BMD in this study. It is known that seropositive RA is associated with more aggressive 
joint disease and is more commonly complicated by extra-articular manifestations than seronegative 
RA.[36-40] In accordance, previous studies showed an independent association between the 
presence of RF and osteoporosis or reduced BMD in established and recent onset RA.[20,27] This 
suggest that there might be a common pathway between (future) local bone involvement in RA and 
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generalized osteoporosis with osteoclasts, stimulated mostly by the RANKL pathway, playing a 
crucial role in the pathogenesis.[11-13] However, although joint damage, disease activity and 
functional disability were related to lower BMD in several studies with established [14,15,17-19] 
and early [24-26] RA patients, these were not associated with osteoporosis or reduced BMD in the 
present study with recently diagnosed RA. This could be explained by the very short disease 
duration of our patients and follow-up might reveal associations between these disease-related 
variables and BMD. 
In agreement with previous studies, osteoporosis and reduced BMD were independently associated 
with the well-known risk factors of low BMI, postmenopausal women and familial 
osteoporosis.[14,16-19,41] In this study, we also, remarkably, found more reduced BMD in the 
spine in men than in women. After adjustment was made for confounders, such as menopausal 
status for females, age was not associated with osteoporosis and reduced BMD in both women and 
men. However, it was remarkable that the highest age group had lower prevalence of reduced BMD 
than the younger groups. This could be due to degenerative changes in the lumbar spine, the 
smaller number of patients and selection of the fittest patients. 
In conclusion, in our large cohort of DMARD and corticosteroid-naïve patients with early, active 
and mostly erosive RA, we found that a longer symptom duration and the presence of RF, 
predictive for aggressive joint disease, was associated with osteoporosis and reduced BMD, 
suggesting that there might be a common pathway between these events. Nevertheless, a 
comparison with Dutch population-based cohorts suggests that the prevalence of osteoporosis in 
our patients overlaps with that of the Dutch population, indicating that generalized osteoporosis in 
recently diagnosed RA is predominantly related to the well-known risk factors unrelated to disease, 
such as being postmenopausal, having familial osteoporosis and a low BMI. Further studies will be 
done in the BeSt cohort to evaluate the effect of disease activity, joint damage progression and 
antirheumatic medication, including the use of corticosteroids and TNF inhibitors, on BMD loss. 
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Abstract 
 
Objectives We examined the effects of four different treatment strategies on bone mineral density 
(BMD) in patients with recently diagnosed, active rheumatoid arthritis (RA) and the influence of 
disease-related and demographic factors on BMD loss after 1 year of follow-up in the BeSt trial.  
Methods BMD measurements of the lumbar spine and total hip were performed in 342 recently 
diagnosed RA patients at baseline and after 1 year. Multivariable regression analyses were performed 
to determine independent associations between disease and demographic parameters and BMD loss 
after 1 year. 
Results Median BMD loss after 1 year was 0.8% and 1.0% of baseline in the spine and the hip, 
respectively. No significant differences between treatment groups, including corticosteroids and the 
anti-TNFα infliximab, were observed with regard to BMD loss after 1 year of treatment. Joint 
damage at baseline and joint damage progression according to the Sharp-van der Heijde score were 
independently associated with more BMD loss after 1 year. The use of bisphosphonates 
independently protected against BMD loss. 
Conclusion After 1 year of follow-up in the BeSt study, we did not find differences in BMD loss 
between the four treatment strategies, including high dose of corticosteroids and anti-TNFα. Joint 
damage and joint damage progression are predictors of high BMD loss, which emphasizes that 
BMD loss and erosive RA have common pathways in their pathogenesis.  
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Accelerated generalized bone loss is regarded as a complication in rheumatoid arthritis (RA) [1,2] 
and an increased risk of hip [3-5] and vertebral fractures [5-7] has been demonstrated in patients 
with RA.  
Previous studies showed that treatment of RA with disease-modifying antirheumatic drugs 
(DMARDs) generally do not have any effect on bone mineral density (BMD).[8-11] On the other 
hand, it is well known that treatment with corticosteroids may negatively influence the rate of 
BMD loss in RA patients, however this effect might be neutralized by the suppression of 
inflammatory activity, an important risk factor for high BMD loss in RA.[12-17] In contrast, 
treatment with tumor necrosis factor alpha antagonist (anti-TNFα) might protect against BMD 
loss.[18-20]  
It is thought that the pathogenesis of generalized osteoporosis and local bone erosions share 
common pathways.[21] This hypothesis is strengthened by the finding that osteoclasts, stimulated 
mainly by the receptor activator of nuclear factor kappaB ligand (RANKL), play a central role in 
both pathophysiological mechanisms.[22-25] In accordance with this, high BMD loss in RA 
patients was associated with joint damage progression, disease activity, functional disability and 
immobility in previous longitudinal studies, even in early RA.[26-29] While the efficacy of calcium 
and vitamin D supplements is not very clear, the use of bisphosphonates is protective against, 
especially corticosteroid induced, BMD loss.[30-34]  
The extent and the risk factors of BMD loss have not been studied in recently diagnosed RA 
patients while treated aggressively with DMARDs, corticosteroids or anti-TNFα. In this 
longitudinal study with a large cohort of patients with recently diagnosed, active RA, we evaluated 
the changes in BMD in the lumbar spine and the total hip after 1 year of treatment in the BeSt 
study and we studied the influence of disease-related and demographic factors on BMD loss in 
recent onset RA that might indicate a common pathway between rheumatoid inflammation and 
generalized osteoporosis.  
 
Patients and methods 
 
Patients All measures were performed in the setting of the BeSt study.[35] 508 patients, who met 
the definition of RA as defined by the ACR 1987 revised criteria, were included in the trial. Other 
inclusion criteria were symptom duration <2 years and active disease with ≥6 of 66 swollen joints 
and ≥6 of 68 tender joints. Patients with previous treatment with DMARDs and increased serum 
liver enzymes and creatinine (>150 mmol/L) were excluded. The inclusion and exclusion criteria 
were expanded reported previously.[35] The BeSt study was conducted by rheumatologists 
participating in the Foundation for Applied Rheumatology Research (FARR), in 18 peripheral and 
2 university hospitals in the Western part of the Netherlands. The medical ethics committee at each 
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participating center approved the study protocol and all patients gave written informed consent 
prior to participation in the study. 
Study design The BeSt study is a multicenter, randomized clinical trial designed to compare the 
effectiveness of four different treatment strategies in patients with recently diagnosed, active RA. In 
case of insufficient response to therapy, based on the disease activity score (DAS) in 44 joints >2.4, 
the medication was immediately adjusted by proceeding to the next step according to the 
pharmacoprotocol.  
The patients assigned to sequential monotherapy (group 1) started with 15 mg/week methotrexate 
(MTX), which could be increased to 25-30 mg/week and subsequent steps were sulphasalazine 
(SSZ) and leflunomide monotherapies. The patients assigned to step-up combination therapy 
(group 2) also started with 15 mg/week MTX, which could be increased to 25-30 mg/week and in 
the next steps SSZ and hydrochloroquine could be added. The patients assigned to initial 
combination therapy with prednisone (group 3) started with the combination 7.5 mg/week MTX, 
2000 mg/day SSZ and 60 mg/day prednisone quickly tapered to 7.5 mg/day in 7 weeks and MTX 
could be increased to 25-30 mg. The patients assigned to initial combination therapy with 
infliximab started with infliximab (group 4) 3 mg/kg at weeks t=0, 2, 6 and every 8 weeks thereafter 
and MTX 25-30 mg/week, the dose of infliximab could be increased step by step to 6 mg/kg, 7.5 
mg/kg and finally 10 mg/kg. If the clinical response was consistently adequate (DAS ≤2.4 for at 
least 6 months), medication was tapered until 1 drug remained in maintenance dose, which was 
MTX 10 mg/week, SSZ 2000 mg/day or leflunomide 10 mg every other day. The treatment 
protocol is previously described more expanded.[35] 
In case of calcium intake <1000 mg/day and serum vitamin D level below the local reference value, 
suppletion of 500-1000 mg/day calcium and 400 IE/day vitamin D (colecalciferol) was advised at 
baseline. Alendronate, 10 mg/day or 70 mg/week, or risedronate, 5 mg/day or 35 mg/week, was 
advised if the baseline BMD measurement showed a T-score, number of standard deviations (SD) 
from the mean BMD of young, healthy persons, ≤-2.5 SD in the spine and/or hip in non-
corticosteroid-users or a T-score ≤-1 SD, the American College of Rheumatology (ACR)-
recommended threshold for corticosteroid-induced osteoporosis, in corticosteroids-users. 
BMD measurement 342 of the 508 patients received BMD measurements of the lumbar spine L2-4 
antero-posterior view and the total hip at baseline and after 1 year in 14 out of 20 centers where 
dual energy X-ray absorptiometry (DEXA) was available. The BMD measurements were carried out 
using a Hologic 4500 QDR (Hologic, Waltham, MA, USA) in eight centers and a Lunar DPX 
(Lunar, Madison, WI, USA) in six centers.  
T-scores were determined according to references provided by the manufacturers (Lunar: UK or US 
references, Hologic: Hologic’s spine and NHANES femur references). Changes in BMD were 
expressed as the change after 1 year in absolute BMD values compared with baseline BMD.  
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The rates of change after 1 year of follow-up calculated from serial measurements, assessed by the 
same machine, measurement procedure and references for each patient, on different machine types 
are comparable.[36] Changes in BMD after 1 year of treatment were divided in tertiles with high 
and low BMD loss, with the median percentage BMD loss used as cut-off point, and no BMD 
loss/BMD increase. 
Demographic and clinical variables Demographic and clinical data were obtained by specially trained 
research nurses who were blinded to the allocated treatment group. The DAS, based on the number 
of swollen joints, the ritchie articular index for pain in tender joints, the visual analogue scale for 
patient’s global assessment of disease activity (0-100 mm) and the erythrocyte sedimentation rate, 
and the Dutch validated health assessment questionnaire (HAQ), measuring functional disability, 
were obtained three-monthly. Radiographic joint damage at baseline and after 1 year was assessed 
according to the Sharp-van der Heijde score (SHS) scored independently by two blinded assessors. 
The intra-observer coefficients were 0.93 and 0.94 and the interobserver coefficient was 0.93. The 
mean of the scores of the two assessors was used for analysis. A patient was classified as having 
erosive disease at baseline if the mean erosion score was >0.5. Progression of joint damage after 1 
year was defined as SHS progression greater than the smallest detectable change (SDC). 
Statistical analysis Changes in BMD between the four treatment strategies were compared by 
regression analyses adjusted for use of bisphosphonates, vitamin D and calcium supplements, 
hormone replacement therapy (HRT) and intra-articular steroids. Potential contribution of the 
demographic and disease-related variables as independent predictors of BMD loss was evaluated by 
multivariable regression analyses performed as forward (conditional) procedures and adjusted for 
age, gender, menopausal status, race, smoking and alcohol status. Additionally, symptom duration, 
joint damage, RF status, DAS and HAQ were adjusted for each other and disease-related variables 
after 1 year were corrected for their baseline values. Further, use of bisphosphonates, vitamin D, 
calcium, HRT and intra-articular steroids were adjusted for each other. The adjusted odds ratios 
obtained by regression analyses were corrected into relative risks with the formula of Zhang et al. to 
interpret the magnitude of the associations more appropriately.[37] All tests were two tailed and p-
values ≤0.05 were considered statistically significant.  
 
Results 
 
Patient characteristics 342 patients received BMD measurements in the lumbar spine and the total 
hip at baseline and after 1 year. In 16 patients no hip measurement was performed at baseline 
and/or after 1 year, 2 of these due to bilateral hip prosthesis, others due to logistic reasons. Two 
patients didn’t receive spine measurements at both time points. 
Table 1 shows the baseline characteristics of the 342 patients. The group of patients in whom BMD  
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was measured did not differ significantly from the patients in whom BMD was not measured 
(n=166) with regard to the distribution in treatment strategies, demographic and disease variables 
(data not shown). The baseline demographic and disease variables were not significantly different 
between the four treatment groups (table 1).   
In table 2, the treatment with anti-resorptive agents and intra-articular steroid injections during 
follow-up is listed. Patients in group 3 used more bisphosphonates, calcium and vitamin D 
supplements than patients in the other groups (p <0.0001, p=0.004, p=0.01, respectively). 
 
Table 1. Baseline demographic and disease characteristics in the 4 treatment groups. 
 Treatment Group 
 
 
Sequential 
monotherapy  
 
n=81 
Step-up  
combination therapy  
 
n=84 
Initial 
combination 
with prednisone   
n=89 
Initial 
combination  
with infliximab                    
n=88 
Demographic variables 
Age, years, † (n=342) 
 
54 (13) 
 
55 (14) 
 
54 (13) 
 
54 (14) 
BMI, kg/m2, † (n=328) 27 (4) 26 (4) 27 (4) 26 (4) 
Caucasian race, % (n=342)  93 93 96 93 
Women, % (n=342)  69 79 67 69 
Postmenopausal, % (n=342) 30 33 32 32 
Age at menopause, years, † 47 (6) 48 (5) 47 (5) 48 (6) 
Current smoker, % (n=342) 
Cigarettes/day, ‡ 
46 
15 (7-24) 
41 
10 (10-20) 
32 
14 (7-20) 
30 
14 (5-20) 
Previous clinical fractures  
>30 years, % (n=341)  
Postmenopausal fractures, % 
9 
 
0 
14 
 
5 
16 
 
7 
13 
 
5 
Familial osteoporosis, % 
(n=341) 
11 13 17 22 
Disease related variables  
Symptom duration, weeks, ‡ 
(n=342) 
23 (14-58) 27 (15-54) 23 (14-58) 22 (13-38) 
Positive IgM RF, % (n=342) 67 61 66 64 
DAS, † (n=342) 4.5 (0.9) 4.4 (0.8) 4.3 (0.8) 4.3 (0.9) 
HAQ score, 0-3 scale, † 
(n=333) 
1.4 (0.7) 1.4 (0.6) 1.4 (0.7) 1.4 (0.7) 
Total SHS, 0-448 scale, ‡ 
(n=337) 
4 (2-9) 5 (2-8) 3 (1-7) 4 (2-9) 
Erosive disease, % (n=337) 73 68 67 76 
Calcium intake, mg/day, † 
(n=340) 
906 (360) 935 (351) 938 (350) 932 (363) 
† mean (standard deviation); ‡ median (interquartile range); BMI (body mass index); RF (rheumatoid factor); DAS 
(disease activity score); HAQ (health assessment questionnaire); SHS (Sharp-van der Heijde score).     
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Table 2. Treatment with anti-resorptive agents and intra-articular steroids injections during follow-up.  
                                           Treatment Group 
 Sequential 
monotherapy 
n=81 
Step-up  
combination 
therapy  n=84 
Initial 
combination with 
prednisone  n=89 
Initial combination 
with infliximab  
n=88 
Bisphosphonates use,  
% (n=342) 
9 8 27 6 
No. of months used  
during follow-up, ‡ 
9 (6-9) 8 (3-9) 9 (6-9) 6 (5-11) 
Calcium suppl.,  
% (n=342) 
21 18 39 21 
No. of months used  
during follow-up, ‡ 
9 (6-12) 9 (3-10) 9 (9-12) 9 (8-12) 
Vit D suppl.,  
% (n=342) 
9 12 23 8 
No. of months used  
during follow-up, ‡ 
9 (6-9) 9 (5-9) 9 (7-9) 9 (6-9) 
Calcium and/or vitamin 
D, % (n=342) 
26 24 43 21 
HRT use,  
% (n=342) 
14 13 16 17 
No. of years used, ‡ 10 (3-17) 9 (2-15) 5 (3-11) 5 (1-10) 
Intra-articular steroids 
injections (min 1-max 6), 
% 
25 25 9 14 
‡ median (interquartile range); HRT (hormone replacement therapy). 
 
More patients received at least once intra-articular steroid injection in groups 1 and 2 than in 
groups 3 and 4 (p=0.01). Patients who used bisphosphonates were more often present in group 3 
and postmenopausal women, older, had a lower BMI and used more often calcium and vitamin D 
suppletion (data not shown). There were no significantly differences in disease-related factors 
between bisphosphonates-users and non-users (data not shown).  
Effect of treatment strategies on BMD change After 1 year of treatment, the median (IQR) BMD 
change was -0.8% (-3.0 to 1.5) of baseline in the spine and -1.0% (-3.3 to 1.4) in the hip.  
Patients who received bisphosphonates and/or HRT had less BMD loss after 1 year in the spine  
(-0.9% [-3.1 to 1.1] versus 0.0% [-2.3 to 2.3], p=0.012), but not in the hip (-1.0% [-3.5 to 1.2] 
versus -0.9% [-3.0 to 2.1], p=0.4), than patients who did not receive these agents.  
There were no statistically significant differences in the BMD changes between the four treatment 
groups (table 3, overall p=0.9).  
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Table 3. Median delta BMD (interquartile range) after 1 year of follow-up, in percentages of baseline, at spine 
and hip in the 4 treatment groups.  
 Spine  Total hip 
Sequential monotherapy -0.2 (-2.7-1.7) -1.2 (-3.2-1.1) 
Step-up therapy -1.3 (-2.9-1.4) -1.0 (-3.7-1.3) 
Combination therapy  
with prednisone 
-1.2 (-3.0-2.0) -0.9 (-4.7-1.6) 
Combination therapy  
with infliximab 
-0.6 (-3.3-1.3) -0.8 (-3.0-1.8) 
 
After adjustments were made for use of bisphosphonates and HRT, calcium and vitamin D 
supplements and intra-articular steroids during follow-up, still no differences in changes in BMD 
were seen between the 4 groups (overall p=0.8, data not shown).  
In group 3 the mean (SD) cumulative dose prednisone was 2.5 (0.5) g/patient during follow-up, 
equivalent to 9.3 mg/day. In group 4, the mean cumulative dose of infliximab was 34.5 (10.9) 
mg/kg/patient, equivalent to approximately 4.5 mg/kg/gift. Subanalyses between current 
prednisone-users and non-prednisone-users and current infliximab-users and non-infliximab-users 
showed no significant differences in BMD changes after 1 year (data not shown).  
Determinants of BMD loss We divided the changes in BMD after 1 year in tertiles and the third 
tertile, with no BMD loss, was used as reference. Univariable regression analyses showed that SHS 
at baseline and SHS progression >SDC (4.18 points) after 1 year were associated with high BMD 
loss in the hip and the spine, respectively. Other disease-related factors, such as high DAS or HAQ 
or a positive RF, were not associated with more BMD loss (table 4, data of the hip are not shown). 
Of the demographic variables listed in table 1, higher age and smoking were associated with BMD 
loss in the hip and patients with BMD loss in the spine included more men than women and more 
postmenopausal than premenopausal women.  
Osteoporosis treatment Of the patients who were advised to use bisphosphonates, based on T-score ≤-
2.5 SD in non-corticosteroids-users or T-score ≤-1.0 SD in corticosteroids-users, 43% were actually 
prescribed oral bisphosphonates (67% alendronate and 33% risendronate). Thirty-five percent of 
the patients with low calcium intake (<1000 mg/day) received calcium supplement and 33% of the 
patients with low 25(OH)vitamin D levels received vitamin D supplement. Seventy percent of the 
patients with calcium and vitamin D supplements did not used bisphosphonates. Patients using 
bisphosphonates, with or without calcium or vitamin D supplements, had less BMD loss in the 
spine. The use of calcium and/or vitamin D, without bisphosphonates, had no effect on bone loss 
after 1 year of treatment. 
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Table 4. Univariable regression analysis of ∆BMD after 1 year of follow-up, in tertiles with high, low and no 
BMD loss, at the spine and the hip (dependent variables) and disease and demographic variables 
(independent variables).  
RR (95% CI) High BMD loss Low BMD loss No BMD loss 
Age, years, ‡ 1.02 (1.01-1.03) 1.00 (0.99-1.01) ref 
Female, †  1.64 (1.08-2.53) 1.55 (1.03-2.46) ref 
Postmenopausal women, † 1.44 (1.22-1.57) 1.18 (0.90-1.40) ref 
Current smokers, ‡ 1.13 (0.78-1.50) 1.39 (1.01-1.75) ref 
BMI, kg/m2, † 0.99 (0.96-1.02) 1.01 (0.97-1.04) ref 
SHS baseline‡ 1.03 (1.01-1.05) 0.99 (0.98-1.02) ref 
SHS progression >SDC, † 1.99 (1.13-3.84) 2.41 (1.19-4.40) ref 
DAS baseline, † 1.01 (0.86-1.17) 1.02 (0.87-1.18) ref 
∆DAS after 6 months, † 1.16 (0.92-1.47) 1.06 (0.84-1.34) ref 
HAQ baseline, † 1.17 (0.97-1.36) 1.07 (0.87-1.27) ref 
∆HAQ after 6 months, † 1.03 (0.69-1.54) 1.31 (0.86-1.98) ref 
Positive RF, † 1.03 (0.82-1.20) 0.96 (0.75-1.15) ref 
Bisphosphonates-users, † 0.34 (0.13-0.77) 0.44 (0.20-0.93) ref 
Vitamin D and/or calcium, † 0.66 (0.36-1.15) 0.71 (0.39-1.20) ref 
The tertile with no BMD loss is used as reference population. † at spine; ‡ at total hip; RR (95% CI) (relative risk    
(95%  confidence interval)); BMI (body mass index); RF (rheumatoid factor); DAS (disease activity score); 
HAQ (health assessment questionnaire); total SHS (Sharp-van der Heijde score); SDC (smallest detectable  change). 
 
Table 5. Multivariable regression analysis of ∆BMD after 1 year of follow-up, in tertiles with high, low and 
no BMD loss, at the spine and the hip (dependent variables) and disease and demographic variables 
(independent variables).  
RR (95% CI) High BMD loss Low BMD loss No BMD loss 
SHS baseline, ‡ 1.03 (1.01-1.05) 0.99 (0.98-1.02) ref 
SHS progression >SDC, † 1.95 (1.06-3.80) 1.94 (1.07-3.10) ref 
Bisphosphonates-users, † 0.44 (0.23-0.87) 0.54 (0.32-0.96) ref 
The tertile with no BMD loss is used as reference population. † at spine, ‡ at total hip. All variables are adjusted for age, 
sex, menopausal status, race, smoking status and alcohol status; symptom duration and RF (rheumatoid factor) status are 
additionally adjusted for symptom duration, RF status,  disease activity score, health  assessment questionnaire and total 
SHS (Sharp-van der Heijde score), except for themselves. Further, use of bisphosphonates was adjusted for use of vitamin 
D, calcium, hormone replacement therapy and intra-articular steroids. RR (95% CI) (relative risk (95% confidence 
interval)); SDC (smallest detectable change).  
 
Multivariable analyses Variables that showed significant associations with BMD loss in the 
univariable analyses where entered in a multiple regression analyses, adjusted for possible 
confounders. Total SHS at baseline and SHS >SDC were independently associated with BMD loss 
in the hip and spine, respectively (table 5). Bisphosphonates, adjusted for other anti-resorptive 
treatment, independently protected against BMD loss in the spine. 
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Discussion 
 
In this large longitudinal study we examined the changes in BMD in 342 patients with recent onset, 
active RA after 1 year of treatment in the BeSt study. The main finding of this study is that there 
are no differences between the treatment groups, including treatment strategies using quickly  
tapered high-dose of corticosteroids and the anti-TNFα infliximab, considering changes in BMD 
after 1 year of follow-up. The independent disease-related determinants of BMD loss in these 
patients were joint damage at baseline, joint damage progression and non-use of bisphosphonates. 
Since BMD change is dependent of many population-specific factors, such as genetic factors, race, 
environmental and dietary influences, age and gender, it is important to compare our data on BMD 
loss with data in the general Dutch population. The Rotterdam study, a population-based 
longitudinal cohort study of 4333 men and women, aged ≥55 years, with BMD measured in the 
femoral neck at baseline and after 2 years, showed a BMD change of -0.4% in men and -0.6% in 
women.[38] In our population, patients aged ≥55 years showed a BMD change of -1.4% in men 
and -1.5% in women in the hip after 1 year. This suggests that the BMD loss in our patients with 
recently diagnosed RA patients treated for 1 year in the BeSt trial is higher compared to the general 
Dutch population, however comparisons should be done with caution due to demographic 
differences between the two populations. 
In previous longitudinal studies, annual BMD changes ranged from -0.3% to -2.4% in the lumbar 
spine and from -0.1% to -4.3% in the hip.[27-29,39-41] The magnitude of BMD loss 
demonstrated in the present study was generally less. An explanation for the relatively small BMD 
loss in our population is the strict monitoring of the disease activity with adequate adjustments in 
treatment during disease flares, DAS >2.4, to suppress the inflammation, which is a risk factor for 
bone loss, immediately. Further, the use of anti-resorptive agents was not allowed in some of the 
previous studies.  
Numerous previous studies had shown glucocorticoid-induced high bone loss in RA 
patients.[16,39] In contrast we did not find more BMD loss in the initial combination group with 
high dose of prednisone compared to the other treatment groups. In line with our results, 
Verhoeven et al. did not find differences in BMD loss between patients treated with SSZ 
monotherapy and combination therapy with high dose prednisone, almost similar to group 3 in our 
study, in patients with early (disease duration <2 years) active RA who were treated for a period of 
56 weeks.[13] A plausible explanation for this is that the beneficial effect of corticosteroids on 
BMD by quick, aggressive suppression of inflammation outweighs the negative influence. 
Several studies showed some inconsistencies concerning the influence of anti-TNFα agents on bone 
loss.[18-20] After 1 year of treatment with infliximab, Vis et al. showed in 102 RA patients 
unchanged BMD in the spine and hip [18], while Lange et al. even showed a significant increase in 
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BMD in 26 RA patients.[19] In the present study, infliximab was not associated with less BMD loss 
compared with the other treatment strategies after 1 year.  
The determinants of BMD loss in this study were joint damage at baseline, joint damage 
progression and the non-use of bisphosphonates. Our results are in line with the results of Forslind 
et al., who showed in recently diagnosed, female RA patients that lower BMD was associated with 
more radiographic damage after 2 years of treatment with DMARDs.[26] Jensen et al. found in 
polyarthritis patients with disease duration <2 years that patients with erosive disease had more 
BMD loss in the hand/forearm than patients with non-erosive disease.[42] The association between 
joint damage and BMD loss suggests that pathophysiological processes involved in generalized 
osteoporosis appear to be common to local destructive joint involvement. This hypothesis is 
strengthened by the finding that osteoclasts, stimulated mostly by RANKL, play a central roll in 
both pathophysiological mechanisms.[22-24]  
Other disease-related factors such as DAS were not associative with BMD loss in our population, 
probably due to the aggressive suppression of the DAS with the DAS-steered treatment.  
Unfortunately, the guidelines for anti-osteoporotic treatment in osteopenic or osteoporotic patients 
were poorly implemented by the rheumatologists in our study. Only 43% of the patients who 
needed bisphosphonates were actually prescribed oral bisphosphonates. In line with previous 
studies, the use of bisphosphonates independently protected against BMD loss.[43-45] Our data 
support that calcium and/or vitamin D alone might be ineffective to reduce BMD loss.[34]  
In conclusion, in patients with recently diagnosed RA, suppression of inflammation with any 
aggressive, effective treatment strategy is essential for preserving BMD. Because of the relationship 
between joint damage and BMD loss, disease activity should be suppressed as early and aggressively 
as possible, not only to prevent future disability due to erosive joint damage but also to prevent high 
BMD loss and associated risks. Furthermore, treatment with bisphosphonates is necessary in order 
to prevent further BMD loss. 
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Abstract 
 
Objectives To evaluate changes in bone mineral density (BMD) in the hands, hip and spine after 1 
and 2 years of follow-up, in relation to antirheumatic and antiresorptive therapies and disease and 
demographic variables in patients with recent-onset rheumatoid arthritis (RA).  
Methods Changes in BMD measured in the metacarpals 2-4 by digital X-ray radiogrammetry and 
in the hip and spine by dual energy X-ray absorptiometry were assessed at baseline and after 1 and 2 
years of follow-up in 218 recent-onset RA patients from the BeSt study, who received one of four 
treatment strategies: sequential monotherapy (group 1), step-up combination therapy (group 2), 
initial combination therapy with tapered high-dose prednisone (group 3), or initial combination 
therapy with infliximab (group 4). 
Results After 1 and 2 years, there was significant BMD loss in all locations, with significantly 
greater BMD loss in the hands than generalized BMD loss in the hip and spine. Initial combination 
therapy with prednisone or infliximab were associated with less hand BMD loss compared with 
initial monotherapy after 1 and 2 years (-0.9 and -1.6%, -0.6 and -1.4%, -1.7 and -3.3%, and -2.6 
and -3.6% for group 4-1 after 1 and 2 years, overall p=0.001 and p=0.014, respectively).  
Progression in erosions was independently associated with increased BMD loss both in the hands 
and hip after 1 year. The use of bisphosphonates protected only against generalized BMD loss in 
the hip and spine. 
Conclusion The association between joint damage progression and both hand and generalized 
BMD loss in RA suggests common pathways between these processes, with hand BMD loss 
occurring earlier in the disease course than generalized BMD loss. 
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Erosions and hand and generalized bone mineral density (BMD) loss in rheumatoid arthritis 
(RA)[1-3] results in functional disability and increased risk of clinical fractures.[4-6] Recent studies 
suggest that pathophysiological mechanisms of focal erosions and hand and generalized BMD loss 
have common pathways mediated by osteoclasts, in particular by the receptor activator of nuclear 
factor-κβ ligand.[7-9]  Clinical studies evaluating BMD in the hands and generalized BMD in the 
hip and spine of patients with early RA showed associations between high BMD loss and disease 
severity, as measured by inflammation parameters, (progressive) joint damage and functional 
disability.[10-14] 
In RA patients, corticosteroids decrease generalized BMD loss by suppression of inflammatory 
activity, but as a side effect, also increase BMD loss.[14-19] Treatment with tumor necrosis factor 
alpha antagonist (anti-TNFα) might protect against generalized BMD loss.[20-22] However, little 
is known about the effect of corticosteroids [23] and anti-TNFα [21] on hand BMD loss. While 
the efficacy of calcium and vitamin D supplements remains inconclusive, use of bisphosphonates 
has been shown to protect against, especially corticosteroid-induced, generalized BMD loss.[24-28] 
The influence of antiresorptive treatment on hand BMD loss is unclear.[29] 
To investigate the possible common pathological mechanisms of erosions and hand and generalized 
BMD loss and the effects of different antirheumatic and antiresorptive treatments on BMD loss, we 
assessed the influence of disease-related factors, antirheumatic treatment strategies and 
antiresorptive treatments on BMD loss in the hands, hip and spine after 1 and 2 years of follow-up 
in patients with recent-onset, active RA.  
 
Patients and Methods 
 
Patients and therapy Details of the BeSt study [30] and one-year changes in generalized BMD loss in 
the hip and the spine from this cohort [14] have been previously reported. This study included 218 
of 508 patients from 8 investigative centers with analogue hand radiographs and dual energy X-ray 
absorptiometry (DEXA) measurements of the hip and the lumbar spine at baseline and 1 and 2 
years follow-up. Inclusion criteria were diagnosis of RA as defined by the ACR 1987 revised criteria, 
symptom duration <2 years, age ≥18 years, and active disease with ≥6 of 66 swollen joints, ≥6 of 68 
tender joints and either an erythrocyte sedimentation rate (ESR) of ≥28 mm/hour or a visual 
analogue scale (VAS) global health of ≥20 mm on a scale of 100 mm. Exclusion criteria included 
previous treatment with DMARDs other than antimalarias and estimated creatinine clearance 
<75%. Patients were randomized to one of the four treatment strategies: sequential monotherapy 
(group 1), step-up combination therapy (group 2), initial combination therapy with tapered high-
dose prednisone (group 3), or initial combination therapy with infliximab (group 4). Treatment 
was adjusted using three monthly calculations of the disease activity score (DAS, based on a 44 joint 
count), with patients progressing to the next treatment step in the protocol if DAS >2.4.  
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Calcium supplement (500-1000 mg/day) was recommended to patients with <1000 mg/day 
calcium intake and vitamin D supplement (colecalciferol 400 IE/day) to patients with serum 
vitamin D level below the local reference value. Antiresorptive therapy with oral alendronate (10 
mg/day or 70 mg/week) or risedronate (5 mg/day or 35 mg/week) was advised to non-corticosteroid 
users with a BMD T-score ≤-2.5 SD in the spine and/or hip and to corticosteroids users with a T-
score ≤-1 SD. The ethics committee at each participating centre approved the study protocol and all 
patients gave written informed consent. 
Hand BMD measurements Standard analogue radiographs of both hands in posteroanterior position, 
digitalized by a high-resolution 300 DPI scanner (Canon Vidar VXR-12 plus), were used to 
measure BMD by digital X-ray radiogrammetry (DXR).[31] Digital radiographs taken at baseline 
and/or during the follow-up period were excluded from the analyses due to lack of comparability 
between the different imaging devices. Mean surrogate hand BMD was calculated from cortical 
thickness from regions of interest measured at the centre of the second, third and fourth 
metacarpals through an automated analysis of a standard projection digital radiograph of the hands 
using the DXR online technology (Sectra, Sweden). Hand BMD measured by DXR seems superior 
to other BMD measurement devices in detecting inflammation related bone loss in patients with 
arthritis.[32-34] To avoid biasing dominant and non-dominant hands and to achieve better 
precision, the mean of both hands was used for the analyses.  
Generalized BMD measurements BMD measurements of the left total hip and the lumbar spine L2-
L4 posteroanterior view at baseline and 1 and 2 years follow-up were performed where DEXA was 
available, using a Hologic 4500 QDR (Hologic, Waltham, MA, USA) in four centers and a Lunar 
DPX (Lunar, Madison, WI, USA) in four centers. All procedures were performed in accordance 
with the manufacturer’s standardized procedures for hip and spine BMD measurements. Despite 
differences between the densitometers, the rates of change in BMD, calculated from serial 
measurements assessed for each patient by the same machine, measurement procedure and 
references, are comparable.[35]  
Clinical measurements The following variables were collected at baseline: symptom duration and 
serum IgM rheumatoid factor (RF); at baseline and three monthly: age, body mass index (BMI), C-
reactive protein (CRP) levels, the use of calcium and vitamin D supplements, hormone replacement 
therapy (HRT) and bisphosphonates, and functional ability as measured by the Dutch validated 
health assessment questionnaire (HAQ); and at baseline and after 1 and 2 years of follow-up: 
menopausal status, age at menopause, smoking status, alcohol status, previous clinical fractures, 
osteoporosis in first degree relatives, estimated daily calcium intake and 25[OH]vitamin D levels. 
The presence of anti-citrullinated protein antibody (ACPA) was determined from serum samples 
obtained at baseline or during follow-up.  
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Disease activity was assessed three-monthly using the DAS, based on the ESR, the number of 
swollen joints and the ritchie articular index for pain in tender joints in a 44 joint count and the 
VAS for patient’s global assessment of disease activity (0-100 mm, 0=best and 100=worst).[36] 
Radiographic joint damage was assessed using the Sharp-van der Heijde score (SHS), scored after 1 
and 2 years of follow-up by two independent physicians blinded for patient-level data and 
treatment assignment. After 1 year, the intra-observer coefficients were 0.93 and 0.94, and the 
interobserver coefficient was 0.93. Erosive disease at baseline was defined as erosion score >0.5. 
Progression of joint damage after 1 year was defined as progression greater than the smallest 
detectable change (SDC), calculated as 4.18 points in the first year of follow-up. 
Statistical analysis All analyses were performed in an intention-to-treat method using all available 
data. Changes in BMD were expressed as changes at 1 and 2 years follow-up in absolute BMD 
values compared with baseline BMD in percentages. Non-parametric tests were performed to 
compare the median percentages of BMD loss in the hands, hip and spine between the treatment 
strategies. The p-values derived by these tests were corrected for multiple comparisons by the step-
down Bonferroni-Holmes adjustment. Multivariable regression analyses, adjusted for the use of 
bisphosphonates, vitamin D and calcium supplements, HRT and intra-articular steroids and 
changes in DAS, HAQ and SHS during follow-up, were used to compare the treatment strategies, 
independently of differences in antiresorptive treatment and disease activity between the groups. 
Association among disease-related variables and changes in BMD in the different measurement sites 
were analyzed by univariable regression analysis. Potential independent predictors of BMD loss 
were evaluated by stepwise multivariable regression analyses performed as forward (conditional) 
procedures, adjusted for treatment group. All tests were two-tailed and p-values ≤0.05 were 
considered statistically significant. 
 
Results 
 
Patient characteristics In 218 patients BMD measurements in the hands, lumbar spine and total left 
hip were performed at baseline and 1 and 2 years follow-up. In 27 patients no hand BMD 
measurements were performed after 1 or 2 years due to logistic reasons and in 20 patients no BMD 
in the hip or spine measurements after 1 or 2 years were performed due to logistic reasons and in 2 
cases due to bilateral hip prothesis. 
The baseline demographic and disease variables were not significantly different between the four 
treatment groups (table 1) or with the rest of the BeSt study population (n=290) (data not shown). 
The majority of patients were middle-aged, postmenopausal women with recent-onset RA. All 
patients had active disease with a mean (SD) DAS of 4.4 (0.9) and median symptom duration of 23 
weeks and 69% of patients had erosive disease at baseline.  
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Table 1. Baseline demographic and disease characteristics of 218 RA patients. 
  
Sequential 
monotherapy 
 
n=55 
Treatment group 
Step-up 
combination 
therapy 
n=46 
 
Initial 
combination 
with prednisone 
n=65 
 
Initial 
combination 
with infliximab 
n=52 
Demographic variables     
Age, years, † (n=218) 55 (13) 54 (14) 55 (14) 54 (15) 
Caucasian race, % (n=218)  95 94 95 94 
Women, % (n=218)  71 83 62 69 
Postmenopausal, % (n=153) 69 62 64 65 
Age at menopause, years, † 48 (5) 47 (5) 46 (5) 48 (6) 
BMI, kg/m2, † (n=216) 26 (4) 25 (4) 25 (4) 25 (4) 
Current smoker, % (n=218) 
Cigarettes/day, ‡ 
47 
12 (6-23) 
35 
10 (10-19) 
35 
15 (7-24) 
27 
14 (7-18) 
Previous clinical fractures >30 years, 
% (n=218)  
Postmenopausal fractures, % 
9 
 
0 
15 
 
9 
17 
 
8 
12 
 
6 
Familial osteoporosis, % (n=218) 15 15 15 21 
Disease related variables  
Symptom duration, weeks, ‡ 
(n=218) 
18 (12-55) 24 (15-41) 22 (13-56) 23 (13-38) 
Positive IgM RF, % (n=218) 64 65 63 62 
DAS, † (n=218) 4.6 (0.9) 4.5 (0.9) 4.4 (0.8) 4.2 (0.9) 
CRP levels, ‡ (n=218) 29 (10-65) 18 (7-38) 21 (10-61) 33 (7-36) 
HAQ score, 0-3 scale, † (n=218) 1.5 (0.7) 1.5 (0.6) 1.4 (0.6) 1.2 (0.7) 
Total SHS, 0-448 scale, ‡, †, 
(n=216) 
4.0 (1.3-7.8) 
6.0 (6.7) 
2.8 (1.0-7.5) 
5.8 (7.7) 
3.5 (1.5-7.3) 
4.9 (5.0) 
4.3 (1.0-9.5) 
6.2 (6.6) 
Total erosions, 0-280 scale, ‡, † 2.0 (1.0-4.0) 
3.0 (3.3) 
1.3 (0.0-4.1) 
3.2 (4.6) 
1.5 (0.5-4.0) 
2.8 (3.4) 
2.5 (0.5-6.8) 
4.0 (4.6) 
Total JSN, 0-168 scale, ‡, † 1.0 (0.0-4.0) 
3.0 (4.2) 
1.3 (0.0-4.5) 
2.6 (3.6) 
1.5 (0.0-3.3) 
2.1 (2.5) 
1.5 (0.0-3.0) 
2.2 (3.0) 
Erosive disease, % (n=216) 77 61 68 69 
Calcium intake, mg/day, † (n=218) 875 (337) 889 (369) 930 (326) 881 (350) 
25(OH)vitamin D level, nmol/l, † 
(n=175) 
53 (26) 47 (27) 50 (25) 60 (31) 
† mean (standard deviation); ‡ median (interquartile range); BMI (body mass index); RF (rheumatoid factor); DAS 
(disease activity score); CRP (C-reactive protein); HAQ (health assessment questionnaire); SHS (Sharp-van der Heijde   
Score); JSN (joint space narrowing). 
 
Osteoporosis treatment The use of osteoporosis treatment during the follow-up is summarized in 
table 2. Of patients advised to take bisphosphonates, only 45% were actually prescribed oral 
bisphosphonates, of which 66% received alendronate and 34% received risedronate. Thirty-nine  
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Table 2. Osteoporosis treatment during first year and first two years of follow-up of 218 RA patients.  
 Sequential 
monotherapy 
n=55 
Step-up  
combination therapy 
n=46 
Initial combination 
with prednisone 
n=65 
Initial combination  
with infliximab 
n=52 
Bisphosphonates use,  
% (n=218) 
7  
15 
9  
17 
29  
32 
4  
15 
No. of months used  
during follow-up, ‡ 
9 (7-11) 
11 (7-12) 
8 (4-9) 
12 (5-12) 
9 (6-9) 
10 (9-12) 
9 (6-12) 
9 (6-12) 
Calcium suppl.,  
% (n=218) 
20 
22 
20 
30 
43 
46 
19 
31 
No. of months used  
during follow-up, ‡ 
9 (6-12) 
12 (12-12) 
9 (2-11) 
12 (11-12) 
9 (8-11) 
12 (6-12) 
9 (8-12) 
12 (10-12) 
Vitamin D suppl., 
 % (n=218) 
6 
11 
15 
22 
22 
22 
10 
12 
No. of months used  
during follow-up, ‡ 
6 (6-12) 
6 (3-12) 
9 (6-9) 
12 (11-12) 
9 (5-9) 
12 (8-12) 
9 (8-11) 
12 (11-12) 
HRT use,  
% (n=213) 
15 
15 
15 
14 
8 
8 
15 
19 
No. of years used ‡ 9 (3-17) 
9 (4-19) 
15 (2-19) 
14 (4-21) 
5 (4-17) 
7 (5-19) 
6 (2-16) 
7 (2-16) 
Intra-articular steroids 
injections (min 1-max 6),  
% (n=218) 
33 
13 
17 
4 
8 
12 
10 
6 
‡ median (interquartile range); HRT(hormone replacement therapy). 
 
percent of patients with low calcium intake received calcium supplement, and 40% of patients with 
25(OH)vitamin D levels below the reference value received vitamin D supplement during the 2 
years of follow-up. Forty-five percent of the patients taking calcium and vitamin D supplements 
were also taking bisphosphonates. Bisphosphonates were prescribed to significantly more patients in 
group 3 (initial combination therapy including prednisone) than in the other groups (29% versus 4-
9%, overall p <0.0001, and 32% versus 15-17%, overall p=0.05 during first and first two years of 
follow-up, respectively); and more patients in group 3 used calcium supplements (43% versus 19-
20%, overall p=0.005 and 46% versus 22-31%, overall p=0.039, respectively). There was a trend for 
increased vitamin D supplements use by patients in group 3 during the first year of follow-up (22% 
versus 6-15%, overall p=0.057). More patients received intra-articular steroid injections in groups 1 
and 2 than in groups 3 and 4 during the first year of follow-up (overall p=0.001).   
Changes in hand and generalized BMD loss After 1 year of treatment, the median (IQR) change from 
baseline in hand BMD was approximately -1.4% (-3.6% to 0.1%; p <0.0001) in the hands 
compared with -0.9% (-2.9% to 1.7%; p <0.0001) in generalized BMD in the hip and -0.5%  
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Table 3. Median (interquartile range) BMD change in the hands, hip and spine, in percentages of baseline, in 
the 4 treatment groups after 1 and 2 years of follow-up. 
 Sequential 
monotherapy 
Step-up  
combination therapy 
Initial combination 
with prednisone 
Initial combination 
with infliximab 
BMD loss in hands 
After 1 year 
After 2 years 
 
-2.6 (-5.4 to -0.8) 
-3.6 (-6.8 to -1.4) 
 
-1.7 (-5.1 to -0.1) 
-3.3 (-6.8 to -0.2) 
 
-0.6 (-2.2 to 0.3) 
-1.4 (-5.4 to -0.1) 
 
-0.9 (-2.8 to 0.5) 
-1.6 (-4.7 to 0.3) 
BMD loss in hip 
After 1 year 
After 2 years 
 
-1.6 (-3.5 to 1.1) 
-1.1 (-2.9 to 2.0) 
 
-0.4 (-2.7 to 2.3) 
-0.2 (-2.6 to 2.3) 
 
-1.0 (-4.6 to 1.7) 
-0.2 (-2.6 to 3.2) 
 
-0.6 (-2.7 to 2.1) 
-0.6 (-3.3 to 2.0) 
BMD loss in spine 
After 1 year 
After 2 years 
 
-0.2 (-2.8 to 2.0) 
-0.4 (-4.6 to 2.6) 
 
-1.1 (-2.5 to 1.4) 
-1.6 (-4.6 to 1.1) 
 
-1.0 (-2.7 to 1.8) 
-0.5 (-3.9 to 2.1) 
 
-0.1 (-3.1 to 1.1) 
-1.0(-3.3 to 1.4) 
 
(-2.8% to 1.5%; p <0.0001) in the spine. Hand BMD loss was significantly greater than generalized 
BMD loss after 1 year (hand versus hip p=0.004, hand versus spine p <0.0001, hip versus spine 
p=0.43). 
After 2 years of treatment, the median (IQR) change in BMD was approximately -2.5% (-6.0% to  
-0.2%; p <0.0001) in the hands compared with -0.5% (-2.8% to 2.1%; p <0.0001) in the hip and 
 -1.0% (-3.9% to 1.6%; p <0.0001) in the spine. Hand BMD loss remained significantly greater 
than generalized BMD loss (hand versus hip and spine p <0.0001, hip versus spine p=0.46). 
Effect of treatment strategies on BMD changes In univariable analyses, patients in the initial 
monotherapy strategy (groups 1) had significantly more hand BMD loss in the hands after 1 year 
than patients in the initial combination therapies (groups 3 and 4) (-2.6, -1.7, -0.6 and -0.9% for 
group 1-4, respectively, overall p=0.001, group 1 versus 3 p=0.000, group 1 versus 4 p=0.021, group 
2 versus 3 p=0.038, group 2 versus 4 p=0.101, table 3).  
Multivariable regression analyses, adjusted for differences in use of antiresorptives between the 
treatment strategies during follow-up, also showed significant less BMD loss in the hands in the 
initial combination therapies (data not shown). The amount of BMD loss in the hands was 
associated with disease severity (figure 1).  
Multivariable regression analyses, adjusted for differences in antiresorptives and changes in disease 
activity (DAS, HAQ and SHS after 1 year) between the groups, showed no significant differences in 
hand BMD loss between the treatment strategies anymore (data not shown). Differences in hand 
BMD loss between the treatment groups remained significant after two years of treatment in 
univariable analyses (-3.6, -3.3, -1.4 and -1.6% for group1-4, respectively, overall p=0.014, group 1 
versus 3 p=0.009, group 1 versus 4 p=0.033, group 2 versus 3 p=0.204, group 2 versus 4 p=0.216). 
However, after correction for disease activity and use of antiresorptives, hand BMD loss was again 
no longer statistically significant between the treatment groups (data not shown). There were no 
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Figure 1. The mean hand BMD loss (in percentages from baseline) and Sharp-van der Heijde (SHS) erosion 
score increase (points) in the 4 treatment groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hand BMD: bone mineral density in the hands measured by digital X-ray radiogrammetry. After 1 year of follow-up, 
significant differences in increase in SHS erosion score between the 4 treatment groups: 1 versus 3 (p=0.038), 1 versus 4 
(p=0.023), 2 versus 3 (p=0.030), 2 versus 4 (p=0.018) and significant differences in BMD loss in the hands between the 4 
treatment groups: 1 versus 3 (p=0.000), 1 versus 4 (p=0.021), 2 versus 3 (p=0.038), 2 versus 4 (p=0.10). After 2 years of 
follow-up, significant differences in changes in SHS erosion score between the 4 treatment groups: 1 versus 3 (p=0.001), 1 
versus 4 (p=0.001), 2 versus 3 (p=0.072), 2 versus 4 (p=0.080) and significant differences in BMD loss in the hands 
between the 4 treatment groups: 1 versus 3 (p=0.009), 1 versus 4 (0.033), 2 versus 3 (p=0.20), 2 versus 4 (p=0.22). 
 
statistically significant differences between the four treatment groups in generalized BMD loss in 
the hip (overall p=0.42 and p=0.52 after 1 and 2 years of follow-up, respectively) and the spine 
(overall p=0.52 and p=0.93, respectively).[14]  
Given the dynamics of DAS-directed treatment adjustments in all four treatment groups, patients 
who started treatment with prednisone (group 3) were eligible for discontinuation of that drug after 
at least 28 weeks (at two years, 82% had discontinued prednisone due to good response or failure to 
respond), whereas patients who did not respond to previous DMARD therapy in groups 2 (step up  
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Table 4. Demographic and disease factors associated with BMD loss in the hands, hip and spine after 1 year 
derived by univariable regression analyses. 
 BMD loss in hands BMD loss in hip BMD loss in spine 
 
Beta 
coefficient 
P-
value 
Beta 
coefficient 
P-
value 
Beta 
coefficient 
P-
value 
Demograhic variables 
Age, years -0.068 0.002 -0.032 0.19 0.012 0.56 
Female gender 0.26 0.71 0.55 0.46 -0.37 0.55 
Postmenopausal status -3.26 0.000 -0.67 0.43 -0.30 0.68 
Smoking status -1.43 0.027 0.801 0.26 0.29 0.62 
BMI, kg/m2 at baseline 0.003 0.97 0.14 0.13 -0.028 0.71 
Disease related variables 
Duration complaints before 
inclusion, weeks 0.002 0.70 0.006 0.19 0.005 0.19 
ACPA positive -0.376 0.55 0.053 0.94 0.721 0.22 
RF positive -1.24 0.055 -0.050 0.94 0.53 0.37 
DAS at baseline -0.068 0.85 -0.18 0.67 0.062 0.85 
∆ DAS 0-1 year -0.26 0.33 -0.23 0.45 0.16 0.52 
CRP at baseline -0.028 0.000 0.004 0.636 -0.008 0.290 
∆ CRP 0-1 year 0.032 0.002 -0.004 0.679 0.008 0.388 
HAQ at baseline -1.12 0.036 -0.079 0.13 0.60 0.16 
∆ HAQ 0-1 year -0.42 0.36 -0.44 0.37 0.062 0.88 
Erosions at baseline -0.046 0.56 -0.20 0.015 0.035 0.62 
JSN at baseline -0.057 0.57 -0.035 0.70 -0.037 0.66 
∆ erosions 0-1 year -0.16 0.012 -0.20 0.003 -0.044 0.44 
∆ JSN 0-1 year -0.046 0.37 -0.055 0.34 -0.024 0.62 
BP use 0-1 year 0.14 0.89 2.58 0.008 4.02 0.000 
Ca suppl. 0-1 year -0.060 0.93 1.59 0.037 1.56 0.015 
Vit D suppl 0-1 year 0.32 0.73 1.91 0.052 1.62 0.048 
HRT use 0-1 year 0.56 0.53 -1.02 0.31 -0.19 0.82 
BMI (body mass index); ACPA ( anti-cyclic citrullinated protein antibody); RF (rheumatoid factor); DAS (disease activity  
score); CRP (C-reactive protein); HAQ (health assessment questionnaire); JSN (joint space narrowing); BP 
(bisphosphonates); Ca suppl. ( calcium supplements); Vit D suppl. (Vitamin D supplements); HRT (hormone 
replacement therapy). 
 
to combination therapy) and 4 (initial combination therapy with infliximab) were allowed to begin 
prednisone starting at 12 and 15 months, respectively. In the patients who used prednisone in all 
groups, the mean (SD) cumulative dose was 2428 (388) mg and 2796 (1197) mg per patient during 
the first year and first two years of follow-up, respectively. Subanalyses adjusted for differences in 
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disease activity and anti-osteoporotic treatment in multivariable analyses showed no differences in 
hand or generalized BMD loss after 1 year between patients exposed to and naive to prednisone 
(data not shown). In the second year of follow-up, patients who did not respond to previous 
DMARD therapy in groups 1, 2 and 3 were allowed to receive infliximab. The mean (SD) 
cumulative dose of infliximab in all groups was 29.5 (8.5) mg/kg and 37.0 (21.9) mg/kg per patient 
during the first and the first two years of follow-up, respectively. There were no differences in hand 
or generalized BMD loss after 1 and 2 years between patients exposed to and naive to infliximab 
(data not shown). 
Determinants of BMD loss Univariable linear regression analyses showed that higher age, 
postmenopausal status and current smoking status were associated with greater hand BMD loss 
after 1 year (table 4), but demographic variables were not associated with generalized BMD loss in 
the hip or spine. Of disease-related variables, progression in erosion scores greater than the SDC 
was associated with increased BMD loss both in the hands and hip after 1 year of follow-up. 
Further, higher CRP levels at baseline and a lower decrease in CRP levels after 1 year and higher 
HAQ scores at baseline were associated with increased BMD loss in the hands and higher erosion 
scores at baseline with increased BMD loss in the hip. There was a trend of increased hand BMD 
loss in RF-positive patients after 1 year (p=0.055). The use of bisphosphonates, calcium and vitamin 
D supplements was associated with reduced generalized BMD loss.  
Multivariable regression analyses showed that postmenopausal status was an independent risk factor 
of BMD loss in the hands (table 5). Increase in erosion score after 1 year was associated with both 
greater hand and generalized BMD loss in the hip. Higher CRP levels at baseline were 
independently associated with increased hand BMD loss. The use of bisphosphonates was 
independently associated with reduced generalized BMD loss in both the hip and spine.  
 
Table 5. Demographic and disease related factors associated with BMD loss after 1 year in the hands, hip and 
spine derived by multivariable analyses. 
 BMD loss in hands BMD loss in hip BMD loss in spine 
 
Beta 
coefficient 
P-
value 
Beta 
coefficient 
P-
value 
Beta 
coefficient 
P-
value 
Postmenopausal status -3.17 0.000 - - - - 
CRP at baseline -0.025 0.000 - - - - 
∆erosions 0-1 -0.12 0.021 -0.19 0.004 - - 
BP use 0-1 - - 2.50 0.011 4.02 0.000 
Data are adjusted for the significant associations derived from the univariable analyses and randomization between the 4 
treatment groups. CRP (C-reactive protein); BP (bisphosphonates). 
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Discussion 
 
In this large longitudinal study we compared changes in hand BMD, measured by DXR, with 
changes in generalized BMD in the hip and the spine, measured by DEXA, in 218 patients with 
recent-onset RA after 1 and 2 years of DAS-steered treatment in the BeSt trial. There are several 
important findings. Hand BMD loss was greater than generalized BMD loss in the hip and spine. 
Patients treated with initial combination therapy with tapered high-dose corticosteroids or anti-
TNFα infliximab had less hand BMD loss due to better suppression of inflammation. Both hand 
and generalized BMD loss were associated with progression of radiographic destruction. 
Bisphosphonates protected only against generalized BMD loss.  
In Caucasian populations, the rate of BMD loss in the metacarpals has been found to be about -1.2 
to -1.5% per year after the menopause.[37] In our population, BMD loss was approximately -2.3% 
after 1 year and -4.4% after 2 years in postmenopausal women, indicating that postmenopausal 
patients with recent-onset RA may experience a 2-fold increase in BMD loss in the hands per year, 
despite aggressive suppression of inflammation by DAS-directed treatment. However, comparisons 
should be interpreted with caution due to possible demographic differences between populations.  
BMD loss in the hands is common in recent-onset RA, whereas generalized BMD loss primarily 
occurs during a later course of the disease.[38,39] Despite significant reduction in disease activity 
over the treatment period, BMD loss in the hands was on average 2 to 3 times more severe than 
generalized BMD loss in the hip or spine in our patients. The majority of our patients with hand 
BMD loss had no generalized BMD loss in the hip (72%) and spine (80%) during 2 years of 
follow-up.  
We found significantly more BMD loss after 1 and 2 years in the hands than in the hip and spine. 
There are several possible explanations for this finding. First, two different techniques were used to 
measure different components of the bone: DXR estimates cortical BMD loss and DEXA measures 
both cortical and trabecular BMD loss. This might indicate that the cortical barrier of bone is more 
exposed to inflammation-induced osteoclasts activation than the trabecular site. However, previous 
studies studying BMD loss in the hands by DEXA, the gold standard for bone assessment, also 
reported more severe hand BMD loss compared to generalized BMD loss in RA patients.[40-42] 
Second, greater changes in BMD in the hands, measured by DXR, than in generalized BMD loss, 
measured by DEXA, may be due to the higher precision of the DXR technique and the averaging of 
three bones in one hand and the averaging of both hands.[31] As a result, DXR may be more 
sensitive in tracing changes in BMD loss than DEXA. Third, the process of hand BMD loss may be 
more sensitive to or more directly influenced by cytokine stimulation originating in adjacent 
inflamed synovial tissue compared to the process of generalized BMD loss at locations with 
undetected local inflammation. Fourth, hand BMD loss that is more severe and difficult to suppress 
may be a reflection of ongoing inflammation that remains undetected by clinical observation. 
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Previously, Brown et al. showed synovitis detected with MRI in RA patients in clinical 
remission.[43] Lastly, the protective effect of bisphosphonates was only observed against 
generalized, and not hand, BMD loss. A previous study showed that bisphosphonates were effective 
against hand BMD loss in non-RA patients.[29] To our knowledge, this is the first study measuring 
the effect of antiresorptive treatment on hand BMD loss in patients with recent-onset RA. A 
possible explanation for the conflicting results is that the inflammation nearby the metacarpals may 
counteract the antiresorptive effect of bisphosphonates due to high resorptive activity of the 
osteoclasts. A limitation to our study is that the guidelines for anti-osteoporotic treatment in 
osteopenic and osteoporotic patients were poorly implemented: only 45% of patients requiring 
bisphosphonates were actually prescribed bisphosphonates during the two years of follow-up. 
However, despite the low prescription, the use of bisphosphonates protected against generalized 
BMD loss.   
We found significantly less hand BMD loss in the initial combination group with high-dose 
prednisone compared with the initial monotherapy groups. In a previous double-blind study 
comparing oral prednisolone 7.5 mg/day for 2 years with placebo in early RA patients, the 
prednisone group had less hand BMD loss measured by DXR after 1 and 2 years.[23] This suggests 
that the benefits from quick effective suppression of disease activity with corticosteroids exceed the 
direct negative influence on hand BMD. We did not find differences in changes in BMD in the hip 
and the spine after 1 and 2 years follow-up between the initial group with prednisone and the other 
treatment groups.[14,17]  
In our study, patients who received initial combination therapy with infliximab had significantly 
less hand BMD loss than patients who received conventional therapy in groups 1 and 2 after 1 year, 
but there were no differences in generalized BMD loss. In a group of 102 RA patients with disease 
duration of 1-49 years, Vis et al. showed consistent BMD in the spine and hip but significant BMD 
loss in the hands (-0.8%) after 1 year of treatment with infliximab.[21] However, comparisons 
should be interpreted with caution due to differences in demographic and RA-related variables 
between the two populations, such as use of antiresorptives and shorter disease duration in our 
population, which is associated with more rapid hand BMD loss.[44] 
The independent associations between focal erosions and hand and generalized BMD loss support 
the current understanding that these three processes share common pathways mediated by the 
cellular action of osteoclasts.[7,45,46] BMD loss involves elevated bone loss in the hands in the 
early course of the disease and generalized BMD loss often during a later phase of RA. 
In conclusion, in patients with recent-onset RA, the suppression of inflammation with effective 
treatment strategies is essential for bone preservation. The association between progressive erosive 
disease and high hand and generalized BMD loss indicates common pathophysiological 
mechanisms, hand BMD loss occurring more often in the early phase of the disease than generalized 
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BMD loss. Identifying therapeutic opportunities to prevent or treat all these forms of bone loss in 
patients with rheumatoid arthritis remains a challenge.  
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Abstract 
 
Objective To investigate the differences in one year changes in metacarpal bone mineral density 
(mBMD) between patients with continuous high (DAS >2.4) or low (1.6≥DAS≤2.4) disease 
activity and patients in continuous remission (DAS <1.6). 
Methods mBMD measurements were performed by DXR in 145 out of 508 patients with 
rheumatoid arthritis (RA) participating in the BeSt study, of which radiographs at baseline and 
follow-up were available in the same format (both analogue or both digital). The association of 
mBMD changes with disease activity was investigated with multivariable multinomial regression 
analysis. Next, clinical variables associated with mBMD gain were identified. 
Results Patients in continuous remission (CR, DAS <1.6 for at least 1 year) had a mean mBMD 
loss of -0.03%, compared to -3.13% and -2.03% for patients with continuous high (HDA, DAS 
>2.4) and low disease activity (LDA, 1.6≤DAS≤2.4), respectively (overall, p< 0.001). Forty-four 
percent of the patients in CR had mBMD loss (≤-3 mg/cm2/year), compared to 70% and 68% of 
the patients with HDA or LDA, whereas 35% of the patients in CR had mBMD gain (≥3 
mg/cm2/year), compared to 6% of the patients with HDA and 11% of the patients with LDA. 
Patients in CR had, compared with HDA, a higher chance of having mBMD gain (OR (95% CI) 
7.5 (1.2-34.2), p=0.013, RR (95% CI) 2.8 (1.3-3.6)), and there was a trend towards a higher 
chance of mBMD gain compared to patients with LDA (OR (95% CI) 4.3 (0.98-18.5), p=0.054, 
RR (95% CI) 2.3 (0.98-3.3)). Continuous remission and a lower age were the only significant 
independent predictors of mBMD gain.  
Conclusion In recent onset RA, increase in metacarpal BMD occurs primarily in patients in 
continuous (≥1year) remission (DAS <1.6) and rarely in patients with a continuous high (DAS 
>2.4) or low (1.6≤DAS≤2.4) disease activity. This indicates that mBMD loss is driven by 
inflammation and that remission should be the treatment goal. 
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Bone damage in rheumatoid arthritis (RA) is present in erosions as well as in accelerated bone 
mineral density (BMD) loss.[1,2] BMD loss in RA is believed to precede radiographic joint 
damage.[3,4] It has been observed in very early stages of RA and even in patients with 
undifferentiated arthritis who developed RA later.[5-7]  
It is believed that BMD loss in RA is primarily the effect of an increased osteoclast activity.[8] 
Osteoclast activity is mainly regulated by tumor necrosis factor alpha (TNF-α), interleukin (IL)-1, 
IL-6, IL-17 and receptor activator of nuclear factor kappa B ligand (RANKL).[9-11] Levels of these 
cytokines are high when disease activity is high [12-20] and thus might contribute to bone loss. 
This is supported by the finding that BMD shows more rapid decrease in active disease compared 
to inactive disease.[21,22] Further, it implies that the extent of BMD loss might be different for 
patients with different levels of disease activity. When disease activity is sufficiently suppressed, the 
balance between osteoclast and osteoblast activity may be restored and BMD loss may be prevented 
or regained. This would indicate that BMD gain might be observed, in particular in patients in 
remission.  
Therefore, the aim of this study was to investigate differences in BMD changes over a period of one 
year between patients with high or low disease activity and patients in remission. It was 
hypothesized that inflammation drives BMD loss and that therefore patients might have an increase 
in BMD in the year that they are in remission. 
 
Patients and methods 
 
Patients For the current analysis, all patients participating in the BeSt trial with standard analogue 
radiographs of both hands over 1 year follow-up, and digital photographs of both hands at the two 
time points were selected. From these, patients with continuous (at all time points during that year 
of follow up) remission (disease activity score (DAS) <1.6), low disease activity (DAS ≥1.6 but ≤2.4) 
or high disease activity (DAS >2.4) were selected. The result is a subpopulation of 145 of the 
original 508 patients participating in the BeSt trial.  
The BeSt trial is a multi-centre, randomized clinical trial comparing four different treatment 
strategies in DMARD-naïve patients who fulfilled the revised inclusion criteria for RA as defined by 
the American College of Rheumatology (ACR) in 1987. Patients were randomized to one of the 
four treatment strategies: sequential monotherapy; step-up therapy; initial combination therapy 
with tapered high-dose of prednisone; or initial combination therapy including infliximab. 
Treatment adjustments were made every three months aiming at a DAS ≤2.4. More details on the 
BeSt study design were previously published.[23-25]  
Hand bone mineral density measurements Digital X-ray radiogrammety (DXR) was used to measure 
metacarpal BMD (mBMD).[26] The analogue radiographs were first digitalized by a high-
resolution 300 DPI scanner (Canon Vidar VXR-12 plus), before mBMD was measured.  
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Mean surrogate mBMD was calculated from cortical thickness at the centre of metacarpals II, III 
and IV through an automated analysis of a standard projection digital radiograph of the hands 
using DXR online technology (Sectra, Sweden). Mean mBMD of both hands was used for the 
analysis in order to avoid bias of the dominant and non-dominant hands. mBMD loss was defined 
as a change in mBMD ≤-3 mg/cm2/year, mBMD gain was defined as a change in mBMD ≥3 
mg/cm2/year and a stable mBMD was defined as a change of -3>mBMD<3 mg/cm2/year, according 
to specifications of the manufacturers average. 
Baseline and follow-up Depending on the continuous level of disease activity over a one year follow 
up period, patients were divided into three groups: patients with continuous high disease activity 
(DAS >2.4), patients with continuous low disease activity (1.6≤DAS≤2.4) and patients with 
continuous remission (DAS <1.6). ‘Baseline’ in this analysis denotes the start of the one year follow 
up period, not inclusion in the trial. Patients with continuous high disease activity were 
predominantly found in the first year after inclusion while patients in continuous remission were 
particularly found in the third and fourth year after inclusion. As a result, some patients were 
treated with anti-rheumatic medication before the ‘baseline’ (start of the follow up period) 
radiograph was taken and others were not. Therefore, all results were corrected for previous 
treatment with antirheumatic medication. For each individual, all demographic and clinical 
variables were adjusted to their specific ‘baseline’ and ‘follow-up’ values. 
Demographic and clinical variables The following ‘baseline’ variables were collected in all patients: 
age, gender, body mass index (BMI), disease activity score (DAS), functional ability as measured by 
Health Assessment Questionnaire (HAQ), presence of IgM rheumatoid factor and anti-cyclic 
citrullinated protein antibodies (ACPA), arthritic symptom duration, race, current smoking and 
alcohol status, postmenopausal status, osteoporosis in first-degree relatives, the use of 
bisphosphonates, calcium, vitamin D and hormone replacement therapy and lastly current and 
previous use of anti-rheumatic medication. 
Radiographic joint damage was assessed according to the Sharp-van der Heijde method.[27] 
Radiographs were scored by two independent readers in random order who were blinded for patient 
identity and treatment allocation. The interobserver correlation coefficient was 0.93 and the 
intraobserver coefficients were 0.93 and 0.94. The mean score from the readers was used for the 
analysis. 
Statistical analysis ‘Baseline’ characteristics were compared between the three defined patient groups. 
Differences were tested using the chi-square test for categorical data and either one-way analysis of 
variance or Kruskal-Wallis test for continuous data, depending on the distribution of the tested 
variable. Multivariable multinomial regression analyses were performed in order to examine the 
association of changes in metacarpal BMD with disease activity. Disease activity score was first 
entered as a continuous variable (weighed mean of the DAS) and next as a categorical variable 
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(three predetermined groups). With a backward selection procedure, using a p-value of 0.10 as the 
removal criterion, associations between disease activity and BMD were indentified as well as 
significant independent predictors of mBMD gain. All results were adjusted for age, gender, BMI, 
‘baseline’ symptom duration, RF and ACPA status, previous treatment, current treatment and 
antiresorptive therapy. Several obtained odds ratios were corrected into relative risks with the 
formula of Zhang and Yu in order to interpret the magnitude of the associations more 
appropriately.[28] 
Lastly, the association between mBMD and the SHS score was investigated in the three disease 
activity groups with a Kruskal-Wallis one way analysis of variance. The p-values derived in these 
tests were corrected for multiple comparisons by the step-down Bonferroni–Holmes adjustment. All 
tests were two-tailed and p-values <0.05 was considered to be statistically significant. 
 
Results 
 
Patients Patient characteristics, for each defined patient group, are shown in table 1. Taken as a 
whole, the selected patients (n=145) were on average 56 years old, most patients were female (68%) 
and postmenopausal (68%) and 50% and 54% of the patients were RF and ACPA positive, 
respectively. Erosive disease was present in 47% of the patients. No differences were found between 
the complete BeSt cohort (n=508) and the three predefined disease activity groups regarding RF 
and ACPA positivity, BMI, smoking and presence of erosive disease. However, compared to the 
complete BeSt cohort, patients in continuous remission were older and more often female and 
patients in continuous remission and continuous low disease activity had lower DAS and HAQ 
scores (data not shown). Further, as expected from the group definition, DAS and HAQ scores were 
significantly and incrementally higher in the continuous low and continuous high disease activity 
groups than in the continuous remission group. As a result of the different years of follow-up after 
inclusion, also previous and current antirheumatic treatment was different among the groups. 
Patients in continuous remission were also older, more often male, and the women more often 
postmenopausal and more patients in continuous remission reported use of alcohol than patients 
with a high or low disease activity. Use of calcium, vitamin D, bisphosphonates and hormone 
replacement therapy was similar in the three groups.  
BMD change  Overall mean metacarpal BMD at ‘baseline’ was 0.58 ±0.08 g/cm2. After one year, 
mean absolute change in mBMD was -0.002 ±0.01 g/cm2 for patients in continuous remission, -
0.019 ±0.01 g/cm2 for patients with continuous low disease activity and -0.018 ±0.02 g/cm2 for 
patients with continuous high disease activity. These values correspond with a mBMD loss of  
-0.034%, -2.03% and -3.13% in patients in continuous remission and with continuous low and   
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Table 1. Baseline characteristics of the total BeSt population and the 3 different disease activity groups. 
Differences between the 3 disease activity groups are presented with p-values. 
 Continuous remission  
 
(DAS<1.6) 
n=57 
Continuous low 
disease activity 
(1.6≤DAS≥2.4) 
n=38 
Continuous high 
disease activity 
(DAS>2.4) 
n=50 
P-value 
Demographic variables     
Women, no. (%) 29 (51) 29 (76) 40 (80) 0.002 
Postmenopausal status, no. 
(%)  
22 (76) 16 (55) 27 (73) 0.002 
Age, years, † 60 (14) 53 (15) 53 (15) 0.014 
BMI, kg/m2, † 25.7 (3.0) 26.0 (2.8) 26.8 (4.8) 0.305 
Caucasian race, no. (%) 55 (97) 34 (90) 47 (94) 0.380 
Current smoker, no. (%) 13 (23) 12 (32) 21 (42) 0.080 
Current alcohol use, no. (%) 33 (58) 15 (40) 10 (20) 0.000 
Familial osteoporosis, no. (%) 11 (20) 6 (16) 11 (22) 0.738 
Disease related variables     
Symptom duration, years, ‡ 3.0 (1.5-3.5) 1.6 (1.3-2.4) 0.6 (0.3-1.1) 0.000 
Time from inclusion in trial, † 2.0 (1.1) 1.2 (0.5) 0.1 (0.3) 0.000 
ACPA, no. (%) 24 (42) 19 (50) 29 (58) 0.260 
RF, no. (%) 29 (51) 19 (50) 30 (60) 0.552 
DAS, ‡ 0.9 (0.6-1.2) 2.1 (1.7-2.4) 4.6 (4.1-5.1) 0.000 
HAQ, ‡ 0.0 (0.0-0.3) 0.4 (0.1-0.6) 1.4 (1.0-2.0) 0.000 
Total SHS, ‡, † 3.0 (0.5-7.8) 
6.5 (9.0) 
2.0 (0.3-12.0) 
7.2 (9.6) 
2.5 (0.0-5.4) 
4.9 (9.6) 
0.414 
SHS JSN score, ‡, † 1.5 (0.0-5.0) 
3.5 (4.8) 
1.0 (0.0-4.5) 
3.4 (5.3) 
0.3 (0.0-2.9) 
2.8 (6.6) 
0.317 
SHS erosion score, ‡, † 0.5 (0.0-2.8) 
3.0 (5.3) 
1.0 (0.0-6.5) 
3.8 (5.2) 
0.5 (0.0-2.5) 
2.1 (3.5) 
0.432 
Erosive disease, no. (%) 24 (42) 21 (57) 23 (47) 0.379 
Metacarpal BMD, g/cm2, † 
(n=363) 
0.59 (0.09) 0.57 (0.08) 0.58 (0.07) 0.488 
† mean (standard deviation); ‡ median (interquartile range); BMI (body mass index); ACPA (anti-cyclic citrullinated 
protein antibodies); RF (rheumatoid factor); DAS (disease activity score); HAQ (health assessment questionnaire); SHS 
(Sharp-van der Heijde score); JSN (joint space narrowing); BMD (bone mineral density). 
 
continuous high disease activity, respectively (overall p <0.001). Accelerated mBMD loss, defined as 
mBMD loss over 3 mg/cm2/year, equal to the upper limit of normal mBMD loss according to 
specifications by the manufacturers average, was found in 44% of the patients in continuous 
remission, 68% of the patients with continuous low and 70% of the patients with continuous high 
disease activity. mBMD gain was observed in 35% of the patients in continuous remission, 
compared to 11% of the patients with continuous low and 6% of the patients with continuous high   
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 Continuous 
remission  
 
(DAS<1.6) 
n=57 
Continuous low 
disease activity  
 
(1.6≤DAS≥2.4) 
n=38 
Continuous 
high disease 
activity 
(DAS>2.4) 
n=50 
P-value 
Treatment related variables 
RA treatment groups, no. (%) 
Sequential monotherapy 
Step up combination therapy  
Initial combination therapy with 
prednisone 
Initial combination therapy with 
infliximab  
 
 
14 (25) 
9 (16) 
15 (26) 
 
19 (33) 
 
 
3 (8) 
11 (29) 
12 (32) 
 
12 (32) 
 
 
16 (32) 
14 (28) 
11 (22) 
 
9 (18) 
 
 
 
0.079 
RA treatment history, (%)  
No treatment 
MTX 
SSA 
Other DMARDs 
Cobra therapy (MTX, SSA, 
prednisone) 
Other DMARD combination therapy 
IFX and MTX 
 
0 
40 
7 
2 
26 
2 
33 
 
0 
11 
8 
3 
32 
32 
32 
 
90 
2 
0 
4 
8 
6 
4 
 
0.000 
0.000 
0.142 
0.777 
0.014 
0.000 
0.000 
RA treatment, no. (%) 
No treatment 
MTX monotherapy 
Other DMARD monotherapy 
Cobra therapy (MTX, SSA, 
prednisone) Other DMARD 
combination therapy 
IFX and MTX 
 
26 (46) 
10 (18) 
2 (4) 
10 (18) 
0 (0) 
9 (16) 
 
0 (0) 
6 (16) 
3 (8) 
12 (32) 
7 (18) 
10 (26) 
 
0 (0) 
29 (58) 
1 (2) 
9 (18) 
1 (2) 
10 (20) 
 
0.000 
0.000 
0.371 
0.203 
0.000 
0.454 
Osteoporotic treatment, no. (%) 
Bisphosphonates 
Calcium supplements 
Vitamin D Supplements 
HRT 
 
10 (18) 
17 (30) 
6 (11) 
5 (9) 
 
5 (13) 
11 (29) 
6 (16) 
6 (16) 
 
7 (14) 
12 (24) 
5 (10) 
10 (20) 
 
0.779 
0.779 
0.661 
0.266 
MTX (methotrexate); SSA (sulphasalazine); DMARD (disease modifying anti-rheumatic drug); IFX (infliximab); HRT 
(hormone replacement therapy). 
 
disease activity. Percentages of patients with stable mBMD were similar in both groups (overall p 
<0.001, figure 1). 
Association between BMD and disease activity In the multivariable multinomial analysis with stable 
mBMD as reference, continuous disease activity, as presented by a weighed mean of the DAS,  
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Figure 1. Dynamics of metacarpal BMD in patients with continuous high disease activity (DAS >2.4), 
continuous moderate disease activity (1.6≤DAS≤2.4) and continuous remission (DAS <1.6) during 1 year 
follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
showed an independent association with mBMD gain. Higher disease activity was inversely 
associated with mBMD gain (OR (95% CI) 0.5 (0.3-0.8), p=0.008). There was a trend towards an 
independent association of higher disease activity with mBMD loss (OR (95% CI) 1.4 (0.98-2.02), 
p=0.064). Also age was independently associated with mBMD loss (OR (95% CI) 1.03 (1.002-
1.06), p=0.039). When components of the DAS were entered in the multivariable analysis instead 
of the DAS itself, only VAS global health showed a significant association with mBMD gain (OR 
(95% CI) 0.96 (0.93-0.99), p=0.005).  
An association between disease activity and mBMD change was identified and next it was 
investigated if there was a dose-response relationship. To do so, categorized DAS, as used to define 
the three disease activity groups, was entered in the multinomial regression analysis with 
adjustments for possible confounders.  
Categorized DAS was independently associated with mBMD gain (table 3). Patients in continuous 
remission had a significantly higher chance of mBMD gain compared to patients with a continuous 
high disease activity (OR (95% CI) 7.2 (1.5-34.2), p=0.013, RR (95% CI) 2.8 (1.3-3.6)) and 
showed a trend towards more mBMD gain compared to patients with continuous low disease 
activity (OR (95% CI 4.3 (0.98-18.5), p=0.054, RR 95% CI 2.3 (0.98-3.3)). Compared to patients 
with continuous high disease activity, patients with continuous low disease activity had a similar 
chance of having mBMD gain (OR 95% CI) 0.6 (0.1-3.5), p=0.559, RR (95% CI) 1.7 (0.3-9.9)). 
Further, mBMD loss was not significantly different for patients in continuous remission and  
  79 
Table 2. Univariable predictive variables of an increase or loss in metacarpal BMD (mBMD) compared to a 
stable mBMD presented in odds ratios (OR) and their 95% confidence intervals (CI).  
 mBMD increase mBMD loss Stable mBMD 
Age, years 1.00 (0.97-1.04) 1.03 (1.00-1.06) ref 
Female gender 1.24 (0.41- 3.75) 1.09 (0.46- 2.56) ref 
BMI, kg/m2 0.87 (0.74-1.01) 0.94 (0.84-1.06) ref 
DAS baseline 0.56 (0.36-0.87) 1.14 (0.90-1.45) ref 
Weighed mean DAS 0.46 (0.26-0.79) 1.22 (0.88-1.69) ref 
SJC baseline 0.88 (0.78-0.99) 1.03 (0.98-1.09) ref 
ESR baseline 0.78 (0.62-0.98) 1.06 (0.96-1.16) ref 
RAI baseline 0.98 (0.95-1.01) 1.01 (0.99-1.03) ref 
VAS global health baseline 0.97 (0.93-1.02) 1.02 (0.99-1.05) ref 
Erosive disease 0.89 (0.80-0.98) 1.02 (0.97-1.07) ref 
ΔSHS 0.86 (0.75-0.98) 1.03 (0.95-1.10) ref 
BMD baseline 0.95 (0.92-0.98) 1.01 (0.99-1.03) ref 
RF positive 0.94 (0.91-0.98) 1.01 (0.99-1.03) ref 
ACPA positive 0.76 (0.26-2.16) 1.41 (0.62-3.21) ref 
Vitamin D and/or  
calcium supplements use 0.71 (0.49-1.02) 1.01 (0.97-1.06) 
ref 
HRT use 0.19 (0.00-111.7) 0.03 (0.00-3.95) ref 
Bisphosphonate use 1.36 (0.48-3.81) 2.24 (0.98-5.11) ref 
Stable BMD is used as reference category. BMI (body mass index); DAS (disease activity score); SJC (swollen joint count); 
ESR ( erythrocyte sedimentation rate); RAI (Ritchie articular index); VAS global health (visual analogue scale global 
health); SHS (Sharp van der Heijde score); RF (rheumatoid factor); ACPA (anti-cyclic citrullinated protein antibodies); 
HRT (hormone replacement therapy).  
 
Table 3. Associations between disease activity and metacarpal BMD (mBMD) presented in odds ratios (OR) 
and relative risks (RR) and their 95% confidence intervals (CI).  
  BMD gain  
(≥0.003 g/cm2) 
Stable BMD 
(-0.003 to 0.003 g/cm2) 
BMD loss  
(≤ -0.003 gm/cm2) 
Remission  
(DAS <1.6) 
OR 
RR 
7.2 (1.5-34.2) 
2.8 (1.3-3.6) 
ref 0.4 (0.1-1.2) 
0.7 (0.4-1.1) 
Moderate DAS  
(1.6≤DAS≤2.4) 
OR 
RR 
1.7 (0.3-9.9) 
1.1 (0.7-1.2) 
ref 0.8 (0.3-2.5) 
0.9 (0.6-1.2) 
High DAS  
(DAS >2.4) 
 ref ref ref 
DAS (disease activity score). 
 
patients with continuous low disease activity when compared with patients with continuous high 
disease activity (OR (95% CI) 0.4 (0.1-1.2), p=0.101, RR (95% CI) 0.7 (0.4-1.1) and OR (95% 
CI) 1.2 (0.4-3.5), p=0.766, RR (95% CI) 0.9 (0.6-1.2), respectively). 
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Figure 2. Mean changes in Sharp-van der Heijde (SHS) score in patients having metacarpal BMD (mBMD) 
gain, stable mBMD or mBMD loss during 1 year follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With stable mBMD as reference, only continuous remission was significantly associated with 
mBMD gain (OR (95% CI) 7.2 (1.5-34.2), p=0.013, RR (95% CI) 2.8 (1.3-3.6)). With mBMD 
loss as reference, continuous remission was again significantly predictive of mBMD gain (OR (95% 
CI) 17.9 (4.2-75.8), p=0.001, RR (95% CI) 3.3 (2.3-3.7)). However, now lower age was also 
significantly associated with mBMD gain (OR (95% CI) 0.95 (0.92-0.99), p=0.007); older patients 
were less likely to have mBMD gain. 
Association between BMD and radiographic damage The mean (median (IQR)) change in SHS in the 
year of follow-up was 0.03 ±0.7 (0 (0-0)) points for patients with mBMD gain, 1.8 ±5.3 (0 (0-1.5)) 
points for patients with stable mBMD and 3.8 ±18.4 (0 (0-2)) points for patients with mBMD loss 
(figure 2). This result was not significantly different (overall p=0.153), probably due to the small 
number of patients with significant progression: 8% showed progression of ≥5 SHS points, 20% 
showed progression ≥2 points and 38% of the patients showed radiographic progression of ≥0.5 
point. Of the patients with mBMD gain, 19% showed radiographic progression of ≥0.5 point, 4% 
progressed ≥2 points and none showed radiographic progression ≥5 points. Of the patients with 
mBMD loss, 46% had radiographic progression of ≥0.5 point, 27% progressed ≥2 points and 10% 
≥5 points. Patients with mBMD gain had significant less often progression of ≥0.5 and 2 points 
than patients with mBMD loss (both p <0.05), but no difference was found regarding progression 
≥5 points (p=0.182). 
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Discussion 
 
In patients with RA, generalized as well as metacarpal BMD loss has been frequently observed. 
[4,6,7,22,29-33] To our knowledge, metacarpal BMD gain has not been reported. Based on 
findings that osteoclast and osteoblast activity are influenced by cytokines and changing with disease 
activity, we hypothesized that inflammation drives BMD loss and that therefore patients might have 
an increase in their metacarpal BMD while they are in remission. We found indeed that an increase 
in mBMD can occur, primarily in patients in continuous remission and rarely in patients with 
continuous high disease activity but also rarely in patients with continuous low disease activity. 
It has been reported that changes in metacarpal BMD precedes radiographic progression [3,4] and 
subsequently functional disability.[34,35] We showed that patients with mBMD gain showed 
hardly any radiographic progression, while patients with stable mBMD or mBMD loss did show 
radiographic progression. However, these differences between the three groups were not significant, 
probably due to the fact that progression rates were low, and few patients showed significant 
progression in this cohort where treatment was aimed at achieving a DAS ≤2.4.  
Continuous remission was the only independent predictor of mBMD gain. No significant 
differences were found in the use of bisphosphonates, calcium, vitamin D and hormone 
replacement therapy between the three disease activity groups. Therefore, it seems unlikely that 
patients in remission had more mBMD gain due to antiresorptive therapy. Furthermore, the 
protective effect of bisphosphanates was only observed against generalized and not metacarpal BMD 
loss.[32] The antirheumatic medication that patients were receiving in the year of observation 
differed also between the three groups. Some patients received DMARD monotherapy, others 
multiple DMARDs and some a combination of DMARDS including prednisone or infliximab. 
Prednisone has shown to have a deleterious effect on bone,[36-38] while infliximab has a positive 
effect on BMD.[39,40] However, all results were corrected for previous and current use of 
prednisone and infliximab. Moreover, no differences in percentages of mBMD loss, mBMD gain or 
stable mBMD were found between patients in remission with medication and patients in drug-free 
remission (data not shown).  
Continuously low disease activity did not appear to have many advantages for BMD outcomes 
compared to continuously high disease activity. Our results indicate that clinical remission, rather 
than low disease activity, should be the goal of treatment in RA. Nonetheless, only 35.1% of the 
patients with continuous remission had mBMD gain, while 43.9% had mBMD loss and 21% 
stable mBMD.  Possibly, unknown factors such as immobilization, dietary and endocrinological 
imbalances or pathophysiological characteristics associated with irreversible joint damage caused 
ongoing BMD loss. It may also be that the remission definition of DAS <1.6 is insufficiently strict 
to identify true clinical remission, or that patients in continuous clinical remission with mBMD loss 
or stable mBMD still had inflammation which remained undetected by clinical evaluation. Signs of 
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synovitis can still be detected with magnetic resonance imaging in patients in clinical 
remission.[41,42] This suggests that residual inflammation might still influence bone turnover and 
thus sustain or increase BMD loss. It therefore appears that metacarpal BMD loss may be a signal of 
ongoing inflammatory activity, and that mBMD measurement may help to identify patients at risk 
for radiographic progression who clinically appear to be in remission.  
In conclusion, in patients with rheumatoid arthritis, an increase in metacarpal BMD can occur, 
primarily in patients in continuous remission (DAS <1.6) and rarely in patients with a continuous 
high (DAS >2.4) or low (1.6≤DAS≤2.4) disease activity. It appears that mBMD loss is driven by 
inflammation and the precursor of joint damage, and this indicates that remission should be the 
treatment goal. 
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Abstract 
 
Objectives To investigate whether accelerated hand bone mineral density (BMD) loss is associated 
with progressive joint damage in hands and feet in the first year of rheumatoid arthritis (RA) and 
whether it is an independent predictor of subsequent progressive total joint damage after 4 years. 
Methods In 256 recent-onset RA patients, baseline and 1-year hand BMD was measured in 
metacarpals 2-4 by digital X-ray radiogrammetry. Joint damage in hands and feet were scored in 
random order according to the Sharp-van der Heijde method at baseline and yearly up to 4 years. 
Results 68% of the patients had accelerated hand BMD loss (>-0.003 g/cm2) in the first year of RA. 
Hand BMD loss was associated with progressive joint damage after 1 year both in hands and feet 
with odds ratios (OR) (95% confidence intervals (CI)) of 5.3 (1.3-20.9) and 3.1 (1.0-9.7). In 
univariable analysis, hand BMD loss in the first year was a predictor of subsequent progressive total 
joint damage after 4 years with an OR (95% CI) of 3.1 (1.3-7.6). Multivariable analysis showed 
that only progressive joint damage in the first year and anti-citrullinated protein antibody positivity 
were independent predictors of long-term progressive joint damage.  
Conclusions In the first year of RA, accelerated hand BMD loss is associated with progressive joint 
damage in both hands and feet. Hand BMD loss in the first year of recent-onset RA predicts 
subsequent progressive total joint damage, however not independent of progressive joint damage in 
the first year. 
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Bone damage in rheumatoid arthritis (RA) includes joint damage and accelerated bone mineral 
density (BMD) loss.[1] Joint damage is provoked by an increased osteoclast and decreased 
osteoblast activation, leading to erosive damage, and by proteolytic pathways, leading to cartilage 
degradation. This is all mostly regulated by TNF-α, IL-1, IL-6, IL-17 and receptor activator of 
nuclear factor kappa B ligand (RANKL).[2-4] It is believed that BMD loss, both localized and 
generalized, is also primarily the effect of increased osteoclast activity in RA.[5] In particular, bones 
in the proximity of inflamed joints are susceptible to BMD loss due to inflammation.[6] 
Furthermore, localized hand BMD loss occurs in an early phase of RA [7] and even in pre-RA 
undifferentiated arthritis,[8] and might precede erosive damage on X-ray.[9,10] 
Dual energy X-ray absorptiometry (DEXA) is the gold standard for measuring BMD. Digital X-ray 
radiogrammetry (DXR) was developed as a method of radiogrammetry to estimate BMD in the 
metacarpals using standard hand radiographs.[11] BMD measured by DXR is highly correlated 
with DEXA measurements and DXR has a high precision for detecting changes in BMD.[11,12] 
Various clinical studies showed the association between hand BMD loss measured by DXR and RA 
severity, including disease activity, functional impairment and joint destruction.[6,13-22] Two 
clinical studies, one of them a pilot study, showed the potential value of BMD loss in hands 
measured by DXR to predict radiographic joint damage in hands.[23,24] However, to date, no data 
are available on the association between hand BMD loss and progressive joint damage in hands and 
feet and on the value of hand BMD loss as predictor of joint destruction in recent-onset RA 
patients who are treated intensively with disease modifying anti-rheumatic drugs (DMARDs) and 
TNF-α inhibitors in a tight control setting. We examined the association between accelerated hand 
BMD loss and progressive joint damage in hands and feet during the first year of recent-onset active 
RA to see whether both types of bone damage have common pathways in their pathogenesis, and 
we investigated whether accelerated hand BMD loss in the first year of RA was an independent 
predictor of subsequent progressive joint damage after four years in patients who are treated in a 
tight control setting. 
 
Materials and methods 
ww 
Patients All measures were performed in the setting of the BeSt, Dutch acronym for Behandel 
Strategieën, i.e. treatment strategies, study.[25] Patients aged 18 years and older, who met the 
definition of RA as defined by the American College of Rheumatology (ACR) 1987 revised criteria, 
with symptom duration of less than two years and active disease with 6 or more of 66 swollen joints 
and 6 or more of 68 tender joints and either an erythrocyte sedimentation rate (ESR) of 28 
mm/hour or more or a visual analogue scale (VAS) global health of 20 mm or more, and who were 
DMARD naïve, were included in the trial from April 2000 to August 2002. Exclusion criteria have 
been reported previously.[25]  
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Of the 508 patients, 236 were excluded from this study predominantly due to switch from analogue 
to digital radiographs. The other 272 patients had analogue radiographs at both baseline and after 
one year and were eligible for this study. The baseline and/or one year follow-up analogue 
radiographs of 16 patients could not be analysed by DXR due to underexposed images (13 patients) 
or improper positioning of the hands (3 patients). Hence, 256 patients were included in the current 
study.  
Study design The BeSt study was conducted by rheumatologists participating in the Foundation for 
Applied Rheumatology Research, in 18 peripheral and 2 university hospitals in the western part of 
the Netherlands. The medical ethics committee at each participating center approved the study 
protocol and all patients gave written informed consent prior to participation in the study. 
After inclusion, patients were randomized to be treated according to one of four treatment 
strategies: sequential monotherapy starting with methotrexate (MTX); step-up combination therapy 
also starting with MTX; initial combination therapy with quickly tapered high-dose prednisone, 
MTX and sulphasalazine, or initial combination therapy with infliximab and MTX. For all groups, 
the protocol described a number of subsequent treatment steps for patients whose response to 
therapy was insufficient, based on the disease activity score (DAS) in 44 joints of more than 2.4. 
The treatment protocol and the effect of the different treatment strategies on hand BMD loss after 
one and two years are described earlier in detail.[6,25]  
Concomitant treatment with non-steroidal anti-inflammatory drugs and intra-articular 
corticosteroids were permitted but not parenteral corticosteroids. In case of calcium intake of less 
than 1,000 mg/day and serum vitamin D level below the local reference value at baseline, 
suppletion of 500 to 1,000 mg/day calcium and 400 IE/day vitamin D (colecalciferol), respectively, 
was advised. Antiresorptive therapy with oral alendronate, 10 mg/day or 70 mg/week, or 
risedronate, 5 mg/day or 35 mg/week, was advised if the BMD measurement at baseline showed at 
a T-score -2.5 standard deviations (SD) or less in the spine and/or hip in non-corticosteroid users or 
a T-score -1 SD or less in corticosteroids users (ACR recommendations).[6] 
Hand BMD measurements Analogue radiographs of both hands in the posterior-anterior view were 
digitized by a high-resolution 300 DPI scanner (Canon Vidar VXR-12 plus, Amstelveen, North-
Holland, the Netherlands) and analysed under blind conditions using the DXR-online (Pronosco 
X-posure system, Sectra, Sweden). According to the manufacturer, there is a very good agreement 
between BMD measured by DXR on original analogue radiographs and on digitalized versions. 
Patients who switched from analogue to digital radiographs were excluded due to lack of 
comparability between the different imaging devices.  
DXR is a computerized version of the traditional technique of radiogrammetry originally proposed 
by Barnett and Nordin.[26] The digitized hand radiograph is subjected to a number of image 
processing algorithms to measure the cortical thickness of three regions of interest around the 
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narrowest part of the second, third and fourth metacarpal bones.[11] A mean surrogate BMD, 
based on the mean volume per area, was calculated in g/cm2 with correction for the estimated 
porosity. Both hands were measured and the mean was used for the analyses.  
Hand BMD loss after one year was categorized in two groups using the cut-off of -0.003 
g/cm2/year, equal to the upper limit of normal BMD loss in the metacarpals according to 
specifications by the manufacturer. 
Radiographic assessment of progressive joint damage Radiographic progression of joint damage in 
hands and feet at baseline and after one to four years were independently scored by two readers, 
blinded for patient characteristics, treatment group and time order, using the Sharp-van der Heijde 
score (SHS).[27] The inter-class correlation coefficient between the readers was 0.98. The mean 
score of the two observers were used for the analyses.  
Progressive joint damage in the first year was defined as an increase in total SHS of 5 units or more 
at year one compared with baseline. In subanalyses, progressive joint damage in hands was defined 
as delta SHS 0 to 1 year 5 units or more, whereas progressive joint damage in feet was defined as 
delta SHS 0 to 1 year 3 units or more, due to a 0.6 times lower maximum score in feet than in 
hands. Subsequent progressive total joint damage in hands and feet was defined as delta SHS 1 to 4 
years 5 units or more. 
Demographic and clinical variables The following variables were collected at baseline: age; sex; and 
symptom duration. At baseline and after one year the following variables were collected: 
postmenopausal status; body mass index (BMI); DAS; based on the number of swollen joints and 
the Ritchie articular index (RAI) for pain in tender joints; the VAS for patient’s global assessment of 
disease activity (0 to 100 mm); ESR; C-reactive protein (CRP); serum IgM rheumatoid factor (RF), 
defined as positive or negative according to locally applied assays and cut-off units; and functional 
disability by the Dutch validated health assessment questionnaire (HAQ). The presence of anti-
citrullinated protein antibodies (ACPA) was determined from serum samples obtained at baseline or 
during follow up. The presence or absence of ACPA is a stable characteristic.[28]  
Statistical analyses All analyses were performed in an intention-to-treat method using all available 
data. To determine the associations between hand BMD loss and progressive joint damage in hands 
and feet after one year, multivariable logistic regression analyses were performed adjusted for age, 
gender, postmenopausal status, BMI, HAQ, baseline SHS, treatment group, and the use of intra-
articular steroids and antiresorptive drugs (bisphosphonates, vitamin D and calcium supplements 
and hormone replacement therapy (HRT)).  
The sensitivity, specificity, and positive and negative predictive value of hand BMD loss with regard 
to total progressive joint damage in the first year were calculated.  
Various baseline demographic and disease-related factors and one-year follow-up disease-related 
factors were analysed regarding prediction of subsequent progressive total joint damage after four 
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years by univariable logistic regression analyses adjusted for age, gender, postmenopausal status, 
BMI and HAQ, and additionally adjusted for the treatment group and use of antiresorptive drugs 
and intra-articular steroids during the first year follow-up in case of one-year follow up variables. 
The following factors were analysed: baseline demographic factors (gender, age ≥50 years, 
postmenopausal status and BMI ≥25 kg/m2), baseline disease-related factors (symptom duration ≥6 
months, presence ACPA and RF, number of swollen joints ≥10, RAI ≥10, ESR ≥30 mm/hr, CRP 
≥10 mg/L, HAQ ≥1.057 units [29] and SHS ≥1 unit) and one-year follow-up disease-related factors 
(high area under the curve (AUC) of number of swollen joints, RAI, ESR and CRP and delta HAQ 
≤-0.22 units,[30] total SHS ≥5 units and hand BMD loss >-0.003 g/cm2). Both significant (p-value 
<0.05) and borderline significant (0.05<p<0.10) predictors derived by these univariable analyses 
were entered in multiple multivariable logistic regression analyses to determine the independent 
predictors of subsequent progressive joint damage.  
 
Results   
Patient characteristics The baseline characteristics of the 256 patients included in the study and 252 
patients excluded are shown in table 1. Patients included had shorter disease duration, were less 
frequently ACPA positive and had less damage in the feet, especially less cartilage degradation, 
compared with the non-included patients. With regard to randomization into the four treatment 
groups by age, sex, RF, DAS, ESR level, CRP level, HAQ score, hand SHS and BMD (obtained in 
107 patients at baseline who were excluded from this study), there were no significant differences 
between patients who were enrolled in this study and who were not. 
Of the study population, 65% were females, 66% of them postmenopausal, and the mean age was 
54 years. At baseline the patients had a median symptom duration of 24 weeks and mean (SD) 
DAS of 4.4 (0.9). RF was positive in 62% of the patients and 70% had at least one erosion in hands 
and feet. 
Changes in hand BMD and joint damage in hands and feet in the first year The median (interquartile 
range (IQR)) hand BMD change was, in absolute value, -0.0088 g/cm2 (-0.021 to -0.0005) and in 
percentage of baseline BMD -1.4% (-3.8% to -0.1%) after one year. On the individual level, 68% 
of patients had accelerated hand BMD loss of more than -0.003 g/cm2, from now on called hand 
BMD loss. The mean (SD) progression of total SHS in hands and feet, and SHS in hands and feet 
separately was 3.0 (11.3), 1.9 (7.0) and 1.1 (5.0), respectively. After one year 18%, 12% and 11% 
of the patients had progressive total joint damage of 5 units or more, hand joint damage 5 units or 
more and feet joint damage of 3 units or more, respectively.  
In patients with hand BMD loss the mean (SD) progression of total SHS after one year was 4.0 
(13.6) compared with 1.1 (2.6) in patients without hand BMD loss (p=0.036 derived by non- 
parametric test). Hand BMD loss after one year was significantly associated with higher progression 
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Table 1. Baseline demographic and disease characteristics from patients from the BeSt cohort who are 
included and not included in this study. 
 Patients included in study 
n=256 
Patients not included in 
study n=252 
P-value 
Demographic variables 
Age, years, † 
 
54 (14) 
 
54 (13) 
 
0.941 
Women, %  65 70 0.208 
Postmenopausal, %  66 68 0.817 
Randomization between  
the treatment groups, %  
Sequential monotherapy: 25 
Step-up therapy: 23 
Initial combi therapy  
with prednisone: 27 
Initial combi therapy  
with infliximab: 26 
Sequential monotherapy: 25 
Step-up therapy: 25 
Initial combi therapy  
with prednisone: 25 
Initial combi therapy  
with infliximab: 25 
 
 
0.921 
Disease related variables  
Symptom duration, weeks, ‡ 24 (14-53) 23 (13-53) 0.929 
Disease duration, weeks, ‡ 2 (1-5) 3 (1-5) 0.011 
ACPA positive, %, n=247  
(not all baseline) 
54 70 0.000 
RF positive, %  62 68 0.175 
DAS, † 4.4 (0.9) 4.4 (0.9) 0.529 
ESR, ‡ 37 (19-54) 36 (19-57) 0.781 
CRP, ‡ 20 (9-58) 26 (10-55) 0.272 
HAQ score, 0-3 scale, † 1.4 (0.6) 1.4 (0.7) 0.276 
Total SHS, 0-448 scale, ‡, †( n=248) 
Erosion score, 0-280 scale, ‡, † 
JSN score, 0-168 scale, ‡, † 
Total SHS hands, 0-280 scale, ‡, † 
Erosion score hands, 0-160 scale, ‡, † 
JSN score hands, 0-120 scale, ‡, † 
Total SHS feet, 0-168 scale, ‡, † 
Erosion score feet, 0-120 scale, ‡, † 
JSN score feet, 0-48 scale, ‡, † 
5.9 (8.2) / 2.5 (0.5-8.5) 
2.8 (4.7) / 1 (0.0-3.5) 
3.0 (4.8) / 1.0 (0.0-4.1) 
3.0 (4.8) / 1.0 (0.0-3.5) 
0.9 (1.8) / 0.0 (0.0-1.0) 
2.1 (3.9) / 0.0 (0.0-3.0) 
2.8 (5.4) / 0.5 (0.0-3.0) 
1.9 (3.9) / 0.5 (0.0-2.0) 
0.9 (2.0) / 0.0 (0.0-1.0) 
8.7 (12.7) / 4.3 (1.0-11.0) 
3.9 (6.2) / 1.5 (0.0-5.0) 
4.8 (7.7) / 2.0 (0.0-5.6) 
4.6 (8.4) / 1.0 (0.0-5.0) 
1.4 (3.1) / 0.5 (0.0-1.0) 
3.1 (6.0) / 0.50 (0.0-3.6) 
4.1 (7.2) / 1.5 (0.0-4.5) 
2.5 (4.6) / 0.5 (0.0-2.5) 
1.7 (3.4) / 0.0 (0.0-2.0) 
0.024* 
0.011* 
0.041* 
0.217* 
0.112* 
0.247* 
0.011* 
0.123* 
0.013* 
Presence erosive damage ≥1 unit, % 
(n=248) 
Presence erosive damage hands ≥1 unit, % 
Presence erosive damage feet ≥1 unit, % 
70 
28 
40 
74 
34 
46 
0.321 
0.166 
0.205 
Hand BMD, g/cm2, †  0.59 (0.08) 0.59 (0.09) (n=107) 0.870 
† mean (standard deviation); ‡ median (interquartile range); * P-values derived from non-parametric tests. ACPA (anti- 
citrullinated protein antibodies); RF (rheumatoid factor); DAS (disease activity score); ESR (erythrocyte sedimentation 
rate); CRP (C-reactive protein); HAQ (health assessment questionnaire); SHS (Sharp-van der Heijde score); JSN (joint 
space narrowing); BMD (bone mineral density). 
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rates both in hands (2.5 (8.4) versus 0.8 (1.7), p=0.033) and feet (1.4 (5.9) versus 0.4 (1.5), 
p=0.047). The cumulative probability plots of changes in total SHS and changes in hands and feet 
SHS separately after one year in patients with and without hand BMD loss are shown in figure 1.  
Multivariable logistic regression analyses adjusted for possible confounders were performed to study 
the independent associations between hand BMD loss and progressive total joint damage in hands 
and feet. Progressive total joint damage in hands and feet after one year was independently 
associated with hand BMD loss with an odds ratio (OR) (95% confidence interval (CI)) of 10.6 
(2.6-42.7; p=0.001). In separate analyses, hand BMD loss was associated with progressive joint 
damage in both hands and feet after one year, although more strongly in hands (OR (95% CI) 5.3 
(1.3-20.9)) than in feet (3.1 (1.0-9.7)). Both erosion and joint space narrowing (JSN) score in 
hands and feet contributed equally to the association with hand BMD loss (data not shown).  
Sensitivity, specificity and predictive value of hand BMD loss in the first year The sensitivity of hand 
BMD loss for detecting progressive total joint damage after one year was 39 of 45 (87%) and the 
specificity 74 of 203 (36%). The positive predictive value, the probability of the presence of  
 
Figure 1. Cumulative probability plot of changes in Sharp-van der Heijde score (SHS). Results are shown in 
both hands and feet, in only hands and in only feet after one year in recent-onset active rheumatoid arthritis 
patients with accelerated hand BMD loss (triangles) and without accelerated hand BMD loss (circles) after 
one year. 
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progressive joint damage when hand BMD loss is present, was 39 of 168 (23%), whereas the 
negative predictive value, the probability of absence of progressive joint damage when hand BMD 
loss is absent, was 74 of 80 (93%).  
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Figure 2. Mean progression of total Sharp-van der Heijde (SHS) in hands and feet after up to four years in 
patients with (black columns) and without (white columns) hand BMD loss in the first year of rheumatoid 
arthritis.  
 
The differences in mean total SHS progression after 1, 2, 3 and 4 years between patients with and without hand BMD 
loss in the first year are all significant (p <0.05 derived by non-parametric tests). 
 
Predictors of subsequent progressive radiographic damage after four years The mean (SD) cumulative 
progression of total SHS in hands and feet was 3.0 (11.3), 4.9 (14.5), 5.8 (16.7) and 6.6 (13.3) 
after one to four years compared with baseline. After one to four years, 18%, 26%, 27% and 30% 
of the patients, respectively, had progressive total joint damage of 5 units or more. The association 
between hand BMD loss in the first year and progressive total joint damage remained over time up 
to four years (figure 2).  
The mean (SD) progression of total SHS was 2.9 (7.6) after four years compared with year one and 
14% of the patients had progressive total joint damage of 5 units or more after four years compared 
with year one. To investigate whether hand BMD loss in the first year could predict long-term 
damage progression, univariable logistic regression analyses were performed with subsequent 
progressive total joint damage after four years of 5 units or more compared with year one as 
dependent variable and various potential baseline and one year follow-up predictors as independent 
variables adjusted for possible confounders (table 2). Of the baseline variables, the presence of 
ACPA, RF and joint damage at baseline were significant predictors of subsequent progressive total 
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Table 2. Baseline and 1-year follow-up predictors of subsequent progressive total joint damage in hands and 
feet after 4 years derived from univariable logistic regression analyses. 
OR (95% CI) Progressive total joint damage 1-4 ≥5 units 
 Beta 
coefficient 
   OR (95% CI) P-value 
Baseline variables    
Female gender -0.28 0.76 (0.38-1.49) 0.418 
Age ≥50 years -0.11 0.90 (0.47-1.71) 0.744 
Postmenopausal status 0.56 1.75 (0.70-4.40) 0.232 
BMI ≥25 kg/m2 -0.54 0.58 (0.31-1.11) 0.100 
Symptom duration ≥6 months -0.02 0.98 (0.52-1.87) 0.958 
Presence ACPA 1.57 4.80 (1.39-16.6) 0.001 
Presence RF 1.14 3.11 (1.43-6.78) 0.004 
Number of swollen joints ≥10 -0.42 0.66 (0.32-1.33) 0.243 
Ritchie articular index ≥10 -0.39 0.68(0.34-1.36) 0.276 
ESR ≥30 mm/hr 0.12 1.13 (0.59-2.18) 0.714 
CRP ≥10 mg/L 0.63 1.88 (0.82-4.31) 0.136 
HAQ ≥1.057 units -0.39 0.67 (0.35-1.30) 0.240 
SHS ≥1 unit 1.99 7.29 (1.70-31.14) 0.007 
First year follow-up variables    
High AUC number of swollen joints -0.002 0.998 (0.991-1.006) 0.692 
High AUC Ritchie articular index -0.003 0.997 (0.992-1.003) 0.325 
High AUC ESR 0.002 1.002 (1.001-1.004) 0.003 
High AUC CRP 0.003 1.003 (1.001-1.004) 0.000 
Delta HAQ ≤-0.22 units 0.273 1.31 (0.56-3.09) 0.531 
Progressive SHS ≥5 units 3.42 30.7 (9.4-100.1) 0.000 
Hand BMD loss >0.003 g/cm2 1.15 3.14 (1.30-7.57) 0.011 
All variables are adjusted for age, gender, postmenopausal status, body mass index (BMI) and health assessment 
questionnaire (HAQ). First follow-up variables are additionally adjusted for treatment group and the use of intraarticular 
corticosteroids injections and anti-resorptive therapy (bisphosphonates, calcium and vitamin D suppletion and hormone 
replacement therapy). OR (95% CI) (odds ratio (95% confidence interval)); ACPA (anti-citrullinated protein antibodies); 
RF (rheumatoid factor); ESR (erythrocyte sedimentation rate); CRP (C-reactive protein); SHS (Sharp-van der Heijde 
score); AUC (area under the curve).  
 
joint damage after four years. Of the one-year follow-up variables, a high AUC of ESR and CRP, 
progressive total joint damage of 5 units or more and hand BMD loss were significant predictors of 
subsequent progressive joint damage after four years. The association of hand BMD loss with 
subsequent progressive joint damage was less strong (OR (95% CI) 3.1 (1.3-7.6)) than the 
association with progressive joint damage in the first year (OR (95% CI) 30.7 (9.4-100)).  
Multiple multivariable regression analyses were performed to investigate the predictive ability of 
different factors and the mutual interaction between them. In the first multivariable model, all 
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Table 3. Baseline and 1-year follow-up predictors of subsequent progressive total joint damage in hands and 
feet after 4 years derived from multivariable logistic regression analysis.  
 Progressive total joint damage 1-4 ≥ 5 units 
 Beta 
coefficient 
   OR (95% CI) P- value 
Baseline variables    
Presence ACPA 1.20 3.14 (1.37-6.12) 0.015 
Presence RF 0.59 1.80 (0.55-6.08) 0.314 
SHS ≥1 unit 0.85 2.55 (0.48-13.0) 0.342 
First year follow-up variables    
High AUC ESR 0.001 1.001 (0.998-1.004) 0.444 
High AUC CRP 0.001 1.001 (0.999-1.004) 0.339 
Progressive SHS ≥5 units 3.35 27.1 (10.9-67.4) 0.000 
Hand BMD loss >0.003 g/cm2 0.30 1.30 (0.38-3.84) 0.688 
R2, adjusted 0.534 
All variables with a P<0.10 in the univariable analyses were entered in this multivariable analysis corrected for age, gender,  
postmenopausal status, body mass index (BMI) and health assessment questionnaire and first year follow-up variables 
additionally corrected for the use of anti-resorptive therapy (bisphosphonates, calcium and vitamin D suppletion and 
hormone replacement therapy) and intraarticular corticosteroid injections during first year and treatment group during. 
OR (95% CI) (odds ratio (95% confidence interval)); ACPA (anti-citrullinated protein antibodies); RF (rheumatoid 
factor); SHS (Sharp-van der Heijde score); AUC (area under the curve); ESR (erythrocyte sedimentation rate); CRP (C-
reactive protein); SHS (Sharp-van der Heijde score).  
 
(borderline) significant predictors from the univariable analyses were entered, adjusted for possible 
confounders (table 3). The presence of ACPA was an independent predictor of progressive joint 
damage with an OR (95% CI) of 3.1 (1.4-6.1).  
Progressive joint damage in the first year was a strong and independent predictorf subsequent 
progressive joint damage with an OR (95% CI) of 27.1 (10.9-67.4). Hand BMD loss in the first 
year with the diagnosis of RA was not an independent predictor anymore (p=0.688). The adjusted 
R2, estimating the proportion of variance in progressive joint damage that is explained by the 
predictors, was 0.53.  
In the second multivariable model all (borderline) significant predictors from the univariable 
analyses were entered, except progressive joint damage in the first year, adjusted for possible 
confounders (table 4). Hand BMD loss in the first year was a predictor of subsequent progressive 
joint damage independent of the presence of auto-antibodies, joint damage at baseline and high 
AUC (area under the curve) of ESR (erythrocyte sedimentation rate) and CRP with an OR (95% 
CI) of 3.0 (1.1-8.8). The adjusted R2 was considerably lower at 0.29.  
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Table 4. Baseline and 1-year follow-up predictors, progressive SHS of 5 units or more in the first year 
excluded, of subsequent progressive total joint damage in hands and feet after 4 years derived from 
multivariable logistic regression analysis.  
 Progressive joint damage 1-4 ≥ 5 units 
 Beta  
coefficient 
   OR (95% CI) P-value 
Baseline variables    
Presence ACPA 1.30 3.95 (1.17-15.0) 0.017 
Presence RF 0.11 1.10 (0.38-2.98) 0.803 
SHS ≥1 unit 1.81 5.78 (1.23-28.1) 0.020 
First year follow-up variables    
High AUC ESR 0.002 1.002 (0.999-1.004) 0.160 
High AUC CRP 0.002 1.002 (1.000-1.004) 0.059 
Progressive SHS ≥5 units - - - 
Hand BMD loss >0.003 g/cm2 1.10 3.00 (1.12-8.81) 0.035 
R2, adjusted 0.290 
All variables with a P <0.10 in the univariable analyses, except progression Sharp-van der Heijde score (SHS) of 5 units or 
more in the first year, were  entered in this multivariable analysis corrected for age, gender, postmenopausal status, body 
mass index (BMI) and health assessment questionnaire and first year follow-up variables additionally corrected for the use 
of anti-resorptive therapy (bisphosphonates, calcium and vitamin D suppletion and hormone replacement therapy) and 
intraarticular corticosteroid injections during first year and treatment group during.  
OR (95% CI) (odds ratio (95% confidence interval)); ACPA (anti-citrullinated protein antibodies); RF (rheumatoid 
factor); AUC (area under the curve); ESR (erythrocyte sedimentation rate); CRP (C-reactive protein).  
 
To explore further the usefulness of progressive joint damage in the first year as a predictor of 
subsequent progressive damage, joint damage progression in the first year was divided in to four 
groups: no progression (SHS ≤0 unit, the reference group), dubious progression (0<SHS<5 units), 
moderate progression (5≤SHS<10 units) and high progression (SHS ≥10 units). They were then 
entered in a third multivariable regression analysis together with all (borderline) significant 
predictors from the univariable analyses and possible confounders. This analysis showed that even 
dubious progressive joint damage was an independent predictor of subsequent progressive joint 
damage with an OR (95% CI) of 5.5 (1.3-24) and that the ORs (95% CIs) were considerably 
higher when the progressive joint damage in the first year was moderate, 68 (14-345), or high, 144 
(20-1045).  
 
Discussion 
  . 
This study into the association between hand BMD loss and radiographic joint damage progression 
shows that in the first year of RA hand BMD loss is associated with progressive joint damage in 
hands and feet, and that the association seems stronger with damage in hands than in feet. 
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Moreover, hand BMD loss in the first year predicts subsequent progressive total joint damage: 
however, not independent of progressive joint damage in the first year.  
The relation between BMD loss and progressive joint damage in the first year of RA suggests that 
both types of bone damage share common pathways in their pathogenesis and are the result of the 
same inflammatory process. It is thought that BMD loss in RA patients is caused, just like joint 
damage, by increased osteoclast activation, mainly regulated by TNF-α, IL-1, IL-6, IL-17 and 
RANKL.[2,3] This is also in line with in vitro studies showing increased osteoclast functional 
activity in RA patients with generalized osteopenia.[5] A stronger association between hand BMD 
loss and progressive joint damage in hands compared with damage in feet also suggests that bones in 
the direct proximity of the inflammatory activity are more susceptible to BMD loss due to, besides 
the systemic, the local effect of high pro-inflammatory cytokine levels originating in adjacent active 
arthritis of the hand joints. On the other hand, it may also be partially explained by methodological 
issues. Firstly, less joint damage in feet can be detected due to less evaluated joints in feet than in 
hands. To limit this problem, we used a lower cut-off point to define progressive damage in feet (3 
units in feet versus 5 units in hands due to 0.6 times lower maximum score in feet) and after this 
correction the percentages of patients having progressive joint damage in the hands and in feet were 
similar. Secondly, the patients in this subanalysis had significant less damage in the feet than the 
patients who were excluded from this subanalysis; however, in absolute terms, our population had 
active disease with high DAS and erosions present in the majority of patients at baseline. 
In the first year of RA, hand BMD loss was seen in 68% of the patients, whereas progressive joint 
damage was seen in only 18%. There are several explanations for this disassociation. First, localized 
BMD loss occurs mostly earlier in and more often during the disease course than advanced joint 
damage to bone and cartilage, especially in recent-onset RA.[9,10] This is emphasized by the 
sensitivity, specificity and predictive value of hand BMD loss with regard to progressive joint 
damage in the first year. Both the sensitivity and negative predictive value were high, 87% and 
93%, respectively, whereas the specificity and positive predictive value were low, 36% and 23%, 
respectively, suggesting that most patients with progressive joint damage also have hand BMD loss 
at the same time, whereas in most patients with hand BMD loss progressive joint damage is absent. 
A second explanation might be that the technique of measurement of BMD loss by DXR is more 
sensitive to detect significant changes in cortical BMD during a follow-up period, while progressive 
joint damage as measured by the semi-objective SHS method is less sensitive to detect significant 
changes in structural damage, both erosions and JSN, during the same follow-up period.  
We showed that hand BMD loss in the first year of RA is a predictor of subsequent progressive total 
joint damage, independent of the presence of auto-antibodies and joint damage at baseline. This is 
in accordance with the findings of Hoff and colleagues, who in RA patients with mean disease 
duration of 2.2 years at inclusion also showed that hand BMD loss was a predictor of progressive 
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damage in hands after 5 and 10 years, independent of baseline predictors, such as joint damage at 
baseline and the presence of ACPA.[24] However, hand BMD loss is probably predicting 
progressive joint damage because hand BMD loss itself incorporates the effect of inflammation over 
time, as opposed to other factors that are static measures of the situation at baseline. Therefore we 
compared the predictive value of hand BMD loss with changes in other potential one-year follow-
up predictors in multivariable regression analyses, and found that radiographic progressive joint 
damage is a much stronger predictor for subsequent progressive damage and that hand BMD loss 
was not predicting subsequent progressive damage independent of progressive damage in the first 
year probably due to the common inflammatory pathway between BMD loss and joint damage. 
As progressive joint damage in the first year is superior as a predictor of further joint damage 
progression, in daily practice hand BMD loss after one year will not add to the identification of 
patients at risk for further destruction in recent-onset active RA. However, as hand BMD 
measurements by DXR are highly precise in detecting changes,[12] early BMD evaluation, at three 
to four months after disease onset or even in the undifferentiated stage of the disease, might be a 
useful tool to predict poor outcome in these patients.  
It might be argued whether progression of SHS is useful in clinical practice as a predictor, because it 
is a complicated scoring method that requires special training to perform. To mimic the daily 
clinical practice of radiographic assessment, we categorized the progression of joint damage in four 
categories: patients with no, dubious, moderate or high progression. We found that even patients 
with dubious progressive damage in the first year had 5-fold more subsequent progressive damage, 
and with moderate and high progression even 65-fold and 138-fold more than patients with no 
progression, while hand BMD loss was associated with 3-fold more subsequent damage. 
Furthermore hand BMD loss measured by the DXR technology also requires special equipment, in 
general not available in medical centers, or payments for the measurements when the online service 
is used. 
Further the fact that there are significant differences in baseline variables between patients who were 
included in this trial and patients who were not included might be argued. The included patients 
have shorter disease duration, are less often ACPA positive and have less joint damage at baseline, 
suggesting that patients with relatively less active disease were included in this trial. Nevertheless, in 
absolute terms, the included patients had high disease activity with erosive damage in the majority, 
even in this early stage of the disease. 
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Abstract 
Objective To explore the role of local inflammation in OA by studying the association between 
metacarpal BMD loss and progressive hand OA over 2 years.  
Methods Using the Kellgren-Lawrence (KL) grading scale and the OARSI atlas, standardized hand 
radiographs of 181 patients with primary OA at multiple sites (mean age 60 years, 80% females, 
mean BMI 27) were assessed for hand OA at baseline (KL ≥2 in ≥2 hand joints) and progressive 
hand OA over 2 years (≥1 point increase in total osteophyte and joint space narrowing score in 
patients with hand OA at baseline). Changes in BMD were measured over 2 years in metacarpals 2-
4 by digital X-ray radiogrammetry. Accelerated BMD loss was defined as loss of more than 3 
mg/cm2/year. Logistic regression analyses were performed to assess the associations between BMD 
loss and progressive hand OA. 
Results The baseline prevalence of hand OA was 68% and, after 2 years, 32% of these patients had 
progressive hand OA. Accelerated BMD loss was present in 79% of the patients with progressive 
hand OA compared to 60% and 57% of the patients with non-progressive hand OA and no hand 
OA, respectively. BMD loss was independently associated with progressive hand OA compared to 
non-progressive hand OA with a RR (95% CI) of 2.1 (1.1-4.3).  
Conclusion Accelerated metacarpal BMD loss is associated with progressive hand OA, which may 
suggest that local inflammation plays a role in the progression of hand OA. 
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Osteoarthritis (OA) is a heterogeneous disease characterized by degradation of articular cartilage, 
changes in subchondral bone, and osteophyte formation at the joint margins leading to joint failure. 
The disease has a major impact on the patient by increased morbidity and mortality and on society 
by high health care costs.[1]  
The pathogenesis of OA is incompletely understood, but thought to be multifactorial involving 
degenerative, biomechanical, metabolic, hormonal, and genetic factors.[2] Within OA, hand OA 
seems to be a separate subset of the disease compared to knee and hip OA with differences in 
pathogenesis and disease course. Increasing evidence supports the involvement of local and low-
grade systemic inflammation in the pathogenesis of OA, especially in the hands. In the majority of 
hand OA patients inflammatory signs, such as subchondral bone edema and synovitis in 
interphalangeal joints (IPJs) in the hands, have been shown.[3,4] In OA patients increased levels of 
pro-inflammatory cytokines in synovial fluid [5,6] and of high sensitive C-reactive protein in 
peripheral blood are found.[7,8]  
Measurement of localized bone mineral density (BMD) loss over time has been shown to be 
associated with radiographic progression over time in patients with rheumatoid arthritis and to be 
sensitive to indicate inflammatory bone involvement.[9,10] In patients with OA, the amount of 
BMD loss and the relation to the development or progression of OA is less clear. In contrast to data 
of cross-sectional studies,[11-15] longitudinal data on the relation between BMD and OA are 
limited. Two studies investigating changes in BMD in OA showed generalized BMD loss over time 
in hand, hip and knee OA.[16,17] Only one study investigated both BMD and OA parameters 
longitudinally, showing that generalized BMD loss was associated with progressive knee OA.[18] 
To our knowledge no data exists on the association between localized BMD loss and progressive 
OA in the hands. 
We hypothesized that accelerated localized BMD loss might be present in hand OA and associated 
with disease progression, as a marker for an inflammatory pathway of the disease. Therefore, we 
investigated the relationship between changes in BMD at the metacarpals and radiographic 
progression of hand OA over a period of 2 years. 
 
Patients and methods 
 
Study design and patient selection Patients were selected from the Genetics ARthrosis and Progression 
(GARP) cohort.[19] The cohort comprises 191 Caucasian sib pairs with symptomatic primary OA, 
defined according to the American College of Rheumatology (ACR) criteria, at multiple sites in the 
hands or in at least 2 of the following joint sites: hands, knees, hips or spine (cervical and 
lumbar).[20-22] Patients with secondary OA, or with familial syndromes with a Mendelian 
inheritance pattern and a shortened life expectancy were excluded.  
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The medical ethics committee of the Leiden University Medical Center approved the study 
protocol and all patients gave written informed consent prior to participation in the study. 
Of the original 191 sib pairs those with at least one subject with symptomatic hip or knee OA were 
included in a two-year follow-up study.[23] These 210 patients were eligible for the present study. 
Radiographic assessment of hand OA Standardized analogue radiographs of both hands (dorsal-volar) 
were obtained in a single center by the same experienced radiographer at baseline and after 2 years.  
To assess the presence of hand OA, baseline hand radiographs (distal interphalangeal joints [DIPJs], 
proximal interphalangeal joints [PIPJs], 1st IPJs and 1st carpometacarpal joints) were scored by a 
single experienced reader using the Kellgren-Lawrence (K-L) grading scale (scale 0-4 per joint).[24] 
This is a 5-scale scoring system with ascending severity based on the presence of osteophytes, joint 
space narrowing (JSN), sclerosis, and degenerative cyst formation. Hand OA was defined as K-L 
score of ≥2 in at least 2 hand joints.  
To assess OA progression, baseline and 2-year hand radiographs were scored in pairs for osteophytes 
and JSN by consensus opinion of two experienced readers, blinded for patient characteristics and 
time sequence, using the Osteoarthritis Research Society International (OARSI) atlas (scale 0-3 per 
joint for each feature).[25] In case of disagreement the lower, more conservative score, was 
recorded. Progressive hand OA was defined as an increase in the total osteophyte and JSN score of 
at least 1 point over 2 years in patients with hand OA at baseline.   
Intra-reader reliability for the assessment of the prevalence and progression of hand OA, expressed 
by the intra-class correlation coefficient (ICC), based on a random selection of 10% of the 
radiographs, was 0.95 and 0.95, respectively.  
Metacarpal BMD measurements Analogue radiographs of both hands were digitized by a high-
resolution 300 DPI scanner (Canon Vidar VXR-12 plus) and analyzed under blind conditions 
using the digital X-ray radiogrammetry (DXR) online from the Pronosco X-posure system (Sectra, 
Sweden).  
DXR is a computerized version of the traditional technique of radiogrammetry originally proposed 
by Barnett and Nordin to estimate bone strength with radiological assessed cortical bone 
thickness.[26] The digitized hand radiograph was subjected to a number of image processing 
algorithms where the three regions of interests around the narrowest part of the second, third and 
fourth metacarpal bones were automatically identified and subsequently the outer and the inner 
cortical edges of the included cortical bone parts were found.[27] The cortical BMD estimate is 
defined as: BMD = c x VPA x (1-p), where c is a constant; VPA is volume per area and p is 
porosity. DXR can measure changes in BMD with a high precision with smallest detectable 
difference ranging from 1.2 to 2.8 mg/cm2.[28] DXR measurements are highly correlated with 
DEXA measurements at the hip and forearm with correlation coefficients of 0.7 and 0.9, 
respectively.[27] 
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Both hands were measured using the DXR method and the mean was used for the analyses to avoid 
bias regarding dominant and non-dominant hands and to achieve better precision. Accelerated 
metacarpal BMD loss was defined as BMD loss over 3 mg/cm2/year, equal to the upper limit of 
normal metacarpal BMD loss according to specifications by the manufacturer. 
Demographic variables Demographic variables, including age, sex, weight, length, and smoking 
status, and the use of hormone replacement therapy (HRT), bisphosphonates, and calcium and 
vitamin D supplements were collected by standardized questionnaires.   
Statistical analysis Analyses were performed using SPSS, version 17 (SPSS, Chicago, IL, USA) and 
Stata, version 8.0 (Stata, College station, TX, USA). The association between BMD loss and 
progressive hand OA were tested by Mann-Whitney and chi-square tests. The p-values derived by 
multiple comparison tests were corrected by the step-down Bonferroni-Holmes adjustment. To 
determine the independent associations between BMD loss and progressive hand OA, multivariable 
logistic regression analyses were performed adjusted for age, sex, postmenopausal status, body mass 
index, family effect, smoking status, use of HRT, bisphosphonates, calcium and vitamin D 
supplements, and BMD scores at baseline.  
Odds ratios (ORs) and corresponding 95% confidence intervals (CI) were transformed to relative 
risks (RR) with 95% CI using the approximation formula described by Zhang and Yu, since ORs 
for common outcomes in a fixed cohort are not good approximations of RR.[29]  
 
Results 
 
Patient characteristics In 17 of the 210 patients eligible for the present study, 2-year hand 
radiographs were missing. In addition, of 12 patients baseline or 2-year BMD could not be analyzed 
due to improper positioning of the hands and artifacts in regions of interest. Hence, 181 patients 
were included in the present study. There were no significant differences in baseline characteristics 
between the 181 patients included in the current study and the 29 patients who were not included 
(data not shown). 
Baseline demographic and OA and osteoporosis related characteristics are shown in table 1. The 
mean age was 60 years and 80% were women, of which the majority was postmenopausal. At 
baseline 123 patients (68%) had hand OA, defined as at least 2 hand joints with KL ≥2. The mean 
(SD) metacarpal BMD was 0.57 (0.07) g/cm2. Patients with non-progressive hand OA during the 
2-year study period were significantly older and more often postmenopausal at baseline than 
patients with no hand OA and progressive hand OA (table 1). Patients with no hand OA during 
the study period had significantly higher metacarpal BMD at baseline than patients with hand OA. 
There were no other significant differences in baseline characteristics between patients with no hand 
OA and non-progressive and progressive hand OA (table 1). 
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Table 1. Demographic and OA and osteoporosis related baseline characteristics of the total study population 
and the patients with no, non-progressive and progressive hand OA during the 2-year study period. 
 
 
 
Study 
population 
n=181 
 No  
hand OA 
n=58 
Non-progressive 
hand OA 
n=84 
Progressive 
hand OA 
n=39 
Overall 
P-
value 
Demographic and OA related 
variables 
Age, years, † 
 
60 (7) 
  
59 (7) 
 
62 (7) 
 
58 (6) 
 
0.001 
Women, no. (%)  145 (80)  45 (78) 69 (82) 31 (80) 0.8 
Postmenopausal, no. (%) 133 (92)  38 (86) 69 (100) 26 (82) 0.003 
BMI, kg/m2, † 27 (4)  27 (4) 26 (3) 26 (3) 0.2 
Current smokers, no. (%)  33 (18)  14 (24) 15 (18) 4 (10) 0.2 
Hand OA, no. (%) 123 (68)  - - - - 
Osteoporosis related variables   
Metacarpal BMD, † 0.57 (0.07)  0.60 (0.06) 0.56 (0.08) 0.57 (0.06) 0.027 
HRT use, no. women (%) 25 (17)  9 (19) 11 (16) 5 (16) 0.8 
Bisphosphonate use, no. (%) 6 (3)  2 (4) 3 (4) 1 (3) 1.0 
Calcium supplement use, no. (%)  5 (3)  2 (4) 3 (4) 0 (0) 0.5 
Vitamin D supplement use, no. (%) 3 (2)  0 (0) 2 (2) 1 (3) 0.5 
† mean (standard deviation); BMI (body mass index); BMD (bone mineral density); HRT (hormone replacement 
therapy). 
 
Changes in hand OA and BMD after 2 years Of the total population, 58 patients (32%) who did not 
have hand OA at baseline, did not develop hand OA during the 2-year study period. Of the 123 
patients with hand OA at baseline, 39 patients (32%) had progressive hand OA, defined as at least 
1 point increase in total osteophyte and JSN score over 2 years, while 84 patients (68%) had non-
progressive hand OA. Of the women 31 (31%) had progressive hand OA compared to 8 men 
(35%) (p=0.918).  
In the total population, the median (IQR) metacarpal BMD change after 2 years was -9.9 (-17.6 to 
-3.1) mg/cm2 which was -1.7% (-3.2% to -0.6%) of baseline BMD. On the individual level, 114 
(63%) of the 181 patients had accelerated BMD loss, i.e. more than -6 mg/cm2 over 2 years. 
Women had more BMD loss than men (table 2).  
Progressive versus non-progressive versus no hand OA and BMD loss Patients with progressive hand OA 
had higher BMD loss over 2 years compared to patients with non-progressive hand OA and patients 
without hand OA (table 3). There were no significant differences in BMD loss over 2 years between 
patients with non-progressive hand OA and no hand OA (table 3).  
Accelerated BMD loss occurred in 31 of the 39 patients (79%) with progressive hand OA compared 
to 50 of the 84 patients (60%) with non-progressive hand OA and 33 of the 58 patients (57%) 
with no hand OA (table 4). In multivariable analysis, accelerated BMD loss was independently  
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Table 2. Changes in metacarpal BMD, in absolute value and percentage of baseline BMD, in the total 
population and in women and men separately over 2 years. 
 Total population 
n=181 
Women 
n=145 
Men 
n=36 
P-value 
Median (IQR) change in BMD  
over 2 years, in mg/cm2 
-9.9 (-17.6 to -3.1) -10.0 (-18.4 to -3.9) -6.9 (-11.9 to -0.4) 0.029 
Median (IQR) change in BMD  
over 2 years, in % of baseline BMD 
-1.7 (-3.2 to -0.6) -3.4 (-1.9 to -0.7) -1.1 (-2.0 to -0.1) 0.009 
Accelerated BMD loss,  
<-6 mg/cm2, no. (%) 
114 (63) 94 (65) 20 (56) 0.302 
IQR (interquartile range). 
 
Table 3. Changes in metacarpal BMD, in absolute value (mg/cm2) and in percentages of baseline BMD, in 
patients with progressive hand OA, non-progressive hand OA and no hand OA over 2 years. 
  Progressive hand OA 
Group 1 (n=39) 
Non-progressive hand OA 
Group 2 (n=84) 
No hand OA 
Group 3 (n=58) 
Median (IQR) change in BMD 
over 2 years, in mg/cm2 
-12.6 (-23.3 to -6.5) -8.5 (-15.1 to -3.2) -9.2 (-17.4 to -2.2) 
P-value, overall 0.025 
P-value, group 1 versus 2* 0.033 
P-value, group 1 versus 3* 0.040 
P-value, group 2 versus 3* 0.858 
Median (IQR) change in BMD 
over 2 years, in % of baseline BMD 
-2.2 (-4.1 to -1.4) -1.4 (-2.9 to -0.6) -1.4 (-3.1 to -0.4) 
P-value, overall  0.032 
P-value, group 1 versus 2* 0.045 
P-value, group 1 versus 3* 0.042 
P-value, group 2 versus 3* 0.604 
*P-values are corrected for multiple testing by the step-down Bonferroni-Holmes adjustment. 
 
associated with progressive hand OA compared to non-progressive hand OA over 2 years with a RR 
(95% CI) of 2.1 (1.1-4.3) (table 4). This association with BMD loss concerned both osteophyte 
and JSN progression equally over 2 years (data not shown). Accelerated BMD loss was also 
independently associated with progressive hand OA over 2 years when compared to no hand OA 
(data not shown). There was no association between accelerated BMD and non-progressive hand 
OA (table 4). 
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Table 4. Associations between progressive hand OA and non-progressive hand OA and no hand OA and 
accelerated metacarpal BMD over 2 years. 
 Univariable analyses                                                                                     Multivariable  
                                                                                                       Analysis 
 Progressive  
hand OA, no. 
Non-progressive  
hand OA, no. 
P-value RR (95% CI) RR (95% CI) 
Accelerated 
BMD loss 
31 50 0.030 2.0 (1.1-4.0) 2.1 (1.1-4.3) 
Non-accelerated 
BMD loss 
8 34    
 Non-progressive 
hand OA 
No hand OA P-value RR (95% CI) RR (95% CI) 
Accelerated 
BMD loss 
50 33 0.755 1.0 (0.8-1.3) 0.9 (0.6-1.2) 
Non-accelerated 
BMD loss 
34 25    
Multivariable analyses are adjusted for age, sex, postmenopausal status, body mass index, family effect, smoking status, the 
use of hormone replacement therapy, bisphosphonates, calcium and vitamin D supplements, and BMD scores at baseline. 
RR (95% CI) (relative risk (95% confidence interval)). 
 
Discussion 
 
This is the first study to evaluate localized BMD loss in relation to radiographic progression of hand 
OA. We have shown that accelerated metacarpal BMD loss is associated with radiographic 
progression of hand OA over a period of 2 years. Since localized BMD loss is a marker of 
inflammatory activity in RA,[9,10] our study supports the growing evidence for the involvement of 
inflammatory pathways in the pathogenesis of hand OA.[3-8]  
Previously Sowers et al. studied cortical bone loss, using a semi-objective method on plain 
radiographs, in female patients with progressive hand OA showing an increased likelihood of greater 
cortical area loss over 23 years.[30] The prolonged observation period leaves room for other 
explanations than inflammatory pathways driving both bone loss and joint damage in OA, such as 
immobility and estrogen deficiency. We demonstrated, with the sensitive and fully automated 
method of DXR, that the association is already evident after a relatively short period of 2 years, 
making a common inflammatory pathway more likely. Moreover, sensitivity analysis adjusting for 
age, sex, postmenopausal status, BMI, family effect and the use of HRT and additionally adjusted 
for functional limitations and pain, measured by Health Assessment Questionnaire (HAQ) or 
Australian/Canadian OA Hand Index (AUSCAN), as surrogate for immobility, showed unchanged 
associations and risk estimates.  
We did not find any differences in BMD changes over 2 years in patients with non-progressive 
hand OA compared to patients with no hand OA. This supports our hypothesis: the amount of 
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local BMD loss is comparable between patients with non-progressive hand OA and patients 
without hand OA due to no/little inflammatory activity in both situations. At this time we can only 
speculate whether finding hand OA with or without signs of inflammation indicates that there may 
be two types of osteoarthritic disease, or that there is one type, that can be either active or not.  
A subset of hand OA, that is said to be inflammatory, is erosive OA, which is based on the presence 
of subchondral erosions, indicating that there is loss of subchondral bone. In our population a small 
proportion of patients had erosive OA (12%).[31] Sensitivity analysis showed the same effects in 
those with and without erosive OA. However, this may be due to the small number of patients with 
erosive OA. 
There are some limitations of our study. Firstly, since hand OA is a heterogeneous disease with 
entities varying from mild disease to erosive, destructive hand OA, our conclusions might not be 
relevant for all entities of hand OA. Secondly, BMD was measured by DXR. Generally dual energy 
X-ray absorptiometry (DEXA) is considered the gold standard for measuring BMD. However, 
DXR and DEXA BMD measurements are highly correlated. Furthermore, DXR has a high 
precision to detect changes in BMD and seems to identify OA patients with low BMD better than 
quantitative ultrasound.[27,28,32] DXR measures bone loss in the metacarpals, enabling to assess 
effects locally in the hands such as inflammation, without measuring the extra bone formation by 
osteophytes which can lead to ‘false’ high BMD measurements. Thirdly, although there was a clear 
association between hand OA progression and BMD loss, 60% of patients with non-progressive 
hand OA had accelerated bone loss. This may be due to the high proportion of females or advanced 
age in our population or due to the fact that mild progressive hand OA is not traceable with the 
used methods on X-rays during the relatively short follow-up period of 2 years. Finally, one might 
suggest that the degree of osteoporosis might have influenced the readers scoring the radiographs for 
OA. However, at the time of the radiographic assessment the readers were unaware of the objective 
of the present study.  
In summary, we showed that accelerated metacarpal BMD loss is associated with progressive hand 
OA, suggesting that localized BMD loss and radiographic progression of hand OA share common 
pathophysiological pathways that may be predominantly inflammatory. Further research is needed 
to understand these mechanisms in order to develop possible therapeutic interventions for OA.  
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Abstract 
Objectives To investigate the association between systemic and local inflammation and incident 
and progressive radiographic secondary osteoarthritis (OA) in interphalangeal joints (IPJs) over 
three years in rheumatoid arthritis (RA) patients and the effect of TNF-α inhibitor infliximab on 
secondary OA in IPJs.  
Methods In the present observational longitudinal study baseline and 3-year hand X-rays of 416 
recent-onset RA patients were scored for osteophytes and erosions in IPJs, blinded for time, using 
OARSI atlas and Sharp-vanderHeijde score. The associations between inflammatory factors and 
incident and progressive secondary OA in DIPJs and PIPJs and the effect of infliximab compared to 
DMARD treatment on secondary OA were analyzed by multivariable regression and GEE analyses. 
Results 67% of the patients were female with, at baseline, a mean age of 54 years and OA present 
in DIPJs and PIPJs in 37% and 13%. Three years later, new secondary OA in DIPJs and PIPJs was 
seen in 11% and 10%, and progressive secondary OA in 36% and 35%. High ESR over three years 
and progressive erosive damage were risk factors for incident secondary OA in DIPJs, but not in 
PIPJs. At joint level, progression of erosions was associated with both incident and progressive 
secondary OA, only in DIPJs. Infliximab treatment was associated with lower incident secondary 
OA in PIPJs (RR (95% CI) 0.5 (0.2-1.0)), independent of decrease in inflammation. 
Conclusion Incident and progressive secondary OA in DIPJs over three years was associated with 
high inflammatory activity in RA. Infliximab treatment reduced incident secondary OA in PIPJs 
independent of decrease in inflammation, suggesting that anti-TNF-α therapy might be effective 
against secondary hand OA via other pathways than suppression of inflammation. Further studies 
in populations of primary hand OA are necessary to determine the role of anti-TNF-α in treatment 
of primary hand OA. 
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Osteoarthritis (OA) is a heterogenous group of conditions with alterations in articular cartilage, 
bone and synovium.[1] A frequently involved site is the hand where it leads to considerable loss in 
function and quality of life.[2] At present, drug therapies used in OA are limited to symptomatic 
treatment. 
The pathogenesis of OA is incompletely understood, but thought to be multifactorial involving 
degenerative, biomechanical, metabolic, hormonal and genetic factors.[3] Increasing evidence 
supports the involvement of low-grade systemic and local inflammation in the pathogenesis of OA. 
A two- to threefold increase in high sensitive C-reactive protein levels is seen in OA patients.[4-7] 
High resolution magnetic resonance imaging demonstrated subchondral bone edema, synovial 
enhancement and bone erosions in interphalangeal joints (IPJs) in the majority of OA patients.[8,9] 
Pro-inflammatory cytokines are found in increased levels in synovial fluid of OA joints,[10-12] and 
heritable differences in cytokine production are associated with the development and progression of 
OA.[13,14] Hence, inhibitors of cytokines might be considered as potential candidates for disease-
modifying therapy in OA.[15-17]  
One of the pro-inflammatory cytokines involved in OA is tumor necrosis factor alpha (TNF-α): 
increased TNF-α production and increased p55 TNF-α receptor expression on chondrocytes imply 
the intervention of TNF-α on joint destruction in OA.[18-23] It is shown that TNF-α inhibitors 
are able to suppress nitric oxide production in human cartilage.[24] Two pilot studies using anti-
TNF-α therapy in erosive hand OA reported some improvement in clinical efficacy measures, 
however the studies were small and therefore inconclusive.[25,26]   
In the present study we took advantage of the fact that in patients with rheumatoid arthritis (RA) 
simultaneous development and progression of secondary hand OA exists. In a trial in recent-onset 
active RA patients who were treated with TNF-α inhibitors and conventional disease-modifying 
anti-rheumatic drugs (DMARDs) we investigated the associations between systemic and local 
inflammatory factors and incident and progressive radiographic secondary osteoarthritis in IPJs over 
three years and the effect of treatment with TNF-α inhibitor infliximab on incident and progression 
of secondary OA in IPJs in RA patients. 
 
Patients and methods 
 
Patients The present study is an exploratory observational longitudinal study analyzing data from 
the BeSt study, an ongoing multicenter, randomized clinical trial designed to compare the efficacy 
of four treatment strategies in recent-onset active RA patients, independent of the confirmatory 
strategy for any of the trial’s endpoints.[27] In short, between April 2000 and August 2002, 508 RA 
patients (ACR 1987 revised criteria) with symptom duration less than two years and active disease 
were included. Inclusion and exclusion criteria were reported previously in detail.[27] 
Rheumatologists participating in the Foundation for Applied Rheumatology Research in 18 
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peripheral and 2 university hospitals in the western part of the Netherlands designed and conducted 
the BeSt study. The medical ethics committee at each participating center approved the study 
protocol and all patients gave written informed consent prior to participation in the study. 
Study design According to the pharmacoprotocol of each treatment arm, patients could be treated 
with the TNF-α inhibitor infliximab in combination with methotrexate 25 mg/week, either as 
initial treatment or as delayed treatment after failing on at least three previous DMARDs 
(‘infliximab group’). Patients started with infliximab 3 mg/kg/8 weeks and in case of insufficient 
response, a disease activity score (DAS) in 44 joints >2.4, the dose was increased step by step to 6, 
7.5, and 10 mg/kg. If the DAS was ≤2.4 for at least six consecutive months, the dose of infliximab 
was reduced in reverse order to 3 mg/kg and stopped. Patients who did not receive infliximab 
during the study period (‘no infliximab group’) were treated with DMARDs (methotrexate, 
sulphasalazine, leflunomide, hydrochloroquine) and prednisone, either as monotherapy or 
combination therapy. DAS, including the Ritchie articular index, the 44 swollen joint count, the 
erythrocyte sedimentation rate (ESR) and a general health assessment on a visual analogue score, 
was measured three-monthly during the follow-up period. In all patients, treatment adjustments, 
previously described in detail, were based on aiming at DAS ≤2.4.[27] Concomitant treatment with 
NSAIDS and anti-resorptives was permitted. 
Radiographic assessment of secondary OA in IPJs Radiographs of both hands were obtained at baseline 
and after three years. Osteophytes were scored in 8 distal IPJs (DIPJs), 8 proximal IPJs (PIPJs) and 
2 1st IPJs by one reader, blinded for patient characteristics, treatment and chronological order, using 
the Osteoarthritis Research Society International atlas (scale 0-3 per joint).[28] The scores of 1st 
IPJs were merged with the scores of PIPJs. Intra-reader variability for assessment of osteophytes in 
DIPJs and PIPJs, depicted by the intra-class correlation coefficient (ICC) based on an at random 
selection of 30 pairs of hand radiographs, was 0.91 and 0.90 with a smallest detectable change 
(SDC) of 0.9 units for both joint groups.  
OA in IPJs, and DIPJs and PIPJs, at baseline was defined as an osteophyte score of at least 1 unit in 
IPJs, and DIPJs and PIPJs, respectively. At patient level, incident and progressive secondary OA in 
DIPJs and PIPJs was defined as an increase in total osteophyte score ≥SDC (=0.9 units for DIPJs 
and PIPJs) over three years in absence and presence, respectively, of OA at baseline in DIPJs and 
PIPJs. At joint level, incident and progressive secondary OA was defined as an increase in 
osteophyte score ≥1 unit in one joint over three years in absence and presence of OA in that joint at 
baseline. 
Radiographic assessment of erosions in IPJs Erosions were scored in 18 IPJs at baseline and after three 
years using the Sharp-van der Heijde score (SHS) method (scale 0-5 per joint) by the same reader in 
a second session, blinded for all data.[29] According to the SHS method all erosions, whether 
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typical of RA or OA, are scored. The ICC for assessment of erosions in DIPJs and PIPJs was 0.94 
and 0.97 with SDCs of 1.3 and 1.1 units.  
Erosive disease in DIPJs and PIPJs at baseline was defined as an erosion score ≥1 unit in DIPJs and 
PIPJs, respectively. At patient level, progressive erosive damage in DIPJs and PIPJs was defined as 
an increase in erosion score ≥SDC (1.3 units for DIPJs and 1.1 units for PIPJs) over three years in 
DIPJs and PIPJs. At joint level, progressive erosive damage was defined as an increase in erosion 
score ≥1 unit over three years. 
Statistical analysis Analyses were performed using SPSS, version 17 (SPSS, Chicago, IL, USA).  
To determine the independent demographic (input: age, gender and BMI) and inflammation-
related (input: RF, baseline ESR, area under the curve [AUC] of ESR over three years, baseline 
erosion score and progressive erosion score over three years ≥2 units) of incident and progressive 
secondary OA in DIPJs and PIPJs, multivariable logistic regression analyses were performed in 
which all variables were entered and adjusted for anti-resorptive treatment (bisphosphonates, 
calcium and vitamin D supplements and hormone replacement therapy [HRT]).  
The association between osteophytes and erosions was further explored at joint level by generalized 
estimating equations (GEE). GEE is a regression technique that allows analyzing longitudinal or 
clustered data while adjusting for within-patient correlation. GEE requires an a priori working 
correlation structure in order to adjust for the within-patient correlation. Based on the data an 
exchangeable correlation structure was chosen here. Increase in osteophyte score of ≥1 unit after 
three years was entered as dichotomous dependent variable. Increase in erosion score of ≥1 unit 
after three years, presence of OA at baseline and joint group (categorised in DIP and PIP joint 
group) were entered into the model, adjusted for age, gender, BMI and anti-resorptive treatment 
and additionally for erosion scores at baseline. 
The effect of infliximab treatment versus no infliximab, thus DMARD, treatment on incident and 
progressive secondary OA in DIPJs and PIPJs were analyzed by multivariable logistic regression 
analyses, adjusted for age, gender, BMI and anti-resorptive treatment and variables differing 
between the treatment groups at baseline and during study period. These analyses were repeated 
while additionally adjustments for systemic and local inflammatory factors to study whether the 
effect of infliximab on secondary OA could be explained by suppression of inflammation.  
The odds ratios (OR) with 95% confidence intervals (95% CI) were transformed to relative risks 
(RR) and corresponding 95% CI using the approximation formula described by Zhang and Yu as 
OR for common outcomes in a closed cohort are not good approximations of RR.[30]  
 
Results 
 
Patient characteristic In 416 of the 508 RA patients hand radiographs at baseline and after three 
years were available and these patients were included in the present study. Baseline characteristics of 
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Table 1. Baseline demographic and disease related characteristics of the total study population and infliximab 
and no infliximab group. 
 Total group 
n=416 
 Infliximab group 
n=178 
No infliximab group 
n=238 
P-value 
Demographic variables      
Age, years, † 54 (14)  52 (14) 56 (13) 0.001 
Women, %  67  70 65 0.280 
Postmenopausal, % (n=279) 67  63 71 0.225 
BMI, kg/m2, † (n=398) 26 (4)  26 (4) 26 (3) 0.720 
Disease related variables      
Inflammatory symptom duration, 
weeks, ‡ 
23 (14-53)  27 (15-56) 22 (13-42) 0.040 
Positive IgM RF, %  65  68 63 0.345 
HAQ score, 0-3, † 1.4 (0.7)  1.4 (0.6) 1.3 (0.7) 0.469 
ESR, mm/hr, ‡ 37 (20-56)  34 (18-58) 37 (22-51) 0.987 
Erosion score, † 
IPJs, 0-90 
DIPJs, 0-40  
PIPJs, 0-50  
 
0.4 (1.9) 
0.1 (0.9) 
0.3 (1.4) 
  
0.5 (2.4) 
0.1 (0.7) 
0.4 (2.0) 
 
0.3 (1.3) 
0.1 (1.0) 
0.2 (0.8) 
 
0.536* 
0.246* 
0.842* 
≥1 erosion, % 
IPJs 
DIPJs 
PIPJs 
 
21 
10 
16 
  
18 
12 
13 
 
23 
9 
19 
 
0.317 
0.413 
0.184 
Osteophyte score, † 
IPJs, 0-54 
DIPJs, 0-24 
PIPJs, 0-30 
 
1.7 (3.8) 
1.3 (2.7) 
0.4 (1.5) 
 
 
 
 
1.2 (3.0) 
0.9 (2.2) 
0.3 (1.3) 
 
2.0 (4.3) 
1.6 (3.0) 
0.5 (1.7) 
 
0.006* 
0.009* 
0.533* 
≥1 osteophyte, % 
IPJs 
DIPJs 
PIPJs 
 
38 
37 
13 
  
30 
29 
12 
 
44 
42 
14 
 
0.004 
0.010 
0.535 
† mean (standard deviation); ‡ median (interquartile range); BMI (body mass index); RF (rheumatoid factor); HAQ 
(health assessment questionnaire); ESR (erythrocyte sedimentation rate). *P-values derived by non-parametric tests. 
 
these patients are demonstrated in table 1. The baseline characteristics were not significantly 
different between the patients in the present study and the total study population (data not shown). 
67% were female, of whom 67% were postmenopausal at baseline. The mean age was 54 years and 
315 patients were over the age of 45. At baseline, OA was present in IPJs in 39% of women and 
36% of men. OA occurred more often in DIPJs (37%) than in PIPJs (13%). Only 8 patients 
(7.9%) below the age of 45 (mean (SD) 40 (3.9)) had OA in DIPJs and just one of these patients 
had also OA in PIPJs. Erosive disease was present in IPJs in 21% of the patients. Although erosions 
were more often seen in PIPJs (16%), a considerable number of patients had also erosions in DIPJs 
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Table 2. Distribution of changes in osteophyte scores, in units, over three years in 416 patients with absence 
and presence of OA in IPJs, DIPJs and PIPJs at baseline 
  ≤-3 -2 -1 0 1 2 3 4 5 6 7 ≥8 
No OA at baseline              
All IPJs 0 0 0 226 13 7 5 0 3 1 1 1 
DIPJs 0 0 0 233 14 9 4 2 1 0 0 0 
PIPJs 0 0 0 327 20 6 6 2 0 0 0 1 
OA at baseline              
IPJs 2 10 19 52 33 19 13 4 1 2 0 4 
DIPJs 1 7 16 74  27 17 6 1 0 2 1 1 
PIPJs 2 3 9 21 11 6 2 0 0 0 0 0 
 
 (10%). The patients who were treated with infliximab were significantly younger, had longer 
inflammatory symptom duration and less osteophytes in DIPJs at baseline. The finding of less 
osteophytes in the infliximab group was explained by the lower age (data not shown).  
Incident and progressive secondary OA in IPJs The distribution of changes in osteophyte scores in 
DIPJs and PIPJs over three years is shown in table 2. Incident secondary OA occurred in 31 
patients (12%) in all IPJs, in 30 patients (11%) in DIPJs and in 35 patients (10%) in PIPJs. 
Progressive secondary OA was present in 76 patients (48%) in IPJs, in 55 patients (36%) in DIPJs 
and in 19 patients (35%) in PIPJs.  
Incident and progressive secondary OA in IPJs and demographic and inflammatory factors 
The association between various demographic and inflammation-related factors and incident and 
progressive secondary OA were analyzed by univariable logistic regression analyses (table 3). To 
determine the independent risk factors of incident and progressive secondary OA multivariable 
analyses were performed (table 4). Higher age was independently associated with incident secondary 
OA in DIPJs and PIPJs and female gender only with incident secondary OA in DIPJs. High AUC 
of ESR and progressive erosion score over three years were associated with incident secondary OA 
in DIPJs, however these associations were not statistically significant. Progression of erosions over 
three years was associated with progressive secondary OA in PIPJs but not independently. None of 
the other demographic and inflammation-related factors were related to progressive secondary OA 
in DIPJs and PIPJs.  
Table 5 summarizes the results of the GEE analyses. The presence of an osteophyte in an 
interphalangeal hand joint at baseline increased the chance of having an increase in the osteophyte 
score in the same joint during the study period with a RR (95% CI) of 1.6 (1.2-1.9) and increase of 
osteophyte score was more often seen in DIPJs than in PIPJs with a RR (95% CI) of 1.7 (1.1-1.5). 
Progressive erosion score in an interphalangeal hand joint was associated with an increase in the 
osteophyte score in the same joint with a RR (95% CI) of 2.5 (0.9-6.4). Interaction and post hoc 
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Table 3. Associations between demographic and inflammatory factors and incident and progressive secondary 
OA in DIPJs and PIPJs over three years derived by univariable logistic regression analyses 
RR (95% CI) (relative risk (95% confidence interval)); BMI (body mass index); RF (rheumatoid factor); AUC (area under the 
curve); ESR (erythrocyte sedimentation rate). 
 
analyses showed that progressive erosive damage in a single joint was significantly associated with 
both incident and progressive OA only in DIPJs (p=0.036 and 0.045, respectively), not in PIPJs.  
Effect of infliximab on incident and progressive secondary OA in IPJs During the study period 178 
(43%) patients were treated with infliximab. The median (IQR) cumulative infliximab dose was 40 
(24-61) mg/kg during a median (IQR) period of 13 (9-21) months. The patients from the ‘no 
infliximab group’ were treated with conventional DMARDs: 60% with combination therapy, 
mostly methotrexate and sulphasalazine with prednisone and/or hydrochloroquine. After three 
years, 58% still received monotherapy (60% methotrexate, 31% sulphasalazine monotherapy, 9% 
other), and 13% had discontinued all treatment due to clinical remission. Patients in the infliximab 
group received less bisphosphonates (12% versus 22%, p=0.013) due to lower corticosteroid use, 
but more hormone replacement therapy (21% versus 11%, p=0.005) due to more perimenopausal 
women. There were no significant differences in the use of NSAIDS and specific COX 2 inhibitors 
between the treatment groups (data not shown). None of these treatments had effect on incident 
 DIPJs PIPJs 
 Incident secondary  
OA (n=263) 
Progressive secondary 
OA (n=153) 
Incident secondary 
OA (n=362) 
Progressive secondary 
OA (n=54) 
 
 
RR 
(95% CI) 
P-
value 
RR 
(95% CI) 
P-
value 
RR 
(95% CI) 
P-
value 
RR 
(95% CI) 
P-
value 
Demograhics 
Age <50 year 
       50-60 year 
       ≥60 year 
 
1 
1.8 (1.1-2.5) 
3.0 (1.5-4.5) 
 
0.023 
0.003 
 
1 
1.0 (0.4-2.0) 
1.1 (0.6-1.4) 
 
0.957 
0.771 
 
1 
1.6 (0.8-3.0) 
2.8 (1.8-3.5) 
 
0.162 
0.000 
 
1 
0.2 (0.01-2.1) 
1.2 (0.5-1.5) 
 
0.290 
0.731 
Female gender 1.4 (1.1-1.5) 0.014 1.1 (0.8-1.2) 0.573 1.1 (0.9-1.3) 0.312 1.0 (0.6-1.2) 0.817 
BMI <25 kg/m2 
BMI 25-30 kg/m2 
BMI ≥30 kg/m2 
1 
0.9 (0.5-1.5) 
1.3 (0.5-2.9) 
 
0.813 
0.617 
1 
1.04 (0.7-1.4) 
1.3 (0.5-2.7) 
 
0.858 
0.619 
1 
0.7 (0.4-1.3) 
1.1 (0.7-1.4) 
 
0.295 
0.754 
1 
1.1 (0.4-2.7) 
2.0 (0.3-9.2) 
 
0.898 
0.488 
Disease related 
Positive RF 
 
1.1 (0.8-1.3) 
 
0.541 
 
1.2 (0.9-2.2) 
 
0.260 
 
0.9 (0.6-1.1) 
 
0.676 
 
1.0 (0.6-2.4) 
 
0.983 
Baseline ESR ≥30 
mm/hr 
1.4 (1.0-1.6) 0.031 0.9 (0.6-1.2) 0.599 1.0 (0.7-1.3) 0.978 1.4 (0.8-1.8) 0.165 
AUC ESR 0-3 
year ≥30 mm/hr 
2.8 (1.5-5.0) 0.003 1.4 (0.9-2.0) 0.090 1.4 (0.8-2.6) 0.255 1.1 (0.5-1.9) 0.880 
Baseline erosion 
score ≥1 unit 
1.4 (0.4-4.0) 0.599 1.2 (0.9-1.9) 0.383 2.3 (0.98-4.7) 0.059 1.2 (0.4-3.0) 0.729 
∆ erosion score 0-
3 year ≥2 units 
5.5 (1.3-18.3) 0.023 1.7 (0.4-7.2) 0.505 1.1 (0.3-4.0) 0.923 5.5 (0.6-22.3) 0.121 
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Table 4. Independent associations between demographic and inflammatory factors and incident and 
progressive secondary OA in DIP and PIP joints over three years derived by multivariable logistic regression 
analyses 
Following variables were entered in the multivariable analyses: age, gender, body mass index, presence of rheumatoid 
factor, baseline ESR, area under the curve (AUC) erythrocyte sedimentation rate (ESR) 0-3 year, baseline erosion score 
and progressive erosion score 0-3 year, adjusted for anti-resorptive treatment during study period. RR (95% CI) (relative 
risk (95% confidence interval)). 
 
Table 5. Associations between presence of hand OA at baseline, distribution over the joints (DIPJs and PIPJs) and 
progressive erosive damage and changes in osteophyte scores over three years at joint level in IPJs derived by 
generalized estimating equations 
 Delta osteophyte score ≥1 unit per joint 
 RR (95% CI) Overall P-value 
Presence hand OA at baseline 1.6 (1.2, 1.9) 0.003 
DIPJs versus PIPJs 1.7 (1.1, 1.5) 0.006 
Delta erosion score ≥1 unit per joint 2.5 (0.9, 6.4) 0.078 
All data are adjusted for age, gender, BMI and anti-resorptive treatment and delta erosion score ≥1 unit is additionally  
adjusted for erosive damage at baseline. RR (95% CI) (relative risk (95% confidence interval)). 
   
or progressive secondary OA over three years (data not shown). Treatment with infliximab was 
associated with less incident secondary OA in PIPJs, however not statistically significant (6% versus 
13%, p=0.059, table 6, figure 1A). Five patients treated with infliximab (24%) had progressive 
secondary OA in PIPJs versus 14 (42%) of the patients not treated with infliximab (p=0.163, table 
6, figure 1B). In multivariable analyses, adjusted for age, gender, menopausal status, BMI, 
inflammatory symptom duration, OA at baseline and the use of anti-resorptive treatment during 
the study period, treatment with infliximab showed a trend towards less incident secondary OA in 
PIPJs with a RR (95% CI) of 0.5 (0.2-1.1) (p=0.087, table 6). Extra adjustments for changes in 
systemic and local inflammatory factors over three years did not change the association between 
infliximab treatment and incident secondary OA in PIPJs, which suggests that the effect of  
 DIPJs PIPJs 
 Incident  
secondary OA  
Progressive 
secondary OA  
Incident  
secondary  OA 
Progressive 
secondary OA 
 RR (95% CI) P-value RR (95% CI) RR (95% CI) P-value RR (95% CI) 
Age <50 year 
       50-60 year 
       ≥60 year 
1 
1.7 (0.9, 2.5) 
3.5 (1.8, 5.2) 
 
0.073 
0.002 
 
- 
- 
1 
1.6 (0.8, 2.4) 
2.9 (1.8, 3.6) 
 
0.191 
0.001 
 
- 
- 
Female gender 1.5 (1.2, 1.6) 0.003 - - - - 
AUC ESR 0-3 
year ≥30 mm/hr 
1.6 (0.9, 2.1) 0.081 - - - - 
∆ erosion score 0-
3 year ≥2 units 
5.1 (0.9, 15.6) 0.068 - - - - 
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Table 6. Incident and progressive secondary OA in DIPJs and PIPJs over three years between the infliximab and 
‘no infliximab group’ derived by chi-square tests and univariable and multivariable logistic regression analyses 
 DIPJs PIPJs 
 Incident secondary 
OA 
Progressive 
secondary OA 
Incident  
secondary OA 
Progressive 
secondary  OA 
Chi-square analyses No. /total 
(%) 
P-
value 
No. /total 
(%) 
P-
value 
No. /total 
(%) 
P-
value 
No. /total 
(%) 
P-
value 
Infliximab group 14 /125 
(11) 
0.920 20 /53 
(38) 
0.737 9 /157 (6) 0.059 5 /21 (24) 0.16
3 
No infliximab group 16 /138 
(12) 
35 /100 
(35) 
 26 /205 
(13) 
14 /33 
(42) 
  
Logistis regression analyses RR  
(95% CI) 
P-
value 
RR  
(95% CI) 
P-
value 
RR  
(95% CI) 
P-
value 
RR  
(95% CI) 
P-
value 
Infliximab group, unadjusted 1.0  
(0.5, 1.9) 
0.920 1.1  
(0.7, 1.7) 
0.737 0.5  
(0.2, 0.9) 
0.027 0.6  
(0.2, 1.3) 
0.16
3 
Infliximab group, adjusted for 
demographics* 
0.8  
(0.4, 1.7) 
0.578 1.2  
(0.7, 1.8) 
0.490 0.5  
(0.2, 1.1) 
0.087 0.6  
(0.2, 1.5) 
0.47
7 
Infliximab group, adjusted for 
demographics and cumulative 
inflammatory activity** 
0.6  
(0.2, 1.3) 
0.182 1.1  
(0.6, 1.7) 
0.682 0.5  
(0.2, 1.0) 
0.059 0.5  
(0.1, 1.6) 
0.33
2 
 *Adjusted for age, gender, BMI and anti-resorptive treatment. 
 ** Adjusted for age, gender, BMI, and anti-resorptive treatment, presence of RF, baseline ESR, AUC ESR 0-3 years,   
 baseline erosion score and progressive erosion score over 3 years. 
RR (95% CI) (relative risk (95% confidence interval)). 
 
infliximab on incident secondary OA in PIPJs is independent of suppression of inflammatory 
activity over three years (table 6). After adjustment for inflammatory activity during three years, the 
effect of infliximab on incident secondary OA in DIPJs was also getting more substantial, but not 
significant, with a RR (95% CI) of 0.6 (0.2-1.3) compared to 1.0 (0.5-1.9) in the unadjusted 
analysis. Infliximab did not have an effect on progressive secondary OA in DIPJs and PIPJs. 
 
Discussion 
 
The present study showed, by an alternative approach evaluating secondary OA outcome in patients 
with RA, two important findings: 1) there is a link between inflammation, measured by high ESR 
and progressive erosive damage over three years, and incident and progressive secondary OA in 
DIPJs but not in PIPJs; and 2) there is a clear trend towards an inhibitory effect of treatment with 
infliximab on incident secondary OA in PIPJs, not in DIPJs, independent of the effect of infliximab 
on inflammatory activity during three years. 
There has been increasing evidence that both low-grade systemic and local inflammation is playing 
a role in the pathogenesis of primary OA.[4-9] We found that high systemic and local inflammation  
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Figure 1. Incident (A) and progressive (B) secondary OA in PIPJs over three years in the infliximab and no 
infliximab group. 
 
Figure A: incident secondary OA is defined as an increase in osteophyte score ≥1 unit in absence of OA at baseline, thus 
26/205=12.7% incident secondary OA in PIPJs in the no infliximab group compared to 9/157=5.7% in the infliximab 
group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B: progressive secondary OA is defined as an increase in osteophyte score ≥1 unit in presence of OA at baseline, 
thus 14/33=42.4% progressive secondary OA in PIPJs in the no infliximab group compared to 5/21=23.8% in the 
infliximab group. 
23.8% progressive 
secondary OA in PIPJs 
12.7% incident 
secondary OA in PIPJs 
5.7% incident secondary 
OA in PIPJs 
42.4% progressive 
secondary OA in PIPJs 
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during three years, measured by high AUC of ESR (at patient level) and progressive erosive damage 
(at joint level), was significantly associated with incident and/or progressive secondary OA in DIPJs 
in RA patients, suggesting that systemic inflammation might play a role in the development of 
secondary hand OA. The differences in association between inflammation and the development of 
secondary OA in DIPJs and PIPJs in RA patients could be due to differences in the level of 
inflammation at the different joint levels in RA patients and in differences in the role of 
inflammation with regard to the pathophysiological mechanisms of secondary OA between DIPJs 
and PIPJs. 
Previous studies showed that joint tissues in primary OA are the site of active production of TNF-α 
enhancing joint destruction.[18-23] Two pilot studies and one case report showed positive results 
of anti-TNF-α treatment in primary OA patients.[25,26,31] The first pilot study was an open-label 
study and showed in 12 patients with inflammatory erosive hand OA treated with adalimumab 40 
mg/2 weeks for three months significant improvement in the number of swollen joints and similar 
trends in other outcome measures.[25] The second pilot study was a 1-year placebo-controlled 
double-blind study and showed in 10 female patients with erosive hand OA treated with monthly 
intra-articular injections of infliximab 0.1 mg/ml or physiological saline for one year significant 
improvement in pain scores and non-significant reduction of radiographic score in IPJs in the 
infliximab group.[26] However, these studies were small and therefore inconclusive. We found a 
clear trend towards an inhibitory effect of infliximab on incident secondary OA: infliximab 
treatment resulted in a twofold decrease in incident secondary OA in PIPJs in RA patients, 
independent of the effect of infliximab on suppression of inflammation. This suggests that 
treatment with TNF-α inhibitors might be effective against development of secondary OA, however 
not by inflammatory pathways, but by other bone linked pathways. This corresponds with the 
absence of an association between inflammation and secondary OA in PIPJs and the observed 
increasing trend towards a more protective effect of infliximab against incident secondary OA in 
DIPJs after adjusted for cumulative systemic and local inflammatory activity during three years. 
Osteophytes are thought to be formed by mesenchymal stem cells present in the periosteum or 
synovial lining undergoing chondrogenesis, followed by endochondral ossification and deposition of 
bone.[32] The process is not fully understood, but key factors appear to be transforming growth 
factor beta and insuline-like growth factor-I.[32] We speculate that TNF-α might also play a role in 
the process of osteophyte formation, since inhibition of TNF-α appears to suppress it. Therefore we 
think that our data on secondary hand OA might also be relevant for primary hand OA, suggesting 
that treatment with TNF-α inhibitors might reduce the development or progression of primary 
hand OA and this might be possibly via other mechanisms than suppression of inflammation. Large 
randomized, placebo-controlled, clinical trials in primary hand OA are needed to confirm this. 
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A limitation of the present study is that the development and progression of secondary OA is 
studied in a RA cohort. First, in this setting the evaluation of two diseases in a single joint might be 
less reliable. Second, the value of radiographic evaluation by the presence of osteophytes, in stead of 
the much wider used joint space narrowing, might be argued, however the evaluation of cartilage 
degradation was not preferred in this study due to high occurrence in both diseases. The focus on 
osteophytes might introduce the possibility of underestimation of incident and progressive 
secondary OA, however any possible misclassification of OA is non-differential with regard to 
treatment because the radiographic changes were assessed blinded for the treatment group. 
Furthermore changes in bone and cartilage seem to be tightly coupled in OA,[33] emphasized by 
the protective effect of alendronate on both cartilage degradation and osteophyte formation in a rat 
model.[34] Third, a minority of the patients had OA at baseline and a 3-year follow-up period is 
relatively short for OA processes, hence the numbers of patients who had incident and progressive 
secondary OA in IPJs over three years was rather small, especially progressive secondary OA in 
PIPJs was only seen in 19 patients. A longer follow-up period might reveal more incident and 
progressive secondary OA and therefore add power to find associations between inflammation and 
TNF-α inhibition and incident and progressive secondary OA. 
In conclusion, our study showed that high systemic and local inflammation is linked to incident 
and progressive secondary OA in distal interphalangeal joints over three years in recent-onset active 
RA patients. Treatment with a TNF-α inhibitor might decrease incident secondary OA in proximal 
interphalangeal joints, independent of the suppression of inflammation. The value of anti-TNF-α 
in treatment of primary hand OA is still unknown and needs further research. 
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9Summary and general discussion
 132 
This thesis focuses on the effect of inflammatory activity and anti-inflammatory treatment on bone 
mineral density (BMD) loss in recent-onset rheumatoid arthritis (RA), and on localized BMD loss 
and the effect of tumor necrosis factor alpha (TNFα) inhibition in (secondary) hand osteoarthritis 
(OA).  
 
Chapter 1 gives a general introduction on RA and OA, addressing especially etiology, bone 
destruction, including joint damage and BMD loss, and treatment options.  
With regard to RA, in the past decade a revolution took place in the treatment of patients 
diagnosed with the disease. New developments in anti-rheumatic treatment, including the advent of 
biologicals, the more early and intensive treatment approach, and validated monitoring tools 
resulted in better disease outcomes, higher quality of life, and decrease in sick leave; in other words 
less burden on patient and society.  
The BeSt study, acronym for Behandel Strategieën, i.e. treatment strategies, pulls its weight on this 
revolution. The inventors of the BeSt study introduced a novel study design comparing four 
different treatment strategies in which treatment adjustments were made continuously when low 
disease activity, defined as disease activity score (DAS) ≤2.4, was not reached in patients with 
recent-onset RA. On the other hand, treatment could be tapered to monotherapy in a maintenance 
dose, and thereafter even to zero when longstanding, i.e. six consecutive months, low disease 
activity, DAS ≤2.4, or clinical remission, DAS <1.6, was reserved. The treatment strategies were: 
group 1. sequential monotherapy starting with methotrexate (MTX), group 2. step-up combination 
therapy starting also with MTX, group 3. initial combination therapy with MTX, sulphasalazine 
and quickly tapered high dose of prednisone, and group 4. initial combination therapy with MTX 
and TNFα inhibitor infliximab. In the initial combination groups, group 3 and 4, low disease 
activity was reached earlier, and therefore a greater reduction of joint damage progression was seen 
compared to the initial monotherapy groups, group 1 and 2.[1] The studies described in chapters 
2-6 and 8 have been conducted as part of the still ongoing BeSt study. 
One of the hallmarks of RA is bone destruction, including joint damage, and localized and 
generalized BMD loss. It is known that the inflammation-driven, activated osteoclast, mediated 
particularly through the osteoprotegerin/receptor activator of NK-kappaB ligand (OPG/RANKL) 
signaling system, is the most crucial cell in the pathogenesis of joint damage. The direct effect of 
this inflammation-driven mechanism on BMD loss is less clear. When inflammatory activity plays 
an important role in the etiology of BMD loss, anti-inflammatory treatment might influence this 
towards less BMD loss. Nevertheless, on the other hand, the in RA frequently used corticosteroids 
are notorious in having a catabolic effect on bone. Localized BMD loss in the hands is proposed as 
an outcome measure for bone involvement in RA. The value of localized BMD loss in an early stage 
of the disease to predict subsequent destructive disease, compared to other well-known predictors, is 
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not clear. It is thought that, just as in RA, inflammatory activity might play an important role in the 
development and progression of hand OA. Consequently, strong anti-inflammatory agents, such as 
TNFα inhibitors, might diminish or stop bone destruction in hand OA. 
 
In this thesis, the relation between inflammation, and localized and generalized BMD loss was 
investigated in recent-onset RA. The effect of novel, dynamic treatment strategies with anti-
rheumatic drugs, including corticosteroids and anti-TNFα, and anti-resorptive drugs on BMD loss 
was studied. Furthermore, the value of localized BMD loss in the hands to predict subsequent joint 
destruction, in comparison to other well-known predictors, was analyzed. The role of inflammation 
in progression of hand OA was studied by assessing localized BMD loss in the hands. The possible 
effect of anti-TNFα treatment on incident and progressive hand OA was examined by its effect on 
secondary hand OA in RA. 
 
Generalized osteoporosis in recent-onset RA 
 
Generalized osteoporosis is a well-known complication in patients with uncontrolled, longstanding 
RA with severe joint destruction, functional disability, and immobilization, resulting in a two-fold 
increase in risk of hip and vertebral fractures.[2] In order to unravel the common inflammatory 
mechanisms between generalized osteoporosis and joint destruction, osteoporosis data from just 
diagnosed patients with active, and anti-rheumatic treatment naïve RA were collected in a cross-
sectional study. In chapter 2 we show that osteoporosis, defined as T-score ≤2.5 SD, is found in 
11%, 4%, and 9% in the hip and/or spine, in only the hip and, in only the spine, respectively, of 
the newly diagnosed, active, DMARD- and corticosteroid-naïve patients with RA. Besides well-
known risk factors for generalized osteoporosis, such as postmenopausal status, low body mass 
index, and familial osteoporosis, the presence of rheumatoid factor, and longer duration of 
inflammatory symptoms are associated with osteoporosis and/or reduced BMD, indicating that 
generalized osteoporosis is an inflammation-driven process. However, still, in this very early, 
treatment-naïve, stage of the disease, the prevalence of osteoporosis in our postmenopausal RA 
patients is roughly comparable with the prevalence in two Dutch cohorts with postmenopausal 
women from the general population, emphasizing the importance of both early anti-inflammatory 
and anti-osteoporotic intervention, including stimulating physical activity, reducing risk of falls, 
and starting anti-osteoporotic medications in patients at high risk for fractures, in order to prevent 
high occurrence of osteoporosis and accelerated generalized BMD loss in RA.[3-5] 
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Generalized BMD loss in the first year of RA 
 
Accelerated generalized BMD loss seems to be inflammation-driven in RA. The effect of different, 
modern, anti-rheumatic treatment strategies, including corticosteroids and the anti-TNFα 
infliximab, on generalized BMD over time is unknown. In chapter 3 we demonstrate that BMD 
loss after 1 year is 1.0% and 0.8% of baseline BMD in the hip and spine, respectively. This is 
considerably higher than the BMD loss of around 0.5% after 2 years in the femoral neck in the 
general Dutch population above 55 years.[6] No significant differences in generalized BMD loss are 
observed between the treatment groups, including corticosteroids and infliximab, after 1 year of 
treatment, suggesting that the effect of these drugs on suppressing disease activity outweighs any 
negative effect on generalized bone metabolism. The use of calcium and/or vitamin D suppletion 
does not protect against generalized BMD loss, but the use of bisphosphonates does. Patients with 
more progressive destructive disease are more susceptible for accelerated BMD loss during the first 
year, independent of the allocated treatment group, emphasizing that erosions and generalized 
BMD loss share a common inflammation-driven pathway in RA. 
 
Localized and generalized BMD loss in the first years of RA 
 
It is thought that localized BMD in the proximity of inflamed joints is more prone to degradation 
due to inflammation than generalized BMD in the hip and spine where RA is less active. In chapter 
4 we confirm that there is significantly more localized BMD loss in the hands than generalized 
BMD loss in the hip and spine after 2 years of treatment (median loss 2.5% versus 0.5 to 1.0% 
after 2 years). While generalized BMD loss is after 2 years again not significantly different between 
the four treatment groups, localized BMD loss in the hands after 1 and 2 year(s) is significantly less 
in the initial combination groups due to earlier suppression of the inflammation during the first six 
months of the treatment (median localized BMD loss 3.6%, 3.3%, 1.4%, and 1.6% for group 1-4 
after 2 years). There are no significant differences in localized BMD loss between initial 
combination therapy including quickly tapered high dose of prednisone and initial combination 
therapy including the TNFα inhibitor infliximab. This emphasizes that the anti-inflammatory effect 
of induction therapy with corticosteroids exceeds the direct catabolic effect of it on BMD, and that 
initial combination therapy with the anti-TNFα infliximab is not superior with regard to BMD loss 
to initial therapy including quickly tapered high dose of corticosteroids. Above all, early and 
intensive suppression of inflammation is crucial to prevent, especially localized, BMD loss. 
Underlining further the role of inflammation on BMD, both generalized and localized BMD loss 
are associated with progressive erosive damage in the joints. The use of oral bisphosphonates 
protects against generalized BMD loss, however, not against localized BMD loss. This indicates that 
oral alendronate 10 mg/day or 70 mg/week and risedronate 5 mg/day or 35 mg/week might be 
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insufficient to protect localized BMD by too little counteraction of the high resorptive activity of 
osteoclasts originating in adjacent inflamed synovial tissue. Above all, in order to reduce and stop 
inflammation-driven localized BMD loss effectively, suppression of inflammation is essential. 
 
Localized BMD gain in RA patients in remission 
 
High inflammatory activity results in both joint damage progression and localized BMD loss. 
Adequate suppression of inflammation might result in a reversal of damage given the constant 
dynamics of bone formation and bone resorption. Repair of erosive damage in case of adequate 
suppression of inflammation is sometimes seen, and it is thought that gain in BMD is more often 
the case and easier detectable. We studied whether gain in localized BMD could be detected by the 
fully automatic and sensitive technique digital X-ray radiogrammetry (DXR). In chapter 5 it is 
shown that RA patients in continuous clinical remission (DAS <1.6) during 1 year have, at group 
level, no BMD loss whereas patients with continuous low or high disease activity, 1.6≤DAS≤2.4 
and DAS <2.4, respectively, have significant BMD loss (0% versus 2% and 3%). At patient level, 
35% of the patients in continuous remission haves gain in BMD compared to only 11% and 6% of 
the patients with low and high disease activity. Moreover, patients with BMD gain show zero 
Sharp-vanderHeijde damage progression compared to 2 and 4 points in patients with stable BMD 
and BMD loss, respectively. These data again confirm that localized BMD in the hands is a 
dynamic marker resembling sensitively the current state of inflammatory activity in RA patients. It 
also suggests that remission, rather than low disease activity, is the optimal outcome at which to aim 
treatment decisions in patients with RA.  
 
Localized BMD loss as predictor for destructive RA 
 
Peri-articular and localized BMD loss is found in early phases of RA, before the stage of joint 
destruction, and even in the undifferentiated phase of the RA process.[7,8] In chapter 6 we 
demonstrate the value of changes in localized BMD in the hands, measured by DXR, to predict 
subsequent joint destruction in early RA. In the first year, the sensitivity and negative predictive 
value of BMD loss in the hands for detecting progressive total joint damage are quite high, 87% 
and 93% respectively, whereas the specificity and positive predictive value are low, 36% and 23%, 
respectively. Localized BMD loss in the first year of RA predicts subsequent progressive joint 
damage in hands and feet after 4 years. However, joint damage progression in the first year is almost 
a ten-fold stronger predictor. It is possible that earlier BMD evaluation, for instance three to four 
months after disease onset or even in the undifferentiated phase of arthritis, might still be a useful 
tool to predict poor outcome in RA patients. 
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Inflammation and progressive hand OA 
 
As shown in the previous chapters, localized BMD loss in the hands is a dynamic marker for 
inflammatory activity, and is associated with progressive joint destruction in RA. It is believed that 
systemic and local inflammatory activity also plays a role in pathogenesis of hand OA. In chapter 7 
this is investigated by studying the association between localized BMD loss in the hands and 
progression of radiographic hand OA over 2 years in the Genetics, ARthrosis and Progression 
(GARP) study. Accelerated BMD loss is twice more often present in progressive hand OA 
compared to non-progressive hand OA or no hand OA, suggesting that inflammation indeed plays 
a role in the etiology of progressive hand OA. This could indicate new targets for therapeutic 
interventions in hand OA. 
 
Effect of anti-TNFα on progressive hand OA in RA 
 
New treatment modalities for hand OA are highly needed because of the high prevalence, the 
substantial burden, and the completely lack of disease modifying drugs. TNFα inhibition might be 
a potential new target in hand OA.[9-11] Chapter 8 addresses secondary radiographic hand OA 
progression in patients with RA treated in the BeSt study. In this RA population, 1 out the 10 
patients haves incident secondary OA, and 1 out the 3 patients progressive secondary OA in the 
interphalangeal joints of the hands over 3 years. High inflammatory activity, measured by high 
erythrocyte sedimentation rate and progressive erosive joint damage over 3 years, is associated with 
incident and progressive secondary OA in the distal interphalangeal joints. Patients receiving 
therapy with infliximab have reduced incident secondary OA in proximal interphalangeal joints, 
independent of the decrease in inflammation, suggesting that TNFα inhibition might be effective 
against secondary hand OA via other bone linked pathways than suppression of inflammation. 
Further research is needed to explore the effect of anti-TNFα treatment in primary hand OA. 
 
Future perspectives 
 
This thesis emphasizes that in recent-onset RA, localized BMD loss and, to a lesser extent, 
generalized BMD loss are inflammation-driven processes, and that therefore early and effective 
remission induction therapy is necessary to stop BMD loss. While TNFα inhibitors might 
theoretically be preferable as bone-preserving anti-rheumatic treatment due to the possible bone 
building effect, this thesis underlines the importance of quick and effective suppression of 
inflammation, irrespective of the choice of the specific agents. Even combination therapy with 
corticosteroids, if given in a quickly tapered high dose, conserves BMD due to the strong anti-
inflammatory effect. Nevertheless the conventional oral antiresorptive agents, especially 
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bisphosphonates, are still necessary to prevent further generalized BMD loss, while they have no 
effect on localized BMD loss.   
 
Since the abundance of osteoclast activity in contrast with osteoblast activity, mainly by the 
RANKL/OPG signaling pathway, seems to be responsible for both joint damage as well as 
generalized and localized BMD loss in RA, the current challenge is identifying therapeutic 
opportunities to treat all forms of bone loss at once. Direct intervention in this pathway by RANKL 
inhibition or OPG stimulation might stop or even repair articular and extra-articular bone damage. 
Recent clinical trials using denosumab, a humanized anti-RANKL antibody, showed even repair of 
RA joint damage, and reversal of localized and generalized BMD.[12,13] Furthermore, in animal 
studies treatment with OPG leads to the presence of osteoblasts, and extra bone formation, 
resulting in arrest, but not repair, of erosions and reversal of generalized BMD loss.[14,15] 
However, treatment with both denosumab and OPG does not result in decrease in inflammatory 
parameters, suggesting a bone-linked, and not a inflammation-linked pathway.[16,17]  
Furthermore, enhancing osteoblast activity by stimulating the Wnt signaling pathway or 
suppressing the Wnt-inhibitor dickkopf-1 are potential molecular targets for prevention and 
treatment of articular and extra-articular bone involvement in RA.  
Another way to target all forms of bone loss in RA is with potent bisphosphonates by their direct 
inhibitory effect on osteoclast activity. Zoledronic acid is a potent third-generation 
aminobisphosphonate that is thought to act by inhibiting osteoclast lifespan.[18] In animal studies 
zoledronic acid effectively suppressed structural joint damage, and localized bone loss, although 
there was no effect on clinical synovitis.[19,20] Studies investigating other bisphosphonates also 
confirm the positive effect of these agents on bone turnover, and the absence of an effect on clinical 
inflammation in RA.[21-23]  
Randomized clinical trials are needed to explore the combined effect of anti-inflammatory drugs 
and agents targeting osteoclasts, directly, such as potent bisphosphonates, or via the RANKL/OPG 
or Wnt signaling pathway, on progression in erosive joint damage, localized and generalized BMD 
loss, fractures, and clinical parameters.  
 
RA is a heterogeneous disease ranging from non-destructive disease responding to monotherapy to 
severe, destructive, and disabling disease refractory to multiple treatments. Therefore tailor-made 
treatment for the individual RA patient would diminish both undertreatment, leading to 
unnecessary bone destruction and disfunctionality, and overtreatment, leading to unnecessary 
adverse events and costs. In spite of recent progress in the field of identifying predictors of 
destructive disease, such as the presence of autoantibodies and joint damage at the time of the 
diagnosis of the disease, there is need for more accurate tools that will allow early and accurate 
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differentiation between aggressive and non-aggressive disease course. Localized BMD loss in the 
metacarpals measured by DXR seems a promising, sensitive, and non-invasive tool to predict rapid 
destructive disease, provided it detects BMD loss earlier than radiographs detect joint damage 
progression. However, after 1 year of follow-up, radiological joint damage progression, according to 
the by van der Heijde modified Sharp score, is a much stronger predictor of subsequent joint 
damage progression than BMD loss measured by DXR. Localized BMD loss during the first few 
months after diagnosis, or even in the undifferentiated phase of the RA process, might have a 
greater predictive value in clinical practice. Further studies are needed on the predictive value of 
early localized BMD loss by DXR in RA or undifferentiated arthritis, and the additional value of it 
when incorporated in known predictive models.[24-26] Furthermore, novel biomarkers, that reflect 
the turnover and activity of the synovium, bone, and cartilage tissues, might improve these 
algorithms further.  
 
In contrast with RA, in OA no disease modifying treatment exists. Local and systemic inflammation 
seems to be an important pathway in the etiology of hand OA. TNFα inhibition decreased the 
incidence of secondary hand OA in our RA population. The potential value of treatment with 
TNFα inhibitors, and other anti-inflammatory drugs, has to be investigated in clinical studies with 
patients with primary hand OA. Furthermore, since TNFα inhibition influenced secondary hand 
OA not by suppression of inflammatory activity, new bone-linked targets for therapeutic 
interventions in hand OA has to be explored.  
 
Conclusions 
 
Patients with recent-onset RA with high inflammatory activity have significant localized and, to a 
lesser extent, generalized BMD loss in the first years of their disease. Early and effective intervention 
with combination anti-rheumatic drugs, including prednisone or infliximab, results in less localized 
BMD loss in the hands. Conventional oral bisphosphonates protect against generalized BMD loss, 
however not against localized BMD loss, in RA. In patients in clinical remission, increase in 
localized BMD is frequently seen. Localized BMD loss in the hands in the first year of RA is 
predictive for subsequent joint damage, however not independent of progressive joint damage. Just 
as in RA, localized BMD loss in the hands is accelerated in progressive hand OA, emphasizing the 
role of inflammatory activity in primary hand OA. Treatment with TNFα inhibition decreases 
secondary hand joint progression in OA probably by direct influencing the bone metabolism.  
Identifying therapeutic strategies and opportunities to treat or prevent all forms of bone loss and 
functional disability in RA and OA remains a challenge. Remission of disease in patients with RA 
and OA is the ultimate target.   
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Nederlandse samenvatting 
 
Dit proefschrift heeft als belangrijkste onderwerp het verlies aan gelokaliseerd en gegeneraliseerd 
botmineraaldichtheid (BMD) in recent gediagnosticeerde reumatoïde artritis (RA). Verder wordt er 
nog een uitstap gemaakt naar gelokaliseerd BMD verlies in primaire hand artrose, en het effect van 
behandeling met tumor necrosis factor alpha (TNFα) blokkade op secundaire hand artrose in 
patiënten met RA. In hoofdstuk 1 wordt een introductie gegeven over het ziektebeeld RA, in het 
bijzonder de anti-reumatische behandeling en het ontstaan van gewrichtsschade en BMD verlies, en 
het ziektebeeld artrose, in het bijzonder de rol van ontsteking in hand artrose. RA is een chronische 
ziekte, waarbij het lichaam eigen cellen aanvalt, en er ontstekingen ontstaan, vooral in de kleine 
gewrichten van de handen en voeten. Ontsteking van het gewrichtskapsel leidt tot de verschijnselen 
van een gezwollen en pijnlijk gewricht, waarbij ook het kraakbeen en bot kunnen worden aangetast 
door hoge afbraak door cellen genaamd osteoclasten en lage aanmaak door cellen genaamd 
osteoblasten. Kraakbeen- en botaantasting zijn waarneembaar op röntgenfoto’s van de handen en 
voeten in de vorm van gewrichtsspleetversmalling en erosies. De gewrichtsschade is grotendeels 
irreversibel.  
In Nederland hebben ongeveer 7 op de 1000 mannen en 11 op de 1000 vrouwen RA, en de 
prevalentie van RA stijgt met de leeftijd. Het ziektebeeld varieert van patiënten met weinig en milde 
gewrichtsontstekingen en -schade tot patiënten met vaak en veel gewrichtsontstekingen en -schade. 
Zowel de gewrichtsontstekingen als de -schade kunnen leiden tot beperkingen in het functioneren, 
en daardoor tot verminderde kwaliteit van leven. Ontstekingen elders in het lichaam, met name in 
het hart en de bloedvaten, en botbreuken door osteoporose bij RA kunnen leiden tot een kortere 
levensverwachting.  
De laatste decennia is de behandeling van RA met sprongen vooruit gegaan. De verbeteringen zijn 
vooral tot stand gekomen door: 1. het vroeg starten met anti-reumatische middelen, 2. het 
combineren van meerdere geneesmiddelen voor meer en sneller effect, 3. het ontwikkelen van 
nieuwe en krachtige anti-reumatische middelen, inclusief de TNFα blokkers, en 4. het doelgericht 
behandelen aan de hand van objectieve ziekteactiviteitsscores, waardoor de ziekte sneller en beter 
controleerbaar is. Echter, het was lange tijd niet bekend welk middel of welk combinatie van 
middelen het meest effectief en het minst toxisch is als eerste stap in patiënten met recent 
gediagnosticeerde RA. Ook was niet bekend welke volgende behandelstappen genomen zouden 
moeten worden bij falen op de eerste stap. Om antwoorden te geven op die vragen werd de BeSt 
studie, acroniem voor Behandel Strategieën, opgezet. Het onderzoek werd uitgevoerd in 20 
verschillende ziekenhuizen in Zuidwest Nederland. Er werden 508 patiënten met recent 
gediagnosticeerde RA geïncludeerd en gerandomiseerd voor behandeling volgens een van de 
volgende behandelstrategieën: 1. sequentiële monotherapie, waarbij werd gestart met methotrexaat, 
en bij onvoldoende effect werd overgegaan op een ander geneesmiddel; 2. step-up 
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combinatietherapie, waarbij eveneens gestart werd met methotrexaat, en bij onvoldoende effect 
andere geneesmiddelen stap voor stap werden toegevoegd; 3. initiële combinatietherapie met 
methotrexaat, sulfasalazine en een hoge dosis prednison in afbouwschema (stootkuur prednison); 4. 
initiële combinatietherapie met methotrexaat en de TNFα blokker infliximab. Aanpassingen van de 
behandelingen binnen deze strategieën waren gebaseerd op 3-maandelijkse bepalingen van de 
ziekteactiviteit, de DAS (disease activity score), door een onderzoeksverpleegkundige. Als er 
onvoldoende verbetering optrad, DAS >2.4, werd de behandeling geïntensiveerd door het 
toevoegen of ophogen van geneesmiddelen; als de ziekteactiviteit voldoende was gedaald, DAS ≤2.4, 
werden geneesmiddelen één voor één afgebouwd. Na 1 jaar bleek dat patiënten behandeld met 
initiële combinatietherapieën (groepen 3 en 4) sneller verbeterden in ziekteactiviteit en 
functioneren, minder gewrichtsschade hadden ontwikkeld, en minder therapieaanpassingen nodig 
hadden, vergeleken met patiënten behandeld met sequentiële monotherapie en step-up therapie 
(groepen 1 en 2). Na 6 jaar heeft de helft van alle patiënten klinisch langdurig geen 
ziekteverschijnselen meer, klinische remissie genoemd, en 1 op de 6 patiënten hoeft zelfs geen anti-
reumatische middelen meer te gebruiken. Deze resultaten onderstrepen de noodzaak van vroege en 
effectieve behandeling om het ontstekingsproces een halt toe te roepen, en om schade aan het bot te 
voorkomen of beperken. 
Osteoporose, in de volksmond ook wel botontkalking genoemd, is een botziekte die wordt 
gekenmerkt door broos bot en afgenomen botsterkte, en die leidt tot hogere risico’s op botbreuken. 
In Nederland hebben ongeveer 2 op de 1000 mannen en 16 op de 1000 vrouwen osteoporose, en 
de prevalentie van osteoporose stijgt met de leeftijd. In patiënten met RA zijn er twee soorten 
osteoporose of, over een bepaalde periode, BMD verlies: 1. gegeneraliseerd, te meten bijvoorbeeld 
in de heupen en wervelkolom, en 2. gelokaliseerd, zichtbaar in de nabijheid van de ontstoken 
gewrichten, bijvoorbeeld in de handen. Uit onderzoek is gebleken dat gegeneraliseerde osteoporose 
2 keer vaker voorkomt in patiënten met langdurige RA dan in de normale bevolking. Een van de 
verklaringen hiervoor is dat ook BMD verlies mede wordt veroorzaakt door ontstekingsactiviteit. 
Onderzoek naar gelokaliseerd en gegeneraliseerd BMD verlies en het effect van verschillende 
behandelstrategieën hierop in recent gediagnosticeerde actieve RA zou meer duidelijkheid brengen 
in de relatie tussen lokale en systemische ontsteking en BMD verlies. 
Terwijl er allerlei behandelingsmodaliteiten bestaan en nog verder worden ontwikkeld voor 
patiënten met RA om het ziekteproces te doen stoppen, zijn de behandelingsmogelijkheden voor 
patiënten met artrose beperkt tot het bestrijden van symptomen. Artrose, in de volksmond ook wel 
gewrichtsslijtage genoemd, is de meest voorkomende reumatische ziekte die gekenmerkt wordt door 
aantasting van het gewrichtskraakbeen en het bot net onder het kraakbeen. In Nederland hebben 
ongeveer 30 op de 1000 mannen en 50 op de 1000 vrouwen artrose, en de prevalentie van artrose 
stijgt sterk met de leeftijd. Patiënten met artrose hebben min of meer evenveel last van beperkingen 
 144 
in het dagelijks leven als patiënten met RA. Recent onderzoek heeft aangetoond dat, net als in RA, 
ook in hand artrose ontstekingsactiviteit een belangrijke rol lijkt te spelen. Dit betekent dat 
krachtige ontstekingsremmers, die ook in RA gebruikt worden, mogelijk ook effectief zouden 
kunnen zijn in patiënten met hand OA.  
 
Gegeneraliseerde osteoporose in recent gediagnosticeerde RA 
 
Gegeneraliseerde osteoporose is een bekende complicatie in patiënten met lang bestaande RA met 
veel gewrichtsschade, beperkt functioneren, en immobiliteit, en leidt tot een 2 keer hogere kans op 
heup- en wervelkolombreuken. De verklaringen voor de hogere prevalentie van gegeneraliseerde 
osteoporose in langdurige RA zijn: 1. het voorkomen van beide ziektes in dezelfde soort 
patiëntengroep, namelijk met name oudere vrouwen, 2. het ontstaan van osteoporose als gevolg van 
RA door langdurige immobiliteit, een bekend risicofactor voor osteoporose, 3. het langdurig 
gebruik van prednison, een bekend veroorzaker van osteoporose, en 4. het ontstaan van osteoporose 
door het ontstekingsproces zelf. Om te onderzoeken of gegeneraliseerde osteoporose een direct 
gevolg van de ontsteking is, moet er gekeken worden naar osteoporose in patiënten met recent 
gediagnosticeerde actieve RA die nog geen anti-reumatische middelen, en dus ook nog geen 
prednison, hebben gebruikt. In hoofdstuk 2 wordt beschreven dat 11% van de patiënten, die 
gemiddeld net 2 weken gediagnosticeerd zijn met RA en nog niet gestart zijn met anti-reumatische 
middelen, osteoporose hebben. Eerder onderzoek liet zien dat dit percentage vergelijkbaar is in de 
algemene Nederlandse bevolking. Echter, naast bekende risicofactoren van gegeneraliseerde 
osteoporose, zoals postmenopauzale status bij vrouwen, laag gewicht, en het familiar voorkomen 
van osteoporose, bleek ook de duur van de ontstekingsklachten en de aanwezigheid van 
reumafactor, een voorspeller voor hoge ontstekingsactiviteit, risicofactoren te zijn van 
gegeneraliseerde osteoporose in RA. Dit suggereert dat gegeneraliseerde osteoporose het gevolg is 
van ontstekingsactiviteit, echter door de korte duur van ontstekingsactiviteit is de prevalentie 
osteoporose in patiënten met pas gediagnosticeerde RA niet hoger dan in de algemene bevolking. 
 
Gegeneraliseerd BMD verlies in het eerste jaar van RA 
 
Gegeneraliseerde osteoporose, over een bepaalde periode BMD verlies genoemd, lijkt dus in RA 
mede veroorzaakt te zijn door het ontstekingsproces zelf. Ook anti-reumatische geneesmiddelen 
hebben verschillende effecten op BMD verlies. Van prednison is bekend dat het meer 
gegeneraliseerd BMD verlies geeft, terwijl de TNF blokker infliximab mogelijk geassocieerd is met 
toename in BMD. Het effect van verschillende moderne behandelstrategieën, één inclusief 
prednison stootkuur en één inclusief infliximab, op gegeneraliseerd BMD verlies is niet bekend. In 
hoofdstuk 3 demonstreren we dat er in het eerste jaar van RA BMD verlies van 1.0% en 0.8% is in 
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de heup en wervelkolom. Dit lijkt aanzienlijk meer te zijn dan het BMD verlies van ongeveer 0.5% 
in de heup na 2 jaar in de algemene Nederlandse bevolking. Er wordt geen verschil gezien in 
gegeneraliseerd BMD verlies tussen de 4 behandelstrategieën in de BeSt studie. Dus, 
combinatietherapie met prednison stootkuur (groep 3) geeft niet meer gegeneraliseerd BMD verlies 
dan combinatietherapie met infliximab. Dit geeft aan dat het negatief effect van prednison op BMD 
teniet wordt gedaan door het sterk ontstekingsremmend effect dat het bot beschermt tegen afbraak. 
Calcium and vitamine D supplementen stoppen gegeneraliseerd BMD verlies in RA op zich niet, 
maar het gebruik van bisfosfonaten wel. Patiënten met meer gewrichtsschade hebben meer 
gegeneraliseerd BMD verlies, wat sterk suggereert dat gegeneraliseerd BMD verlies en 
gewrichtsschade dezelfde onderliggende ontstaansmechanismen hebben. 
 
Gelokaliseerd en gegeneraliseerd BMD verlies in de eerste jaren van RA 
 
Het lijkt in lijn der verwachting dat gelokaliseerd BMD, in de nabijheid van ontstoken gewrichten, 
meer gevoelig zal zijn voor het effect van ontstekingscellen en –mediatoren dan gegeneraliseerd 
BMD in de heup en wervelkolom, waar minder of geen lokaal ontstekingsactiviteit is. In hoofdstuk 
4 tonen we aan dat er na 2 jaar behandeling inderdaad meer gelokaliseerd BMD verlies in de 
handen is dan gegeneraliseerd BMD verlies in de heup en wervelkolom (mediaan verlies 2.5% 
versus 0.5 en 1.0%). Terwijl gegeneraliseerd BMD verlies weer min of meer gelijk is in alle 
behandelgroepen, is er duidelijk minder gelokaliseerd BMD verlies na 1 en 2 jaar in de 
combinatietherapie groepen door de snellere en effectievere remming van de ontstekingsactiviteit 
gedurende de eerste 6 maanden van de behandeling (mediaan verlies 3.6%, 3.3%, 1.4%, en 1.6% 
voor groepen 1-4 na 2 jaar). Dat er geen duidelijke verschillen zijn in gelokaliseerd BMD verlies 
tussen de combinatietherapie met prednison stootkuur en de combinatietherapie met infliximab, 
suggereert dat het beschermend effect van effectieve ontstekingsremming op bot het negatief effect 
van prednison neutraliseert, en dat combinatietherapie met een TNFα blokker niet superieur is aan 
combinatietherapie met prednison stootkuur. Het meest belangrijke voor het behoud van BMD, 
vooral lokaal, is dat ontsteking snel en effectief onderdrukt moet worden in RA. Dat ontsteking 
gerelateerd is aan BMD verlies wordt nog eens benadrukt door de associatie tussen gelokaliseerd en 
gegeneraliseerd BMD verlies en progressieve gewrichtsschade. Verder blijkt het gebruik van 
bisfosfonaten te beschermen tegen gegeneraliseerd BMD verlies, maar niet tegen gelokaliseerd BMD 
verlies in de handen, mogelijk omdat de conventionele orale bisfosfonaten niet sterk genoeg zijn om 
de door de hoge ontstekingsactiviteit aangewakkerde botafbraak te reduceren. Om gelokaliseerd 
BMD verlies te verminderen en te stoppen is dus adequate remming van de ontstekingsactiviteit 
noodzakelijk. 
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Toename in gelokaliseerd BMD in RA patiënten in remissie 
 
Hoge ontstekingsactiviteit resulteert in zowel gewrichtsschade als gelokaliseerd en gegeneraliseerd 
BMD verlies. Effectieve remming van de ontsteking zou kunnen leiden tot afname van botschade 
daar bot een dynamisch orgaan is met continue afbraak en aanmaak. Herstel van erosieve 
gewrichtsschade wordt weleens gezien, maar toename in gelokaliseerd BMD is waarschijnlijk in 
geval van lage of afwezige ziekteactiviteit sneller detecteerbaar door het proces zelf, en de manier van 
meting met de volledig geautomatiseerde en sensitieve techniek digital X-ray radiogrammetry 
(DXR). In hoofdstuk 5 wordt aangetoond dat RA patiënten in continue klinische remissie, DAS 
<1.6, gedurende 1 jaar op groepsniveau geen BMD verlies meer vertonen, terwijl RA patiënten met 
lage of hoge ziekteactiviteit, 1.6≤DAS≥2.4 en DAS >2.4, respectievelijk, aanzienlijk gelokaliseerd 
BMD verlies vertonen (0% versus 2 en 3%). Op patiëntenniveau, hebben zelfs 35% van de 
patiënten in klinische remissie toename in BMD vergeleken met 11% en 6% van de patiënten met 
lage en hoge ziekteactiviteit. De patiënten met toename in BMD hebben ook geen toename in hun 
gewrichtsschade, terwijl patiënten met stabiele BMD en BMD verlies een toename in Sharp-
vanderHeijde schadepunten hebben van 2 en 4 punten, respectievelijk. Deze resultaten bevestigen 
dat gelokaliseerd BMD verlies een dynamische marker is voor de huidige status van 
ontstekingsactiviteit in RA. Tevens suggereren deze resultaten dat remissie, en niet lage 
ziekteactiviteit, het doel is waarop therapie aangepast zou moeten worden om botschade te stoppen. 
 
Gelokaliseerd BMD verlies als voorspeller van destructieve RA 
 
Gelokaliseerd BMD verlies wordt al gezien in de vroege fase van RA, voor er sprake is van 
gewrichtsschade, en zelfs in de ongedifferentieerde fase van het ziekteproces. In hoofdstuk 6 
demonstreren we de waarde van gelokaliseerd BMD verlies, gemeten met DXR, om latere 
gewrichtsschade in vroege RA te voorspellen. In het eerste jaar van de ziekte, is de sensitiviteit en 
negatief voorspellende waarde van BMD verlies in de handen om progressieve gewrichtsschade te 
detecteren hoog, 87% en 93%, respectievelijk, terwijl de specificiteit en positief voorspellende 
waarde laag is, 36% en 23%, respectievelijk. Gelokaliseerd BMD verlies in het eerste jaar voorspelt 
progressieve gewrichtsschade in de handen en voeten in de 3 jaren erna. Echter, gewrichtsschade 
gedurende het eerste jaar is een bijna 10 keer sterkere voorspeller voor latere gewrichtsschade. 
Mogelijk dat eerdere evaluatie van veranderingen in gelokaliseerd BMD gedurende het ziekteproces, 
bijvoorbeeld na 3 maanden na het diagnosticeren van RA, of zelfs in de ongedifferentieerde fase van 
het ontstekingsproces, meer voorspellende waarde heeft in klinische praktijk. 
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Ontsteking en progressieve hand artrose 
 
Zoals beschreven in de eerdere hoofdstukken, is gelokaliseerd BMD verlies in de handen een 
dynamische marker voor ontstekingsactiviteit in RA. Er zijn sterke aanwijzingen dat ontsteking ook 
een rol speelt in het ontstaan dan wel verergeren van hand artrose. In hoofdstuk 7 wordt de 
associatie tussen gelokaliseerd BMD verlies in de handen en progressieve röntgenschade over 2 jaar 
in patiënten met primaire hand OA in de Genetica, ARtrose en Progressie (GARP) studie 
onderzocht. Gelokaliseerd BMD verlies wordt 2 keer zo vaak in patiënten met progressieve hand 
OA gezien dan in patiënten met non-progressieve hand OA of helemaal geen hand OA. Een van de 
mogelijke verklaringen hiervoor is dat ontsteking (progressieve) hand OA medeveroorzaakt, en dit 
indiceert nieuwe targets voor behandelmodaliteiten in hand OA. 
 
TNFα blokker tegen progressieve hand OA in RA 
 
Nieuwe behandelmogelijkheden zijn nodig in hand OA door de hoge prevalentie, hoge belasting 
van patiënt en maatschappij, en het beperkte repertoire aan geneesmiddelen die bovendien enkel 
symptomen bestrijden maar niet het ziekteproces een halt toeroepen. Aangezien ontsteking een 
belangrijke rol lijkt te spelen in hand OA, zou blokkade van TNFα een target kunnen zijn in hand 
OA om het ziekteproces te stoppen. Hoofdstuk 8 adresseert progressie in secundaire artrotische 
gewrichtsschade in patiënten met RA in de BeSt studie. In deze RA patiënten, heeft 1 op de 10 
patiënten nieuwe secundaire hand OA, en 1 op de 3 progressieve secundaire hand OA gedurende 
een periode van 3 jaar. Hoge ontstekingsactiviteit, uitgedrukt in hoge bezinking en progressieve 
erosieve gewrichtsschade gedurende 3 jaar, is geassocieerd met nieuwe en progressieve secundaire 
OA in de distale interfalangeale gewrichten. Patiënten die behandeld werden met de TNFα blokker 
infliximab ontwikkelen minder vaak secundaire OA in de proximale interfalangeale gewrichten, 
onafhankelijk van remming van ontsteking, wat suggereert dat blokkade van TNFα effectief is tegen 
secundaire hand OA door direct effect op het botmetabolisme, en niet indirect via remming van 
ontsteking. Meer onderzoek naar het effect van TNFα blokkers op hand OA zijn nodig. 
 
Toekomstperspectieven 
 
Dit proefschrift benadrukt dat in recent gediagnosticeerde RA, gelokaliseerd BMD verlies en, in 
mindere mate, gegeneraliseerd BMD verlies veroorzaakt wordt door ontstekingsactiviteit, en dat 
daarom vroege en effectieve anti-reumatische behandeling noodzakelijk is om BMD verlies in RA te 
voorkomen. Terwijl, ten aanzien van bescherming van BMD, TNFα blokkers theoretisch gezien de 
voorkeur lijken te hebben door hun mogelijk positief effect op botaanmaak, onderstrepen de 
onderzoeken in dit proefschrift het belang van snelle en effectieve remming van de ontsteking, 
ongeacht de keuze voor de anti-reumatische middelen. Zelfs combinatietherapie met prednison 
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stootkuur beschermt relatief BMD door de sterke remming van ontsteking. Desalniettemin is 
behandeling met anti-osteoporose middelen, met name bisfosfonaten, noodzakelijk om verder 
gegeneraliseerd BMD verlies te voorkomen, echter effect van deze middelen op gelokaliseerd BMD 
verlies ontbreekt. 
 
Daar hoge botafbraak door osteoclasten en lage botaanmaak door osteoblasten verantwoordelijk zijn 
voor zowel gewrichtsschade als gelokaliseerd en gegeneraliseerd BMD verlies in RA, is de uitdaging 
om geneesmiddelen te vinden die alle 3 de vormen van botschade in een keer aanpakken. Directe 
interventie in osteoclast-gerelateerde mechanismes zouden kunnen leiden tot zowel afname in 
gewrichtsschade als afname in gelokaliseerd en gegeneraliseerd BMD verlies. Het nieuw 
geneesmiddel denosumab, dat een stimulator van osteoclasten remt, stopt in klinische onderzoeken 
alle vormen van botschade, en er wordt zelfs herstel van gewrichtsschade en toename van 
gelokaliseerd en gegeneraliseerd BMD gezien. Echter, denosumab heeft geen effect op 
gewrichtsontstekingen. Een ander groep geneesmiddelen die ook een direct remmend effect heeft op 
osteoclast activiteit is de groep van bisfosfonaten. Sterke bisfosfonaten, zoals zoledronaat, lijken, 
naast gegeneraliseerd BMD verlies, ook gewrichtsschade en gelokaliseerd BMD verlies te 
voorkomen, maar hebben geen effect op ontstekingsactiviteit. Nieuwe gerandomiseerde klinische 
studies zijn nodig om het effect van combinatietherapieën met direct osteoclast remmende 
geneesmiddelen, zoals denosumab en zoledronaat, en ontstekingsremmende geneesmiddelen op 
gewrichtsschade, gelokaliseerd en gegeneraliseerd BMD, botbreuken, en klinische parameters te 
onderzoeken. 
 
RA is een heterogene ziekte variërend van een niet-destructieve ziekte goed reagerend op 
monotherapie tot ernstige, destructieve ziekte refractair tegen multipele intensieve behandelingen. 
Gepersonaliseerde anti-reumatische behandeling op maat voor ieder individuele patiënt zou leiden 
tot zowel minder onderbehandeling, en dus minder botschade en functionele beperking, en minder 
overbehandeling, en dus minder onnodige bijwerkingen en kosten. Ondanks recente 
ontwikkelingen ten aanzien van het identificeren van voorspellers van destructieve ziekte, zoals de 
aanwezigheid van autoantistoffen en gewrichtsschade bij de diagnose van de ziekte, zijn meer 
accurate middelen nodig om vroeg en sensitief onderscheid te kunnen maken tussen destructief en 
niet-destructief ziektebeloop. Gelokaliseerd BMD verlies in de handen gemeten met de DXR lijkt 
een veelbelovende en sensitieve parameter om gewrichtsschade in RA te voorspellen, aangezien 
DXR BMD verlies eerder detecteert dan dat er op röntgenfoto’s gewrichtsschade gedetecteerd kan 
worden. Echter, na 1 jaar behandeling, is gewrichtsschade op röntgenfoto’s een sterkere voorspeller 
van latere gewrichtsschade dan BMD verlies gemeten met DXR. Gelokaliseerd BMD verlies 
gedurende de eerste maanden van de ziekte, of zelfs in de ongedifferentieerde fase van het 
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ziekteproces, zou een grotere voorspellende waarde kunnen hebben in klinische praktijk. Meer 
onderzoek naar de voorspellende waarde van gelokaliseerd BMD verlies gemeten met de DXR, en 
de additionele waarde ervan wanneer het geïncorporeerd wordt in bekende voorspelmodellen, is 
nodig in RA en ongedifferentieerde artritis. Bovendien zouden nieuwe biomarkers, die de activiteit 
van het synovium-, bot-, en kraakbeenweefsel reflecteren, deze voorspellingsmodellen wellicht nog 
meer kunnen verbeteren. 
 
In tegenstelling tot RA, zijn er voor patiënten met artrose alleen maar geneesmiddelen die de 
symptomen doen verminderen beschikbaar. Nieuwe kennis over ontstaansmechanismes van artrose 
zouden kunnen leiden tot nieuwe behandelingsdoelen. Ontsteking lijkt een belangrijk rol te spelen 
in het ontstaan en verergeren van hand artrose. TNFα blokkers verminderen de incidentie van 
secundaire hand artrose in patiënten met RA in de BeSt studie. De potentiële waarde van 
behandeling met TNFα blokkers, en andere sterke ontstekingsremmers, moet in patiënten met 
primaire hand OA onderzocht worden. En daar TNFα blokkade secundaire hand OA niet via 
remming van ontsteking beïnvloedt, moet verder onderzoek gedaan worden naar andere 
botafhankelijke targets als behandelopties in hand OA. 
 
Conclusies 
 
Patiënten met recent gediagnosticeerde RA met hoge ziekteactiviteit hebben significant 
gelokaliseerd en, in mindere mate, gegeneraliseerd BMD verlies in de eerste jaren van het 
ziekteproces. Vroege en effectieve interventie met anti-reumatische combinatietherapie, met 
prednison stootkuur of infliximab, resulteert in minder gelokaliseerd BMD verlies in de handen. 
Conventionele orale bisfosfonaten beschermen tegen gegeneraliseerd, echter niet tegen gelokaliseerd 
BMD verlies, in RA. In patiënten in klinische remissie, wordt toename in gelokaliseerd BMD vaak 
gezien. Gelokaliseerd hand BMD verlies in het eerste jaar van het ziekteproces voorspelt latere 
gewrichtsschade, echter niet onafhankelijk van gewrichtsschade in het eerste jaar. Net als in RA is 
gelokaliseerd BMD verlies in de handen geaccelereerd in progressieve hand artrose, wat de rol van 
ontstekingsactiviteit in primaire hand artrose benadrukt. Behandeling met TNFα blokker 
infliximab vermindert secundaire artrotische gewrichtsschade in de handen waarschijnlijk door het 
botmetabolisme direct te beïnvloeden en niet via remming van de ontstekingsactiviteit.  
Het identificeren van behandelstrategieën om alle vormen van botschade en functionele beperking 
te behandelen en voorkomen in RA en artrose blijft een uitdaging. Het bereiken van remissie in 
patiënten met RA en artrose is het ultieme doel. 
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